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ABSTRACT OF THE DISSERTATION 
Regulation of durable adaptive immune response by the c-MYC-AP4 
transcriptional cascade 
by 
Chun (Jim) Chou 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
 
Washington University St. Louis, 2016 
Professor Takeshi Egawa, Chair 
 
The process of amplifying immune responses by expanding a small number of antigen-
specific cells, termed clonal expansion, is an important feature of the adaptive immunity. 
Whereas clonal expansion of cytotoxic T lymphocytes is required for complete 
eradication of intracellular pathogens, proliferation of B lymphocytes in the germinal 
centers (GC) is critical for generating a diverse immunoglobulin gene repertoire from 
which protective antibody carrying multiple mutations can arise. While the proto-
oncogene c-MYC is absolutely required for the activation and cell cycle initiation in 
lymphocytes, its expression is temporally restricted. Activated lymphocytes, however, 
continue to proliferate after c-MYC levels decay to maximize clonal expansion. It 
remains unknown how lymphocytes sustain their proliferative program in the absence c-
MYC. We demonstrated that the c-MYC-inducible transcription factor, AP4 is required 
for sustained expansion of antigen-specific lymphocytes. Mice lacking AP4 in CD8 T 
cells exhibited diminished T cell clonal expansion and succumbed to West Nile virus 
	  
	  
xii 
infection due to uncontrolled viral replication in the central nervous system. Genetic 
ablation of AP4 in B lymphocytes impaired GC growth. These mice failed to control 
persistent viral infection due to blunted neutralizing antibody development. The 
accumulation of AP4 requires IL-2 and IL-21 signals in CD8 T cells and GC B cells, 
respectively, suggesting that AP4 functions as a gauge for extracellular 
microenvironment and scales the magnitude of lymphocyte expansion accordingly. 
Mechanistically, ChIP-seq and gene expression analyses suggest that AP4 compensates 
for early termination of c-MYC by maintaining the transcription of activation signature 
genes initiated by c-MYC.  Thus, both CD8 T and GC B cells have evolved to utilize the 
c-MYC-AP4 transcription factor cascade to maximize immune responses.   
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CHAPTER 1: 
Introduction 
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The central feature of the adaptive immune system is the use of an anticipatory 
repertoire in which each lymphocyte bears a unique antigen receptor 1. This system 
allows for reactivity against a diverse array of antigens, but at the same time limits the 
number of lymphocytes for any given antigen at the steady-state, ranging between tens to 
hundreds for CD8 T cells 2. Thus, an effective adaptive immune response requires the 
selective expansion of few antigen specific cells in a short period of time, a process 
termed ‘clonal expansion,’ to nullify pathogens.  
The magnitude and duration of clonal expansion are commensurate with the 
strength and duration of activation signals that the lymphocytes receive. CD8 T cell 
expansion scales with the amount of pathogen in the initial inoculum and the levels of 
antigen expression by the pathogen 3, 4, 5. Experiments using alternative peptide ligands, 
which represent a wide range of pMHC-TCR affinities, also showed a scaling effect 4, 6, 7, 
8. Similarly, during the germinal center (GC) response, B cells bearing a B cell receptor 
(BCR) of higher affinity than neighboring clones receive more help signals from 
follicular helper T (TFH) cells and consequently undergo more rounds of cell division 9, 10, 
11. An insufficient CD8 T or GC B cell response may result in delayed pathogen 
clearance, leading to chronic infection or death of the hosts 5. In contrast, an over-blown 
CD8 T cell response can cause excessive immunopathology7, 12. Uncontrolled expansion 
and survival of GC B cells nullify affinity maturation. Thus, the ability of lymphocytes to 
scale their responses according to the quality and quantity of activation stimuli is a 
functionally significant feature of the adaptive immune system. 
In this work, we set forth to dissect the molecular mechanisms by which the 
magnitude and duration of adaptive immune responses are regulated. In particular, we 
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sought to identify transcription factors that translate extracellular stimuli, such as antigen 
load and cytokine levels, to the activation and expansion of lymphocytes during the 
course of infection.         
 
1.1 CD8 T cell response during acute infection is controlled by the sequential 
expression of distinct transcription factors. 
A typical course of acute CD8 T cell response consists of three distinct stages: 
priming, expansion, and contraction/memory formation (Figure 1) 13. Once an antigen-
specific CD8 T cell is optimally primed, it can divide as many as 19 times, generating a 
potential 500,000-fold expansion in 7 days 14. In order to support proliferation at such 
dramatic rate, CD8 T cells must undergo drastic changes in metabolism 15. In addition to 
enhanced glucose and amino acid uptake, an increase in aerobic glycolysis meets the 
demand for building blocks of proteins, nucleic acid, and lipids in order to make new 
cells 16. The proto-oncogene c-MYC is rapidly up-regulated after CD8 T cell activation 
and stimulates transcription of key metabolic genes in the aforementioned pathways 17. 
The transcription factor Hif1a, a downstream target of c-MYC, has also been shown to 
regulate glycolysis in activated CD8 T cells 18, but is dispensable for T cell expansion in 
an immunization model 19. A recent report, however, showed hyperactive CD8 T cell 
response when Hif1a was constitutively expressed 20. Although the expression of c-MYC 
is transient, its effects persist. Proliferation of CD8 T cells does not cease after the loss of 
c-MYC; rather, clonal expansion can continue even when mitogenic stimuli are limiting 
in the microenvironment as pathogens are being cleared 21, 22. Maximal CD8 T cell 
expansion provides sufficient tissue surveillance to completely eradicate infected host 
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cells. The molecular mechanisms that sustain proliferation during this period have only 
begun to be understood.  
As CD8 T cells proliferate, a subset differentiates into short-lived effector cells 
(SLECs) in response to environmental cues, including pro-inflammatory cytokines and 
antigen stimulation 23, 24, 25. SLECs are terminally differentiated cells characterized by 
their ability to kill pathogen-infected cells, clonally expand and migrate to inflamed 
tissues and can be readily distinguished by the surface marker expression: 
KLRG1hiCD127lo 26. CD8 T cells acquire effector functions as they proliferate. However, 
whether effector differentiation is coupled to clonal expansion remains unclear: do pro-
inflammatory cytokines induce distinct transcription factors to separately control 
proliferation and differentiation? Alternatively, can one transcription factor 
simultaneously regulate both processes? Recent evidence supports both models. T-bet 
(encoded by the gene Tbx21), a transcription factor induced by interleukin (IL)-12, is 
required for the up-regulation of KLRG1 26. In T-bet-deficient mice, CD8 T cell 
expansion was moderately reduced and effector cells exhibited slightly impaired 
cytotoxic activity 26. Another transcription factor, Blimp-1 (encoded by the gene Prdm1), 
whose expression can be induced by IL-2, IL-12, and IL-21 24, 27, has also been shown to 
regulate effector CD8 T cell response. Mice lacking Blimp-1 in CD8 T cells failed to 
clear influenza virus efficiently due to poor recruitment of CD8 T cells to the lungs 28 and 
reduced IFNγ and granzyme B expression in CD8 T cells 29. However, expansion of 
Blimp1-deficient CD8 T cells appeared to be unaffected 28. These limited examples beg 
for more extensive studies to identify additional transcription factors that instruct CD8 T 
cell response in a cytokine-dependent manner.     
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While over 90% of activated CD8 T cell undergo apoptosis during acute infection, 
a small fraction survive and mature to become memory cells 30. Central memory T (TCM) 
cells, characterized by high surface expression of CD62L and CD127, are capable of 
rapid response upon re-challenge and can be found in circulation and secondary lymphoid 
organs 31. Memory CD8 T cells require IL-7 and IL-15 for survival and maintenance 32, 33. 
Mice lacking the transcription factor Eomesodermin (Eomes) contained reduced number 
of TCM cells due in part to decreased expression of CD122, which is involved in IL-15 
signaling 34. In spite of intensive studies in B cells response, the role of the transcription 
factor B cell lymphoma (Bcl)-6 in memory CD8 T cell differentiation is poorly 
understood. Current data suggest that Bcl6 expression positively correlates with CD8 T 
cells with memory phenotype 35. Thus, distinct transcription factors are activated in a 
stage-specific manner to program clonal expansion, effector differentiation, and memory 
formation of antigen specific CD8 T cells. 
Despite current advancements in elucidating transcriptional control of CD8 T cell 
response, two important questions are yet to be answered. First, what are the transcription 
factors that sustain effector expansion after priming, and second, why do CD8 T cells 
continue to expand when pathogens are cleared from circulation and lymphoid organs? 
 
1.2 Transient T-B interaction induces transcription factors that potentiate continued 
expansion of selected GC B cells. 
The germinal center response (GC) is essential for generating highly protective 
affinity-matured antibody after immunization and pathogen challenge 36, 37, 38. In response 
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to stimulation by T-dependent antigens, B cells form a specialized structure, GC, in 
which secondary diversification of B cell receptor (BCR) genes, expansion and affinity 
maturation take place 39, 40 (Figure 2). GC is functionally divided into the light zone (LZ) 
and the dark zone (DZ) 37, 38. In the LZ, GC B cells compete for help signals from 
cognate follicular helper T cells (TFH) on the basis of their BCR affinity for the antigen 11. 
Clones expressing BCR of higher affinity than neighboring cells are selected for entry 
into the DZ where cell division and somatic hypermutation occur 9, 10, 11. DZ cells then 
migrate back to the LZ to test their mutated BCR and the process of affinity-based 
selection repeats. Through iterative cycles of selection, proliferation, and somatic 
hypermutation, termed “cyclic re-entry”, rare clones capable of producing high affinity 
antibody emerge and differentiate into memory or plasma cells, conferring long-term 
protective humoral immunity to the host. 
The magnitude of GC expansion and the extent of somatic hypermutation are 
determined by the availability of TFH-derived help. In the LZ, GC B cells capture antigen 
from follicular dendritic cells (FDCs) 38, process and present it to cognate T cells and 
receive help signal. Recent studies demonstrated that enhancing B-T interaction through 
targeted antigen delivery is sufficient to shorten S-phase length and promote cell division 
of GC B cells (Figure 2) 9. During GC responses, T cell help is delivered to GC B via 
cell-cell contact or in the form of soluble factors. While stimulation through surface 
CD40L-CD40 ligation is critical for GC formation and maintenance 41, such an 
interaction is lost when selected cells migrate away from T cells towards the DZ. 
Secreted mediators by TFH may provide sustained help to GC B cells at a relatively 
distant location in the LZ. Cytokine production by TFH can be triggered by antigen 
	  
	  
7 
presentation of their cognate B cells 42. Among several TFH-derived cytokines, IL-21 in 
particular, is critical for GC growth, somatic hypermutation and affinity maturation, in 
part, by directly regulating Bcl-6 expression 43, 44. Although it is evident that transient T 
cell help in the LZ can program the extent of proliferation in the anatomically remote DZ, 
the underlying molecular mechanisms remain elusive. 
The proto-oncogene c-MYC is required for cellular activation and initiation of 
highly proliferative states in a variety of rapidly dividing cells, including GC B cells 45, 46. 
Although Myc has recently been identified as an essential regulator for GC formation and 
maintenance downstream of T cell help, it is only expressed in a subset of LZ cells that 
have initiated cell cycle progression on route to DZ 45, 46. However, these selected cells 
undergo extensive cell divisions without detectable levels of c-MYC in the DZ. Thus, 
additional transcription factors induced during transient T-B interaction are required to 
sustain proliferation of DZ GC B cells after c-MYC is downregulated. 
 
1.3 AP4 (encoded by Tfap4) is a transcriptional target of c-MYC 
AP4, encoded by the gene Tfap4, belongs to a superfamily of basic helix-loop-
helix (bHLH) transcription factors (Figure 3) 47. As the name implies, bHLH 
transcription factors contain two distinct and conserved structures: a basic region that 
binds a specific stretch of DNA sequence, so-called E-box motif, and a HLH domain that 
facilitates formation of homo- or hetero-dimers with other bHLH members 48. AP4 has 
been shown to form homodimer with itself and generally does not interact with other 
bHLH factors 47. Little has been known about the function of AP4 despite its 
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identification almost 30 years ago 49. In vitro studies suggest that AP4 is an activator for 
SV40 late transcription 49. A study previously published by our lab showed that AP4 
promotes silencing of Cd4 gene in both the double-negative thymocytes and CD8 T cells 
50. Two reports by the Hermeking lab established AP4 as a downstream target of c-MYC. 
AP4 promotes c-MYC-dependent cell cycle progression by inhibiting the expression of 
p21 51 and enhances c-MYC-mediated epithelial-mesenchymal transition of a colon 
tumor cell line 52. Because c-MYC is absolutely necessary for activation and proliferation 
of lymphocytes, we suspected that AP4, as an inducible target of c-MYC, also plays a 
role during adaptive immune responses.     
 
1.4 Conclusions 
 The mechanisms by which early activation programs are established during 
lymphocyte priming have been studied in details. How these programs are maintained 
over time in proliferating lymphocytes is less understood. Key transcription factors, 
including Myc, Batf and Irf4 are rapidly induced after activation in both CD8 T cells 53, 54, 
55 and GC B cells 45, 46. Deficiencies in any one of these genes result in early defects in 
CD8 T cell clonal expansion 54 53, with Myc ablation showing the most severe phenotypes 
presumably because its master regulator role in initiating general activation programs. 
These data indicate that Myc, Batf, and Irf4 play non-redundant roles in promoting the 
initial expansion of CD8 T cells. None of the three transcription factors, however, persist 
throughout the entire course of clonal expansion. Thus, it remains unclear how CD8 T 
cells continue to expand in the later phase of the immune response. Similarly, Myc, Batf, 
and Irf4 expression are restricted to recently selected cells in the GC, and are 
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downregulated when selected cells proliferate in the DZ. In this study, we identified the 
novel transcription factor AP4, as a key regulator that maintains rapid proliferation of 
lymphocytes after the initial expansion upon activation. In Chapter 2, we demonstrated 
the critical requirement for AP4 in maximizing CD8 T cell clonal expansion and host 
protection from lethal challenge by the neurotropic human pathogen, West Nile virus. In 
Chapter 3, we extended our findings to explain how selected GC B cells undergo 
continued proliferation in the DZ after receiving help signals from TFH in the physically 
separated LZ. The significance of AP4-dependent GC expansion was highlighted by the 
finding that mice lacking AP4 in B cells failed to generate high quality antibody response 
that helps resolve chronic viral infection. Mechanistically, AP4 maintains the 
transcription of activation signature genes induced by c-MYC, thereby sustaining 
proliferation and activation of lymphocytes. 
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Figure 1.1. Sequential activation of transcription factors programs effector CD8 T 
cell responses. a, A schematic diagram showing expansion kinetics of antigen-specific 
CD8 T cells and kinetics of pathogen clearance during acute infection. Priming of CD8 T 
cells in the early phase of infection initiates sustained clonal expansion and effector 
differentiation over a course of week, followed by massive contraction, leaving behind a 
population of memory cells. During acute responses, pathogen is eradicated in the 
lymphoid organ by days 4 to 5 after infection, before the peak of CD8 T cell number on 
day 7. b, Stage-specific activation of distinct transcription factors. Myc, Irf4, and Batf are 
induced early after priming and regulate initial expansion of CD8 T 
cells. Tbx21, Prdm1, Id2, and Zeb2 upregulation is delayed, but essential for proper 
differentiation into effector cells. c, Distinct environmental cues program CD8 T cell 
response by inducing transcription factors. 
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Figure 1.2. Transient interaction with T cells in the LZ potentiates expansion of 
selected GC B cells in the DZ. A schematic diagram showing spatial separation of 
selection events and proliferation of selected cells in the germinal center (GC). In the 
light zone (LZ), GC B cells capture antigen, internalize, and present to cognate follicular 
helper T cells (TFH) and receive help signals through CD40 ligation and cytokine 
receptors. Selected GC B cells migrate to the dark zone (DZ) and undergo rounds of 
proliferation as well as somatic hypermutation. Daughter cells re-enter the LZ to test their 
mutated B cell receptor for antigen capture. Enhanced antigen presentation by B cells 
through DEC205-mediated antigen delivery activates T cells to produced elevated level 
of cytokines. This in turn promotes B cells to increase proliferation in the DZ.  
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Figure 1.3. Domain structure of the AP4 protein. AP4 belongs to the basic helix-loop-
helix (bHLH) transcription factor super family, sharing a domain homology with other 
bHLH family members. The bHLH region contains conserved basic amino acid residues 
(shown in red) and two helices that facilitate binding to DNA with the consensus motif, 
CAGCTG. Unlike most bHLH factors, AP4 also contains two additional leucine rich 
(LR) domains that are required for homodimerization. The C-terminal poly-glutamine 
domain is hypothesized to have transactivation function, but this remains to be tested. 
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CHAPTER 2: 
c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ 
T cells. 
 
 
The contents of this chapter have been previously published in Nature Immunology. 
Chou C, Pinto AK, Curtis JD, Persaud SP, Cella M, Lin CC, Edelson BT, Allen PM, 
Colonna M, Pearce EL, Diamond MS, Egawa T. c-Myc-induced transcription factor AP4 is 
required for host protection mediated by CD8+ T cells. Nat Immunol. 2014 Sep;15(9):884-93 
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2.1 ABSTRACT 
Although cMyc is an essential transcription factor that establishes a metabolically active 
and proliferative state in T cells after antigen priming, its expression is transient. To date, it 
remains unknown how T cell activation is maintained after cMyc down-regulation. Here, we 
identify AP4, encoded by the gene Tfap4, as the transcription factor that is induced by cMyc and 
sustains activation of antigen-specific CD8+ T cells. Despite normal priming, Tfap4–/– CD8+ T 
cells fail to continue transcription of a broad range of cMyc-dependent targets necessary for 
sustained proliferation. Mice lacking AP4 specifically in CD8+ T cells showed enhanced 
susceptibility to West Nile virus infection. Genome-wide analysis suggests that many activation-
induced metabolic genes are shared targets of cMyc and AP4. Thus, AP4 maintains cMyc-
initiated cellular activation programs in CD8+ T cells to control microbial infections. 
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2.2 INTRODUCTION 
Protective immunity by CD8+ T cells is critical for host defense against many pathogens 
that cause death or chronic infection. During an acute infection by a virus or intracellular 
bacterium, antigen (Ag)-specific CD8+ T cells are primed by signals through the T cell receptor 
(TCR), co-stimulatory molecules and cytokine receptors and undergo rapid expansion, effector 
differentiation, and memory cell formation1, 2. In the priming phase, activated CD8+ T cells grow 
in size by increasing global gene transcription and protein translation, and enter the cell cycle3. 
Activated T cells utilize aerobic glycolysis pathways to produce the energy and materials for 
biosynthesis that enables rapid cell division and enhanced cytokine expression4, 5, 6, 7. Previous 
studies established that the transcription factor cMyc is essential for the initiation of global 
cellular activation in activated lymphocytes, as well as other rapidly proliferating cells, including 
cancers and embryonic stem cells8, 9, 10, 11. cMyc is induced by signals through the TCR and IL-2 
receptor (IL-2R)12 and is essential for activation of glycolysis and other metabolic programs. 
cMyc-deficient T cells fail to increase their size and glycolytic activities upon activation13. 
During acute infection, CD8+ T cell expansion persists even after levels of Ag and 
inflammation wane3. While this persistent proliferation may be driven by residual Ag on Ag-
presenting cells (APCs), other evidence suggests that CD8+ T cells, once optimally primed, 
continue to proliferate after levels of Ag and cytokines diminish to sub-optimal concentrations or 
in the absence of Ag in vitro and in vivo14, 15, 16, 17. Expression of cMyc is rapidly induced in 
activated T cells9, 13. Its expression, however, is transient and does not persist throughout the 
duration of T cell expansion9, 18. These findings suggest that other transcription factors maintain 
cMyc-initiated global cellular activation to maximize clonal expansion and effector 
differentiation of T cells during acute responses to pathogen infection. 
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We hypothesized that TCR and cytokine receptor signals during the early stage of 
pathogen infection induce transcription factors, which program CD8+ T cells for a durable 
response. Among the multiple cytokines established as important for CD8+ T cell immune 
responses, IL-2 sustains clonal expansion in vitro and possibly, in vivo19, 20, 21 as well as 
differentiation into effector cells20, 22, 23. In this study, we identified AP4 as a transcription factor 
regulated by TCR and IL-2R signals and demonstrated that AP4 sustains proliferation of Ag-
specific CD8+ T cells in a cell-autonomous manner in acute infection models in vivo. Whereas 
CD8+ T cells lacking AP4 were primed normally and initiated rapid proliferation, they failed to 
sustain clonal expansion compared to control wild-type (WT) cells, leading to a substantial 
reduction in clonal frequency at the peak of response. Although AP4 was dispensable for 
clearance of pathogens in the spleen, mice lacking AP4 specifically in CD8+ T cells failed to 
control infection of West Nile virus (WNV) in the central nervous system, which requires 
sustained antigen-specific CD8+ T cell effector responses for host-mediated clearance and 
survival. Finally, our data suggest that AP4 is necessary to sustain global cellular activity, 
including transcriptome amplification and aerobic glycolysis initiated by cMyc, through 
regulation of a substantial proportion of cMyc target genes. Thus, our data establish that AP4 
regulates the magnitude of acute CD8+ T cell responses to control microbial infection. 
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2.3 RESULTS 
Regulation of AP4 by signaling via the TCR and IL-2R 
Using microarray analysis, we identified ~70 transcription factors whose expression 
changed by greater than 1.8-fold in CD8+ T cells following neutralization of IL-2 (Fig. 1a). In 
addition to previously known IL-2-regulated genes, including Bcl6 and Eomes23, we identified 
Tfap4, which encodes AP4, as a gene that required IL-2 receptor (IL-2R) signaling for sustained 
expression. AP4 is a basic helix-loop-helix protein that regulates viral gene transcription and Cd4 
gene repression in immature thymocytes and CD8+ T cells24, 25, 26. Although AP4 mRNA 
expression was reduced only modestly (2-fold, P < 0.05) upon withdrawal of IL-2 (Fig. 1b), its 
protein expression was substantially diminished (Fig. 1c), suggesting that signals through IL-2R 
are required for sustained AP4 expression at both transcriptional and post-transcriptional levels. 
As retrovirus-driven AP4 expression also required continuous IL-2R stimulation (Fig. 1d), AP4 
protein expression appears regulated predominantly at the post-transcriptional level. The half-life 
of AP4 protein was two to three hours under permissive (+IL-2) or non-permissive (+ anti-IL-2 
neutralizing mAb) conditions (Fig. 1e), with its degradation mediated by the ubiquitin-
proteasome pathway (Fig. 1f). AP4 protein expression was sustained by TCR stimuli or other 
gamma chain cytokines (IL-7 and IL-15) but not by IL-12 or type I interferons (Fig. 2a,b). These 
results suggest that a common pathway converging from TCR and IL-2Rγ chain signaling 
sustains AP4 protein expression. To test this hypothesis, we treated CD8+ T cells with small 
molecule inhibitors of relevant signaling pathways in the presence of TCR or IL-2R signals. 
Both MEK and p38 MAPK inhibitors U0126 and SB203580, respectively, attenuated the 
accumulation of AP4 protein in the presence of TCR or IL-2R stimulation (Fig. 2c). To validate 
the roles of TCR and IL-2R in sustained AP4 expression in vivo, we examined AP4 levels in Ag-
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specific CD8+ T cells during acute infection with the Armstrong strain of lymphocytic 
choriomeningitis virus (LCMV-Arm) (Fig. 3a). AP4 protein was expressed highly in CD8+ T 
cells on days 4 and 5 after infection and the level declined substantially as T cell clonal 
expansion slowed on day 6. By day 7 after infection, AP4 protein expression was abolished and 
correspondingly, Ag-specific T cells showed markedly reduced proliferation. In activated CD8+ 
T cells on day 4.5 after LCMV-Arm infection, AP4 protein was detected specifically in CD25+ 
cells, which receive TCR and/or IL-2R stimulation, but not in CD25– cells, despite similar 
mRNA levels in both subpopulations (Fig. 3b). Furthermore, Ag-specific CD8+ T cells lacking 
CD25/IL-2Rγ expressed reduced, yet still substantial, amounts of AP4 protein four days after 
LCMV-Arm infection (Fig. 3c). We conclude that AP4 is regulated post-transcriptionally in 
CD8+ T cells during their response to pathogens via signaling through TCR and IL-2R in vitro 
and in vivo. 
 
CD8+ T cell population expansion requires AP4 
To assess the function of AP4 in immune responses, we infected Tfap4–/– (ref. 24) and 
congenic wild-type (WT) C57BL/6 mice with LCMV-Arm and examined expansion and 
differentiation of CD8+ T cells. At the peak of acute response in Tfap4–/– mice, the total number 
of CD8+ T cells was reduced by ~3-fold (P < 0.0001), and the number of KLRG1+ terminally 
differentiated CD8+ T cells1 was reduced by 8-fold (P < 0.0001) compared to WT mice (Fig. 
4a,c). T cells specific for the LCMV GP33 epitope also were decreased by 5-fold (P < 0.0001) 
and, among them, KLRG1+ terminal effector cells were diminished by 8-fold (P < 0.0001) in 
Tfap4–/– compared to WT mice (Fig. 4b,d). To determine whether the requirement for AP4 is 
CD8+ T cell-intrinsic, we deleted a loxP-flanked conditional Tfap4 allele specifically in CD8+ T 
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cells using a CD8-Cre transgenic deleter27 (Fig. 5); in these mice, AP4 deletion occurs after 
thymic selection because a Cre transgene is expressed under the control of a Cd8a enhancer 
activated only after thymic selection. We observed a similar reduction in numbers of polyclonal 
and GP33-specific CD8+ T cells and KLRG1+ CD8+ T cells in Tfap4–/– and CD8-Cre+ Tfap4F/F 
mice (Fig. 6). These results indicate that the requirement for AP4 is CD8+ T cell-intrinsic and 
that diminished clonal expansion of Tfap4–/– CD8+ T cells is not due to developmental defects in 
the thymus. CD8+ T cell clonal expansion and effector differentiation also were reduced in 
Tfap4–/– mice infected with the intracellular bacterium Listeria monocytogenes expressing 
ovalbumin (Lm-Ova) (Fig. 7). Memory cells were generated and maintained comparably 
between Tfap4–/– and WT mice following acute infection with LCMV-Arm or Lm-Ova. Numbers 
of GP33-specific CD8+ T cells in the spleen were comparable between Tfap4–/– and control WT 
mice (Fig. 8a,b), and frequencies of GP33-specific memory CD8+ T cells in peripheral blood 
also were similar in Tfap4–/–, CD8-Cre+ Tfap4F/F and control WT mice 60 days after LCMV-Arm 
infection (Fig. 8c). Frequencies of Ova-specific CD8+ T cells in the spleen also were comparable 
between Tfap4–/– and control WT mice 45 days after Lm-Ova infection (Fig. 8d). However, 
Tfap4–/– memory T cells failed to expand efficiently upon secondary challenge (Fig. 9). The 
numbers of Ag-specific CD8+ T cells in the spleen after re-infection with LCMV-Arm or Lm-
Ova were reduced by 4-fold and 8-fold, respectively. Thus, AP4 is essential for expansion of Ag-
specific CD8+ T cells both in primary and recall responses. 
 
AP4 sustains CD8+ T cell clonal expansion 
To compare expansion of Tfap4–/– and WT CD8+ T cells in an identical environment, we 
generated Tfap4–/– mice expressing a Vα2+ Vβ8+ TCR transgene specific for LCMV GP33 (P14) 
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(ref. 28). A 1:1 mixture of Vα2+ Vβ8+ naive CD8+ T cells from Tfap4–/– (Thy1.2/CD45.2) and WT 
(Thy1.1/CD45.2) P14 TCR transgenic mice was adoptively transferred to congenic host CD45.1 
mice. Prior to infection with LCMV-Arm, the ratio of Tfap4–/– to WT P14 T cells was 
approximately 1:1 in the spleen (Fig. 10a). This result is consistent with comparable frequencies 
of CD8+ T cells in various tissues in Tfap4–/– mice under steady state conditions compared to 
control WT mice (Fig. 10b), and indicates that AP4 is dispensable for survival of CD8+ T cells 
and their homing to the spleen and peripheral tissues. To determine whether AP4 was required 
for priming and initial proliferation of P14 T cells, we labeled donor P14 T cells with 
carboxyfluorescein succinimidyl ester (CFSE) prior to adoptive transfer. On day 3 after LCMV-
Arm infection, both Tfap4–/– and WT P14 T cells diluted CFSE to undetectable levels (Fig. 10c), 
which was consistent with the comparable numbers of P14 T cells recovered from the spleen and 
the frequencies of bromodeoxyuridine (BrdU)+ cells following a pulse labeling (Fig. 10d-g). 
These results establish that AP4 is not required for priming and initial proliferation of CD8+ T 
cells during the acute Ag-specific response. Despite the rapid early expansion, the absolute 
number of Tfap4–/– donor cells was substantially reduced compared to WT donor cells at the 
peak of the response after LCMV-Arm infection (P < 0.0001 on day 7, Fig. 10d-f). Control P14 
T cells continued to expand until day 7 post-infection (Fig. 10d). While Tfap4–/– cells continued 
to proliferate until day 7 post-infection, they failed to maintain rapid proliferation rates, as 
judged by frequencies of BrdU-labeled cells on day 4 and later (Fig. 10g). Because CD8+ T cells 
divide as many as 6-7 times per day during a response to acute infection29, the effect of mild but 
continued reduction in BrdU incorporation rates could result in a greater than 10-fold reduction 
in clonal expansion of Tfap4–/– donors compared to control WT cells over 4 days (Fig. 10e,g). 
We also observed reduced clonal expansion, BrdU incorporation, and activation of the mTOR 
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pathway of Tfap4–/– OT-I T cells following Lm-Ova infection (Fig. 11a-c). We did not, however, 
observe changes in the frequency of Annexin V+ cells between Tfap4–/– and WT P14 T cells on 
day 6 after LCMV-Arm infection (Fig. 11d,e). Moreover, ratios between Tfap4–/– and WT P14 T 
cells were similar in the spleen, peripheral blood, mesenteric lymph nodes, lung, liver and kidney 
7 days after LCMV-Arm infection (Fig. 11f), suggesting no substantial difference in trafficking 
of Ag-specific T cells during the acute response to LCMV infection. Furthermore, Tfap4–/– OT-I 
T cells proliferated at similar rates with co-cultured WT OT-I T cells when they were stimulated 
with various concentrations of Ova peptide for 3 days (Fig. 12a). However, Tfap4–/– cells were 
outcompeted in numbers by co-cultured WT cells and failed to blast when kept for a longer 
duration with low concentration of peptide (Fig. 12a,b). Because the induction of IFN-γ 
expression by Tfap4–/– and WT OT-I T cells in response to Ag was comparable (Fig. 12c), it is 
unlikely that AP4 regulates TCR sensitivity per se. These results suggest that AP4 is required for 
sustained T cell proliferation after TCR stimulation. 
 
Protection against infection with WNV requires AP4 
We next tested the contribution of AP4 to CD8+ T cell-mediated protection against a lethal 
viral infection. For this purpose, we utilized the mouse model of WNV infection. WNV is a 
virulent zoonotic RNA virus that causes fatal encephalitis in humans and many strains of inbred 
mice30, 31. CD8+ T cells are required for clearance of the virus in both the peripheral and central 
nervous system (CNS) tissue compartments32. To determine whether AP4 was required for 
protection against WNV infection in a CD8+ T cell-dependent manner, we infected CD8-Cre+ 
Tfap4F/F mice and age-matched control Cre– Tfap4F/F mice with WNV (New York 1999 strain). 
While the majority of control Cre– Tfap4F/F mice survived as expected (compared to WT 
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C57BL/6 mice33), all CD8-Cre+ Tfap4F/F mice died from WNV between days 8 and 13 (Fig. 13a, 
P < 0.0001), which was similar to the lethality observed in Cd8a–/– or MHC class Iα–/– mice32. 
CD8-Cre+ Tfap4F/F mice sustained higher viral loads in the brain compared to control mice on 
day 9 post-infection (Fig. 13b, P < 0.05), indicating that AP4 expression in CD8+ T cells is 
essential for the control of WNV in the CNS. Consistent with our results with LCMV-Arm and 
Lm-Ova infection models, Ag-specific CD8+ T cell expansion was diminished in WNV-infected 
Tfap4–/– and CD8-cre+ Tfap4F/F mice compared to control WT mice in the spleen on day 7 after 
infection (Fig. 14). However, AP4 was dispensable for control of WNV infection in the spleen 
(Fig. 13c). Consistent with this observation, no differences in LCMV-Arm or Lm-Ova burden 
were detected in the spleen and peripheral tissues following acute infection (Fig. 15). These 
results indicate that AP4 is dispensable for control of LCMV-Arm and Lm-Ova in the peripheral 
tissues and WNV in the spleen presumably because clearance of these pathogens begins at an 
early phase of the acute response. In contrast, control of WNV in the CNS requires a more 
prolonged CD8+ T cell response. Thus, AP4-mediated sustained activation of Ag-specific CD8+ 
T cells may be critical for control of certain CNS pathogens. These results also establish that 
AP4 is required for host protection against WNV infection in the CNS in a CD8+ T cell-intrinsic 
manner.  
 
AP4 sustains T cell activation 
Upon priming, T cells expand in size prior to cell division and activate an aerobic 
glycolysis program5, 34. The transcription factor, cMyc, activates glycolysis and amplifies global 
gene transcription and protein synthesis in activated lymphocytes9, 13. cMyc mRNA and protein 
expression was induced rapidly after TCR stimulation, followed by AP4 mRNA up-regulation in 
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activated CD8+ T cells (Fig. 16a,b). AP4 expression in activated CD8+ T cells lacking Myc was 
absent at both protein and mRNA levels, indicating that cMyc is essential for AP4 up-regulation 
(Fig. 16c,d). In agreement with a prior study using human cancer cell lines35, cMyc binds to the 
Tfap4 locus in activated CD8+ T cells (Fig. 16e), further suggesting that AP4 expression is 
augmented by cMyc through direct binding in activated CD8+ T cells. Given these results, we 
hypothesized that AP4 and cMyc might cooperate to regulate cell growth associated with T cell 
activation. In contrast to defective cell growth and metabolic changes in Myc-deficient T cells13, 
activated Tfap4–/– CD8+ T cells underwent normal blast development accompanied by active 
glycolysis in vitro (Fig. 17a-c). Moreover, Tfap4–/– and WT Ag-specific T cells were of 
comparable size three days after LCMV-Arm or Lm-Ova infection in vivo (Fig. 18a-c). 
Differences in gene expression between Tfap4–/– and control WT CD8+ T cells either 3 days after 
anti-CD3 and anti-CD28 antibody-mediated activation in vitro or 2 days after Lm-Ova infection 
in vivo were substantially smaller compared to that observed at later time points with few genes 
relevant to T cell activation or metabolisms altered in culture or at the early time point (Fig. 18d). 
These results suggest that AP4 is dispensable for establishment of the cMyc-dependent cellular 
response to T cell activation. However, at later time points (days 4 and 6), Tfap4–/– P14 or OT-I 
CD8+ T cells were smaller in size than control cells (Fig. 18a-c). The size difference between 
Tfap4–/– and control cells coincided with cMyc down-regulation in Ag-specific CD8+ T cells 
after Lm-Ova infection (Fig. 19). A small fraction of OT-I T cells primed by Lm-Ova infection 
in vivo started to up-regulate cMyc protein as determined using the Myc-GFP fusion protein 
knock-in allele36. Activated OT-I T cells uniformly expressed Myc-GFP as they expanded in size 
until day 3 in vivo (Fig. 19a). Although the activated OT-I cells continued to proliferate and only 
slowly reduced their size on day 4 post-infection, Myc-GFP was down-regulated approximately 
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by 14-fold compared to day 2 and 10-fold compared to day 3 (Fig. 19). In comparison, AP4 
expression in WT cells also was up-regulated as the cMyc level increased after priming and then 
began to decline on day 3 (Fig. 19a). In contrast to the rapid decay of cMyc, AP4 protein 
expression was still detected on day 4 (Fig. 19). Although the methods used to quantitate cMyc 
and AP4 levels are not directly comparable, these results suggest that AP4 expression persists 
longer than cMyc. In addition to the cell size, total RNA content per cell also was reduced in 
Tfap4–/– OT-I T cells compared to WT cells on day 4 (Fig. 20a, P < 0.05). Furthermore, basal 
aerobic glycolysis and the maximum glycolytic capacity in the presence of oligomycin, as 
measured by extracellular acidification rates (ECAR)37 were significantly reduced in Tfap4–/– 
OT-I cells compared to WT cells recovered from the same recipient mice infected with Lm-Ova 
on days 4 and 6 after infection (Fig. 20b, P < 0.0001). Consistent with the metabolic 
measurements, expression of key glycolytic enzymes normalized to a per cell basis by using 
spiked-in control RNA38 was reduced (1.5 to 2.2-fold, P < 0.05) in Tfap4–/– CD8+ T cells 
compared to WT cells on day 4 post-infection (Fig. 20c). The difference was enhanced on day 6 
(4.0 to 5.2-fold, P < 0.05), indicating that AP4 is required for sustained expression of genes 
regulating the glycolytic activity (Fig. 20c). These results suggest that AP4 sustains T cell 
activation after cMyc down-regulation as reflected by glycolytic rates and cell sizes. 
 
AP4 sustains c-Myc-initiated global cellular activity 
To further define how AP4 is required for maintenance of the activation-induced global 
cellular activity established by early expression of cMyc, we analyzed gene expression programs 
of in vivo-activated Tfap4–/– and WT CD8+ T cells using microarray transcriptional profiling at 
the time point in which we detected cell size differences. For accurate assessment of gene 
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expression on a per cell basis, we spiked the cellular RNA with a mixture of control RNAs in 
proportion to the cell number prior to reverse transcription and then profiled cell number-
normalized gene expression in Tfap4–/– and control WT OT-I T cells9, 10. Consistent with the 
smaller size and reduced RNA content of Tfap4–/– cells compared to control WT OT-I T cells, 
global gene expression in Tfap4–/– cells, as determined by the slopes of scatter plots, was reduced 
(P < 0.01) compared to control WT cells (Fig. 21a,b). We identified 1,784 genes that showed 
more than 1.8-fold difference between Tfap4–/– and WT OT-I cells 4 days after Lm-Ova infection. 
A pathway analysis highlighted an enrichment of the 1,784 genes in those related to metabolism, 
transcription and translation (Fig. 21c). To determine whether these differentially expressed 
genes were directly regulated by AP4, cMyc or both, we performed chromatin 
immunoprecipitation analysis (ChIP) using anti-AP4 and anti-cMyc antibodies and profiled AP4- 
and cMyc-bound genes in activated CD8+ T cells that express both AP4 and cMyc (Fig. 22). 
Unbiased analysis of 7,000 peaks of AP4 and cMyc that were selected as statistically significant 
(P < 1.5e-65 for AP4 and P < 5e-9 for cMyc based on peak-calling in Homer39) remarkably 
revealed that more than 50% of AP4 and cMyc peaks overlapped at the gene level (Fig. 23a). 
While transcription factor binding does not necessarily establish biological significance, we 
further examined overlaps between the AP4-cMyc co-bound genes and the 1,784 differentially 
expressed genes. Among the 1,784 genes, nearly a quarter (479 genes) were bound by both AP4 
and cMyc (Fig. 6a), AP4-cMyc co-bound genes were highly enriched in those annotated in 
pathways related to metabolism, general transcription and translation (Fig. 21c marked in red 
and Fig. 22e). Furthermore, the majority of these 479 genes were up-regulated on day 2 after 
Lm-Ova infection in WT OT-I cells that express both cMyc and AP4, remained highly expressed 
on day 4 when cMyc levels waned, and were eventually down-regulated on day 6 following the 
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decline of AP4, suggesting that AP4 regulated these shared cMyc-AP4 target genes as expression 
of cMyc decayed (Fig. 23b). Because expression of these 479 genes was not different between 
Tfap4–/– and WT OT-I T cells on day 2 post-infection (Fig. 18d), the altered expression of these 
genes on day 4 may explain the phenotypes observed in the Tfap4–/– CD8+ T cells. Since the 
ChIP-seq analysis was performed using cells which co-expressed AP4 and cMyc, it remained 
unknown whether AP4 still bound to these loci after cMyc down-regulation in Ag-specific CD8+ 
T cells in response to acute infection. Therefore, we purified CD25+ P14 T cells 5 days after 
LCMV-Arm infection and examined AP4 binding by ChIP assays. As expected, cMyc was 
down-regulated on day 5 after LCMV-Arm infection compared to earlier time points (Fig. 23c). 
Even after the cMyc decay, the majority of previously identified AP4-c-Myc-bound loci retained 
AP4 binding, as assessed by anti-AP4 ChIP (Fig. 23d). These results suggest that cMyc-induced 
AP4 expression is required for sustained transcription of genes associated with CD8+ T cell 
activation and clonal expansion, including metabolism, general transcription and translation 
pathways through direct binding, after cMyc is down-regulated.  
 
AP4 supplements c-Myc function 
Our data thus far suggest that AP4 and cMyc have overlapping functions in activated in 
CD8+ T cells. To determine whether AP4 is dispensable if cMyc expression is sustained, we 
retrovirally expressed a stabilized form of cMyc (MycT58A mutant40, 41) in Tfap4–/– CD8+ T cells 
in our in vitro culture system that recapitulates the cell size difference between Tfap4–/– and WT 
cells (Fig. 24a). In this assay, we optimally primed Tfap4–/– and WT OT-I cells with anti-CD3 
and anti-CD28 antibodies for two days and transferred the activated OT-I cells to a culture of 
irradiated splenocytes pulsed with a low concentration of OVA peptide for 24 h. Ectopic 
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expression of MycT58A or AP4 itself in Tfap4–/– CD8+ T cells rescued the cell size defects under 
conditions of threshold Ag stimulation (Fig. 24b,c). In addition to cell size, MycT58A or AP4 
restored glycolysis, BrdU incorporation, and expression of a subset of cMyc-AP4-cobound genes 
that were down-regulated in Tfap4–/– CD8+ T cells on day 4 post Lm-Ova infection in vivo (Fig. 
24d-f). To determine whether MycT58A expression restored clonal expansion of Tfap4–/– CD8+ T 
cells in vivo, we adoptively transferred cMyc- or AP4-transduced naive Tfap4–/– OT-I T cells and 
control WT OT-I T cells into congenic hosts that were subsequently infected with Lm-Ova. 
Although retroviral expression of AP4 in Tfap4–/– OT-I T cells fully restored clonal expansion 
and KLRG1 expression, MycT58A expression only partially restored clonal expansion (Fig. 24g-i). 
Nevertheless, MycT58A expression increased cell sizes and BrdU incorporation of Tfap4–/– OT-I 
cells comparably to AP4 ectopic expression (Fig. 24j,k). These results suggest that AP4 and 
cMyc have partially overlapping functions in regulating T cell activation and that a temporal 
switch from cMyc to AP4 is necessary for optimal CD8+ T cell clonal expansion. 
To determine whether ectopic expression of AP4 correspondingly rescues defective 
proliferation or cell growth of Myc-deficient cells, we retrovirally expressed AP4 in CD8+ T cells 
in which cMyc was deleted by tamoxifen-inducible Cre recombinase fused to the estrogen 
receptor ligand binding domain (CreERT2)42. To express AP4, we infected CD8+ T cells from 
ROSA26-CreERT2 MycF/F and control Cre– MycF/+ (Myc+/+) or ROSA26-CreERT2 Myc+/+ mice 
with retrovirus following stimulation with anti-CD3 and anti-CD28 antibodies for 24 h. The 
activated T cells were treated with 4-hydroxytamoxifen (4OHT) under resting conditions for two 
days, and proliferation and gene expression of transduced cells were tested upon re-stimulation 
with anti-CD3 and anti-CD28 antibodies (Fig. 25a). We confirmed the absence of cMyc 
expression and ectopic expression of AP4 at the protein level before and after TCR re-
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stimulation and at the mRNA level after re-stimulation (Fig. 25b,c). Retroviral cMyc expression 
rescued, albeit partially, proliferation and cell size increase of Myc–/– cells (Fig. 25d). The 
incomplete rescue by retroviral cMyc expression was probably caused by a delay in cMyc 
expression from the retrovirus immediately after TCR stimulation compared to that from the 
endogenous locus (Fig. 25c). In contrast, AP4 ectopic expression, which was detected already in 
cells prior to TCR stimulation (Fig 25b), failed to rescue proliferation or cell size increases of 
Myc–/– cells (Fig. 25d). Consistent with these results, gene expression profiling by microarray 
revealed little difference between AP4- and empty virus-transduced Myc–/– cells and partially 
rescued gene expression by cMyc transduction (Fig. 25e). These results indicate that AP4 
requires prior expression of cMyc to mediate its effects. Thus, AP4 functionally supplements 
cMyc activity to prolong global cellular metabolism and maximize clonal expansion of CD8+ T 
cells.  
  
	  
	  
35 
2.4 DISCUSSION 
Our study defines a critical role of AP4 in regulating clonal expansion and antiviral 
function of CD8+ T cells in vivo. Our data indicate that AP4 regulates the maintenance phase but 
not the initiation of rapid clonal expansion after antigen priming. Although AP4 is rapidly 
induced after priming of T cells in a cMyc-dependent manner, it is not necessary for initial cell 
growth, induction of glycolytic activity and proliferation during the early phase of acute CD8+ T 
cell responses presumably because cMyc is highly expressed during this phase. Ag-specific 
CD8+ T cells rapidly proliferate and control LCMV-Arm or Lm-Ova infection in an AP4-
independent manner as clearance of these microbes occurs rapidly and does not require full 
clonal expansion of Ag-specific CD8+ T cell. This also is consistent with the normal thymocyte 
cellularity in Tfap4–/– mice24, because cMyc is sufficient for preTCR-driven thymocyte 
proliferation in the late double-negative stage that is relatively short compared to Ag-specific 
CD8+ T cell proliferation in acute responses. In contrast, AP4 expression in CD8+ T cells is 
essential for protection against neurotropic WNV infection likely because control of WNV in the 
CNS requires sustained activity and proliferation of Ag-specific CD8+ T cells. The increased 
susceptibility could be due to reduced clonal expansion leading to fewer cells reaching the tissue 
(quantitative defects) or to defective differentiation as effector cells (qualitative defects). 
Reduced clonal expansion could result from defective proliferation, increased cell death, or  a 
migration defect. Our data suggest that AP4 is required predominantly for sustained rapid 
proliferation. Because CD8+ T cells proliferate rapidly during their acute response to microbial 
infection over several days, even modest reductions in the rate of proliferation can translate into 
substantial reductions in the magnitude of clonal expansion. Because clearance of WNV in the 
spleen and that of LCMV-Arm or Lm-Ova in multiple peripheral tissues was comparable 
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between AP4-deficient and -sufficient mice, it is unlikely that the killing activity or trafficking is 
inherently compromised in the absence of AP4. 
Mechanistically, there are two major possible interpretations of AP4 function in the 
regulation of acute CD8+ T cell responses. One interpretation is that AP4 directly regulates genes 
that are essential for T cell activation. Identification of AP4 and cMyc–bound genes in activated 
CD8+ T cells revealed substantial overlap between targets of the two transcription factors. 
Combined analysis of binding targets and genes down-regulated in AP4-KO cells (1,784 genes) 
showed that approximately a quarter of these differentially expressed genes were shared binding 
targets of AP4 and cMyc. However, when we examined 85 genes out of 1,748 genes that were 
annotated in pathways for metabolism, general transcription and translation, AP4 and cMyc co-
binding was further enriched (~75%). Although transcription factor binding to the genome can 
be promiscuous and does not always have biological significance, this considerable enrichment 
of AP4 and Myc co-targets in the set of genes relevant to T cell activation also supports the 
hypothesis that AP4 contributes to maintenance of expression of these genes. AP4 was 
dispensable for initial up-regulation of these genes upon T cell priming because these pathways 
already are activated by cMyc. In contrast, after cMyc down-regulation during the late phase of 
the acute response, the contribution of AP4 in the regulation of these genes may become critical 
for the maintenance of expression. AP4 binds to these loci not only in CD8+ T cells activated in 
vitro, but also in CD8+ T cells activated in vivo after cMyc expression wanes. With respect to 
cellular carbohydrate metabolism, the differentially expressed genes were enriched for enzymes 
but not transporters, suggesting the altered glucose utilization in Tfap4–/– CD8+ T cells results 
from defective glycolysis rather than its uptake. In contrast, since many genes encoding enzymes 
for glutaminolysis, amino acid transport, and components of protein translation machinery were 
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down-regulated in Tfap4–/– CD8+ T cells, the smaller cell size likely reflects reduced protein 
synthesis from defects at multiple stages. Since expression of Hif1a and components of the 
mTOR pathway was not reduced, the diminished activity of the mTOR pathway may be 
regulated indirectly by AP4.  
As an alternative explanation, AP4 might indirectly sustain activity of Ag-specific T cells 
through sensitizing T cell activation by TCR or cytokine receptor signals independent of cMyc. 
Sensitivity to extrinsic stimuli may not be critical for initial activation of CD8+ T cells in vitro or 
Ag-specific CD8+ T cells during the early phase of acute responses in vivo in the presence of 
abundant Ag or inflammatory cytokines. However, it may be essential in the late phase of the 
CD8+ T cell response in vivo due to declines in Ag and cytokine concentrations. Under these 
circumstances, Tfap4–/– cells might prematurely lose activation, which would secondarily cause 
reduced metabolic activity and clonal expansion. A previous study using Listeria expressing 
altered Ova peptide ligands demonstrated that duration and magnitude of acute CD8+ T cell 
responses in vivo are determined by affinity between TCR and peptide ligands43. Compared to 
Lm-Ova expressing the canonical SIINFEKL epitope, engineered strains expressing low affinity 
variant epitopes showed a reduced magnitude of clonal expansion of OT-I T cells at the peak 
despite normal initial activation and proliferation during the early phase of acute responses. 
Although these phenotypes are similar to those in Tfap4–/– mice, there are differences. Infection 
by pathogens expressing low affinity ligands shortens the duration of clonal expansion by 
triggering earlier contraction and also generates reduced numbers of memory cells after the 
clearance of the infection43. We observed neither of these phenotypes in Tfap4–/– mice after 
infection with Lm-Ova or LCMV-Arm.  
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Although we favor the former interpretation of AP4-dependent maintenance of cMyc 
targets, the two models are not mutually exclusive. Regardless, our results indicate that cMyc-
induced AP4 expression is essential for maximal clonal expansion and sustained T cell activity in 
a temporally regulated manner. Another potential mechanism is the direct regulation of cell cycle 
by AP4. A study using colon cancer cell lines suggested that AP4 is regulated by cMyc and 
promotes cell cycle progression through direct binding to multiple CAGCTG motifs of the 
CDKN1A (p21 CIP1/WAF1) promoter35. While both AP4 and cMyc bind to the Cdkn1a locus, 
Cdkn1a mRNA expression was not different between Tfap4–/– and WT CD8+ T cells. Because 
our data indicate that AP4 is dispensable for cell cycle entry of activated T cells when cMyc is 
expressed, it is unlikely that reduced proliferation of Tfap4–/– CD8+ T cells is caused by 
derepression of Cdkn1a. 
Although mechanisms by which cMyc induces expression of a large set of genes have not 
fully been elucidated, recent studies using activated lymphocytes, embryonic stem cells and 
highly proliferative cancer cells demonstrate that cMyc increases their transcription rates rather 
than simply turning-on and off target genes containing the consensus binding motif 
(“transcriptome amplification”)9, 10, 11. Our data suggests that AP4 has similar functions. While 
both cMyc and AP4 peaks are highly enriched in promoter regions, only one-third of statistically 
significant cMyc binding peaks and 60% of AP4 peaks contain the canonical E-box consensus 
motif (CACGTG for cMyc and CAGCTG for AP4), respectively. These findings suggest that 
AP4 recruitment to target sites may be mediated through protein-protein interactions with 
transcriptional activator complexes for some target genes.  
In conclusion, our study demonstrates that AP4 is a transcription factor that is critical for 
regulation of CD8+ T cell-mediated acute anti-pathogen responses by sustaining metabolic gene 
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expression in the post-Myc phase. Activated T cells utilize AP4 to maintain their activated states 
under conditions of threshold antigen or signaling for complete elimination of pathogens or 
clearance of pathogen-infected cells in non-lymphoid organs.  
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2.5 MATERIALS AND METHODS 
Mice 
Mice containing a loxP-flanked Tfap4 allele were generated in 129P2/Ola-derived E14TG2a ES 
cells essentially as described (Fig. 5a)24. Tfap4–/– mice were described previously24. Both AP4 
mutant strains were backcrossed to C57BL6 mice for more than 10 generations before 
intercrossing or breeding to other transgenic mice. cMyc-flox mice and cMyc-GFP fusion protein 
knock-in mice were described previously36, 44. C57BL6 and B6-Ly5.2 (CD45.1) mice were 
purchased from the National Cancer Institute. OT-I transgenic mice45, Tcra–/– mice46, Il2ra–/– 
mice47, ROSA26-CreERT2 (ref. 48) and B6-Thy1.1 were purchased from the Jackson Laboratory 
and P14 transgenic mice28 were purchased from Taconic. Il2ra–/– P14 T cells were collected from 
mixed bone marrow chimeric mice reconstituted with a mixture of bone marrow cells from Il2ra–
/– (Thy1.2) and WT (Thy1.1) P14 mice. CD8-Cre mice were generated previously in the C57BL6 
background27. All mice were maintained in a specific pathogen free facility at Washington 
University in St. Louis, and all experiments were performed according to the protocol approved 
by Washington University’s Animal Studies Committee. 
 
Infection Experiments  
LCMV-Arm stocks were prepared by infecting BHK cells and titering culture supernatants by 
plaque assay on Vero cells. Mice were infected with 2 x 105 plaque forming units (PFU) of 
LCMV-Arm by intraperitoneal injection. Lm-Ova was inoculated intravenously at a dose of 1 x 
104 colony-forming units (CFU). Infection with WNV (New York 1999 strain) was performed as 
previously described32. For adoptive transfer experiments, CD44– CD62L+ Vα2+ Vβ5+ OT-I or 
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CD44– CD62L+ Vα2+ Vβ8+ P14 donor T cells were purified by fluorescence activated cell sorting, 
and 5 x 105 (for day 3 analysis), 1 to 2 x 104 (for day 4 analysis), or 1 to 3 x 104 (for days 5 to 12 
analysis) cells were transferred intravenously to recipient mice one day before infection. All 
experiments using infectious agents were performed in biosafety level 2 and 3 facilities 
according to the protocols approved by Washington University Institutional Biological and 
Chemical Safety Committee. 
 
Flow Cytometry 
Single cell suspensions were prepared by disrupting spleens manually with frosted glass slides 
followed by erythrocyte lysis with ACK (Ammonium-Chloride-Potassium) solution, or by 
digesting mesenteric lymph nodes, liver, lung and kidney with collagenase B or D (Roche) 
followed by purification using Percoll gradient (GE Healthcare Life Sciences). For sorting of 
naive CD8+ T cells, splenocytes were initially depleted of B220+ cells using magnetic beads 
(Life Technologies) and then stained with monoclonal antibodies prior to sorting CD62L+ CD44– 
CD8+ CD4– cells using a FACS AriaII (BD Biosciences). For analysis, cells were stained with 
monoclonal antibodies, Db-GP33 (Beckman Coulter), or Kb-OVA single chain tetramer and 
analyzed using a FACS LSRII (BD Biosciences) with DAPI staining to exclude dead cells. Data 
were analyzed using FlowJo software (Tree Star Inc.). All antibodies were purchased from 
Biolegend. For intracellular staining for AP4, cells were fixed with 2% paraformaldehyde (PFA) 
for 10 minutes, permeabilized with ice-cold 100% methanol for 30 minutes, and then stained for 
markers with fluorochrome-conjugated monoclonal antibodies and AP4 with affinity-purified 
anti-AP4 polyclonal antibody24 at a concentration of 1.25 µg/ml and Alexa-647 conjugated anti-
	  
	  
42 
rabbit IgG secondary antibody (Cell Signaling). For detection of phosphorylated S6 (p-S6) 
ribosomal protein, cells were fixed with PFA, permeabilized with methanol, and stained for 
surface markers and p-S6 with an anti-p-S6 antibody (Cell signaling #4858P) and Alexa-647 
conjugated anti-rabbit IgG secondary antibody (Cell Signaling).  
 
BrdU labeling 
At different time points after infection mice were administered with 1 mg BrdU by i.p. injection 
two hours before euthanasia. BrdU incorporation was analyzed using an APC-BrdU Flow Kit 
(BD Biosciences) according to the manufacturer’s instruction. For proliferation assays in vitro, 
cells were cultured in media containing 10 µM BrdU for 1 hour prior to analysis.  
 
In vitro T cell stimulation 
Naive CD8+ T cells were cultured in RPMI supplemented with 10% fetal bovine serum (Life 
Technologies) in the presence of soluble anti-CD3 (145-2C11, Biolegend) and anti-CD28 (37.51, 
Bio X Cell) at 0.1 µg/ml and 1 µg/ml, respectively, unless otherwise specified, in multi-well 
tissue culture plates coated with rabbit anti-hamster IgG (MP Biomedicals). For retroviral 
transduction of activated T cells, viral supernatants were prepared by transfecting PlatE cells49 
with TransIT 293 (Mirus Bio) and primed T cells were spinoculated following overnight 
stimulation as described previously24. To retrovirally transduce CD8+ T cells without TCR 
stimulation, naive CD8+ T cells were cultured in the presence of IL-7 (10 ng/ml, Peprotech) and 
IL-15 (100 ng/ml, Peprotech) for 2 days prior to spinoculation. For IL-2 blockade, 2 µg/ml of 
anti-IL-2 (JES6-1A12, Biolegend) was added to the culture. 
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Real-time qRT-PCR 
RNA was extracted using Trizol (Life Technologies), and reverse transcribed using qScript 
supermix (Quanta Bio). Real-time qRT-PCR was performed using DyNAmo ColorFlash SYBR 
green qPCR mix (Thermofisher) and Roche LightCycler 480. Quantities of transcripts were 
normalized against 18S ribosomal RNA (rRNA) using the ΔΔCt method unless otherwise 
specified. Primer sequences are available upon request. For quantitation of gene expression 
normalized against spiked-in RNA, 1 µL of 1:1,000 diluted External RNA Controls Consortium 
(ERCC) RNA Spike-In Control Mixes (Ambion) was added to total RNA extracted from 1 x 105 
cells prior to reverse-transcription. The mixed RNA was used for reverse-transcription and real-
time PCR quantitation. The following primers were used: 18S-rRNA, 
CGGCTACCACATCCAAGGAA and GCTGGAATTACCGCGGCT;                                       
Bcl6, CCTGTGAAATCTGTGGCACTCG and CGCAGTTGGCTTTTGTGACG;                       
Eomes, ACCCAGCTAAAGATCGACCA and GACCTCCAGGGACAATCTGA;                       
Gapdh, CTCACAATTTCCATCCCAGACC and 
CATCAATGGTGCAGCGAACTTTATTGATG;          
Hif1a, CTGGAAACGAGTGAAAGGATTC and CGTAACTGGTCAGCTGTGGTAA;          
Hk2, CAACTCCGGATGGGACAG and CACACGGAAGTTGGTTCCTC;  
Hprt1, AGGTTGCAAGCTTGCTGGT and TGAAGTACTCATTATAGTCAAGGGCA;            
Il2ra, CTCACCTGGCAACACAGATG and GGCTCTGACTTTTCTAGCTTGC;  
Ldha, CTGTTGGCATGGCTTGTG and CATCATCTCGCCCTTGAGTT;  
Myc: AGTGCTGCATGAGGAGACAC and GGTTTGCCTCTTCTCCACAG;  
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Pkm2, CTGTCTGGAGAAACAGCCAAG and TCGAATAGCTGCAAGTGGTAGA;           
Slc2a1, ATGGATCCCAGCAGCAAG and CCAGTGTTATAGCCGAACTGC;  
Tfap4, GGAGAAGCTAGAGCGGGAAC and TTTTGCCGGGATGTAGAGAC;           
ERCC00108, CTATCAGCTTGCGCCTATTAT and GTTGAGTCCACGGGATAGAGTC;  
and LCMV-GP, CATTCACCTGGACTTTGTCAGACTC and 
GCAACTGCTGTGTTCCCGAAAC. 
 
Microarray Analysis 
Total RNA was extracted with a Nucleospin RNA XS extraction kit (Macherey-Nagel). 5 to 50 
ng of total RNA was amplified using PicoSL RNA amplification kit (Nugen) and biotinylated 
with Encore biotin module (Nugen). Labeled RNA was hybridized to Mouse Gene 1.0ST 
microarray (Affymetrix) according to the manufacturer’s instruction. For each experiment, RNA 
was prepared from two to three biological replicates, amplified, labeled and hybridized in a 
single experiment. Data were analyzed using Arraystar (DNA Star) with Robust Multi-array 
Average (RMA) normalization50. For spiked-in microarray analysis, ERCC RNA Spike-In 
Control Mixes were added as described above followed by RNA amplification, labeling and 
hybridization. CEL files were generated using a modified CDF file provided by Affymetrix. Data 
were initially normalized by RMA and signal intensities were further converted by formula 
obtained from linear regression of signals for spiked-in control RNA between samples. 
 
Chromatin Immunoprecipitation 
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CD8+ T cells were purified from C57BL6 mice by positive selection with FlowComp CD8 
Dynabeads (Life Technologies). Purified CD8+ T cells were stimulated with anti-CD3 and anti-
CD28 for 2 days, and fixed with 1% PFA for 10 minutes at room temperature. Chromatin 
shearing and immunoprecipitation were performed as described previously51. Anti-AP4 antibody 
was previously described24. cMyc antibody (sc-764) and anti-phosphorylated RNA polII 
antibodies (ab5095 and ab5131) were purchased from Santa Cruz and Abcam, respectively. After 
immunoprecipitation, DNA was purified with a purification kit (Sigma), and 1-10 ng of DNA 
was used for library construction followed by 50 bp single read sequencing on HiSeq2000 
(Illumina). Sequence tags were mapped onto the NCBI37/mm9 assembly of mouse genome 
using Bowtie2 (ref.52). BedGraph histograms normalized to 1 x 107 reads were generated using 
the Homer package39 (http://biowhat.ucsd.edu/homer/ngs/) and visualized in the IGV browser 
(http://www.broadinstitute.org/igv/). Peak calling was performed using Homer with a -style 
factor option. For analysis of overlapping binding targets and binding motifs, 7,000 AP4 binding 
peaks filtered by P < 1.5e-65 and 7,000 cMyc-binding peaks (P < 5e-9) were analyzed. The 
following primers were used for real-time PCR analysis: Adsl, 
GGAATAATTCTGACAGGCTGCT and GCCCTAGTGGACACTTGGAGTA;                          
Cd4 (promoter), TGGCCTTGAGCTTGTGATTTTTCT and 
GAATCAAGCTGGAGTCTGGAATGT;                                                                                              
Cd4 (silencer), TACGAAGCTAGGCAACAGAGGAAG and TGTGGTCCCGAATGCGTTT;                                                                                                                      
Eif1a, ATCACCAAACAGGCAAGATTTC and GGGTTGCCCTTTTTACATTTCT;             
Eif4a1, ACAACAGACAAGCGAAACAGG and ACATGGCCGCTTGAGAGATT;               
Gapdh, CGCGAGGCTAGAACTTCTCC and TAGTAATCCAACACCCCGACTT;                 
Hk2, AGGCCTCTTCAACACATCCTTA and GTGGGGAAGAATCCTGCTTAG;            
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Hoxa13, TTGTTTCCTGTTGGTTCCAG and AGCCCAAACTTCCCAGAGA;                            
Ldha, CTTCTGAGGCTGAGGAGCAT and CACGATGTCCCTGCAAGAGT;                      
Mthfd2, TGAGGCATTGCAGATTACCATA and CTGTCATACGAGCAGACACAGG;           
Pfkl, GGCTGTGCTTCTCTTAGAGGTC and CTATTCCTTTCTAGGCCACACG;                     
Pkm (promoter), AGCGACTCGTCTTCACTTGACT and GTTCCTGCTGCGATACCTAGAG;                                                                                                                
Pkm (intron), CTACTCAGGTTTGGAGGTGGTC and GAGATGCTCAGAGCTCCCTAGA;                                                                                                                 
Ppat, CACCCAAACACACCACATTC and CCTCTTGAGGCGTTCGATAG;                     
Shmt2, AGCAAAGAGAAGGATACCATCG and GCCTCTTTCACTCGAACTTCAC;          
Tfap4 (promoter), CTGATCAGATGTCTGTTTCAAGG and 
CGCTGCAAATAGTCCTTTGTTT;                                                                                                               
Tfap4 CNS1 (Myc-1), CGAGTAAGCAAGGAAAAGGAAG and 
AGTCGCGACGTTTGTAAATTG;                                                                                                      
Tfap4 CNS2 (Myc-2), GACCCGGCATAGAGAACTACAG and 
AGTCACTAGTCGCACGTTCTCC;                                                                                                                
Tpi1, GATGTCAAGGAAGGGGGTCT and GTGCAGACCTCTCGAATAGCC; and           
Yars, ATCGATTCTTTCGACTCTCTGC and GGGAACTGTCACGCTAGTCC. 
 
Metabolic Measurements 
Extracellular acidification rates (ECARs) were measured using a Seahorse XF96 Analyzer 
(Seahorse Bioscience) essentially as described37. Briefly, CD8+ T cells were purified from 
uninfected mice (for naive) or chimeric mice transferred with a mixture of Tfap4–/– and control 
WT OT-I T cells and infected with 1 x 104 CFU of Lm-Ova. To prepare in vitro activated CD8+ 
T cells, purified naive CD8+ T cells were activated with anti-CD3 and anti-CD28 antibodies 
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without exogenous IL-2 for 24 hours. 0.15 x 106 cells/well of CD8+ T cells from three biological 
replicates were seeded onto a 96 well plate and ECARs were measured in duplicate in XF media 
(non buffered RPMI 1640 containing 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium 
pyruvate) under basal conditions and in response to 1 µM oligomycin. Experiments were 
repeated three times for in vivo activated CD8+ T cell samples and four times for naive and in 
vitro activated CD8+ T cells.  
 
Western blotting 
Whole cell extracts were prepared by lysing cells in Laemmli buffer containing 1% SDS and 2% 
2-mercaptoethanol. Lysates from equal numbers of cells were separated by 8 or 10% SDS PAGE, 
transferred to PVDF membranes (GE Healthcare), incubated with primary antibodies and 
detected with HRP-conjugated species-specific anti-immunoglobulin light chain antibodies 
(Jackson ImmunoResearch) and a Luminata HRP substrate (Millipore). Anti-HDAC1 (ab7028, 
Abcam) and anti-Tubulin beta (Developmental Studies Hybridoma Bank, University of Iowa) 
were used as loading controls. Anti-AP4 antibody was previously described24. The following 
antibodies were purchased: anti-Myc (Cell Signaling, 9402S), anti-phospho Stat5 (PY694) (BD 
Biosciences, 611964), anti-Blimp1 (Genscript, A01647-40), anti-T-Bet (Santa Cruz, sc-21003). 
For translation inhibition and proteasome inhibition, 10 µM of cycloheximide (Sigma) or MG-
132 (Sigma) was added to the cell culture. For inhibition of signaling pathways, 20 nM of U0126 
(Cayman Chemical), 10 µM of SB203580 (Cayman Chemical), 50 nM of wortmannin (Cayman 
Chemical), 5 nM of FK506 (Cayman Chemical), or 2.5 nM of rapamycin (Cayman Chemical) 
was added to the cell culture. 
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Statistical Analysis 
P values were calculated with unpaired two-tailed Student’s t-test for two group comparisons 
and with ANOVA for multiple group comparisons with the Tukey post-hoc test in Prism 6 
(Graphpad) unless otherwise specified. P values < 0.05 were considered significant. 
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Figure 2.1. IL-2 signals maintain AP4 expression. (a) Microarray analysis of transcription 
factor–encoding genes with a difference in expression of >1.8-fold in activated CD8+ T cells 
treated for 12 h with IL-2 (100 U/ml; + IL-2) relative to their expression in activated CD8+ T 
cells treated for 12 h with anti–IL-2 (2 µg/ml; α-IL-2); results are presented as mean signal 
intensity. (b) Quantitative RT-PCR analysis of Eomes, Tfap4 and Bcl6 in CD8+ T cells treated as 
in a; results for cells treated with IL-2 are presented relative to those of cells treated with 
anti−IL-2, set as 1 (dashed line). (c) Immunoblot analysis of AP4 in CD8+ T cells before 
treatment (Pre) or treated as in a; phosphorylated STAT5 (p-STAT5) and β-tubulin serve as 
loading controls. (d) Immunoblot analysis of AP4 in Tfap4−/− CD8+ T cells transduced with 
retrovirus (RV) containing an empty vector (EV) or vector expressing AP4 (above blot) and 
treated as in a (above lanes); the histone deacetylase HDAC1 serves as a loading control 
throughout. (e) Immunoblot analysis of AP4 in CD8+ T cells treated for 0−9 h (above lanes) with 
IL-2 or anti−IL-2 (above blot) in the presence of cycloheximide (10 µM). (f) Immunoblot 
analysis of AP4 in CD8+ T cells treated for 0−12 h (above lanes) with anti−IL-2 in the presence 
of dimethyl sulfoxide (DMSO) or the proteasome inhibitor MG132 (10 µM). Data are from one 
experiment (a), are pooled from two experiments (b; error bars, s.d.) or are representative of four 
experiments (c), or three experiments (d-f). 
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Figure 2.2. Sustained AP4 expression requires signaling via the MAPK pathway. (a,b) 
Immunoblot analysis of AP4 in CD8+ T cells stimulated for 12 h with increasing concentrations 
(wedge) of anti-CD3 (12 h act) or stimulated for 2 d with anti-CD3 alone (Control) or with 
subsequent treatment for 12 h with anti−IL-2 or various cytokines (above lanes; 2 d act + 12 h 
Tx). IFN, interferon. (c) Immunoblot analysis of AP4 in CD8+ T cells stimulated for 48 h with 
anti-CD3 and anti-CD28 alone (Pre-treat) or subsequently treated for 6 h with DMSO, U0126, 
SB203580 or wortmannin (Wort) (left blot), or treated for 24 h with IL-2 followed by treatment 
for various times (above lanes) with U0126, SB203580 or wortmannin (right blot). Data are 
representative of three experiments. 
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Figure 2.3. Signals through CD25 sustain AP4 expression in vivo. (a) Immunoblot analysis of 
AP4, Blimp-1 and T-Bet in P14 T cells adoptively transferred into host mice, assessed at 0−7 d 
(above lanes) after infection of the host with LCMV-Arm. (b) CD25 expression in 
CD44+CD62L− CD8+ T cells from C57BL/6 mice at day 4.5 after infection with LCMV-Arm 
(left), and immunoblot analysis of AP4, Blimp-1 and T-Bet (middle) and quantitative RT-PCR 
analysis of Tfap4 (right) in the CD25lo and CD25hi cells sorted at left. (c) Immunoblot analysis of 
AP4 in Il2ra+/+ and Il2ra−/− P14 donor T cells adoptively transferred into host mice and assessed 
on day 4 after infection of the host with LCMV-Arm. Data are representative of two (a), or three 
(b,c) experiments. 
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Figure 2.4. AP4 is required for the population expansion of antigen-specific CD8+ T cells 
following infection with LCMV-Arm. (a,b) Expression of CD4, CD8α and KLRG1 (a) and 
binding of an H-2Db–gp(33–41) tetramer and expression of CD8α, KLRG1 and CD62L (b) in 
splenocytes from wild-type (WT) and Tfap4−/− mice, assessed by flow cytometry 8 d after 
infection with LCMV. Numbers adjacent to outlined areas (gates) indicate percent CD8α+ T cells 
(a, top), KLRG1+ CD8α+ effector cells (a, bottom), gp(33–44)-specific CD8α+ T cells among 
total splenocytes (b, top), and CD62L+ cells (top left) or KLRG1+ cells (bottom right) among 
gp(33–41)-specific CD8α+ T cells (b, bottom). (c,d) Cumulative results from a (c) and b (d): 
each symbol represents an individual mouse (n = 10 (wild-type) or 8 (Tfap4−/−) mice); small 
horizontal lines indicate the mean (± s.d.). Each symbol represents an individual mouse (n = 5 
per genotype); small horizontal lines indicate the mean (± s.d.); long dashed horizontal lines 
indicate the limit of detection. NS, not significant; *P < 0.0001 (unpaired t-test). Data are 
representative of three experiments (a,b) or are pooled from three experiments (c,d). 
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Figure 2.5. Generation of Tfap4F allele. (a) A gene-targeting strategy shown with 
representative restriction enzyme sites used for screening by Southern blot with a 5’ external 
probe (gray square). LoxP sites were inserted to flank exons 2 to 4 of Tfap4 in ES cells. The 
loxP-neo cassette was deleted in vitro by transient Cre transfection in ES cells prior to blastocyst 
injection. (b) Quantitative RT-PCR analysis of RNA of CD4+ and CD8+ T cells purified from 
Tfap4F/F Cre– or Tfap4F/F CD8-Cre+ mice showing the abundance of the transcript encoding 
Tfap4. Error bars, s.d. (n = 3). *** P < 0.001, NS: not significant by unpaired t-test. 
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Figure 2.6. AP4 is required in a cell-autonomous way for the population expansion of CD8+ 
T cells. (a,b) Flow cytometry analysis showing expression of CD4, CD8α, KLRG1, CD62L and 
H-2Db–gp(33–41)-specific TCR in peripheral blood mononuclear cells (PBMC) from Tfap4–/– (n 
= 7), Tfap4F/F CD8-Cre+ (n = 7) and control C57BL/6 mice (n = 15) on day 8 after LCMV-Arm 
infection. Statistical analysis is shown in (b). Each symbol in d represents an individual mouse; 
small horizontal lines indicate the mean (± s.d.). * P < 0.05, ** P < 0.01, *** P < 0.001, NS: not 
significant by one-way ANOVA. Data pooled from three experiments. 
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Figure 2.7. AP4 is required for the population expansion of antigen-specific CD8+ T cells in 
response to infection with LM-OVA. (a) Flow cytometry analysis showing expression of 
CD8α, KLRG1, CD62L and H2-Kb−OVA-specific TCR in splenocytes of Tfap4–/– and age-
matched C57BL/6 mice on day 7 after LM-OVA infection. OVA-specific CD8+ T cells, and 
KLRG1+ CD62L– effectors and KLRG1– CD62L+ memory precursors are shown with 
rectangular gates with percentages. (b) Statistical analysis of total, KLRG1+ and CD62L+ H2-
Kb−OVA-specific CD8+ T cells. (n = 6 for C57BL/6, 8 for Tfap4–/– mice in two independent 
experiments). Error bars, s.d. Each symbol represents an individual mouse; small horizontal lines 
indicate the mean (± s.d.). * P < 0.05, ** P < 0.01, *** P < 0.001, NS: not significant by 
unpaired t-test. Data are representative of three experiments. 
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Figure 2.8. AP4 is dispensable for CD8 T cell memory formation. (a) Flow cytometry 
analysis of splenocytes showing expression of CD8α, CD127, CD62L and H-2Db–gp(33–41)-
specific TCR on day 60 after LCMV-Arm infection. (n = 4). (b,c) Statistical analysis of absolute 
numbers of gp(33–41)-specific total memory CD8+ T cells and CD62L+ central memory CD8+ T 
cells in the spleen on day 60 after LCMV-Arm infection (b) and frequencies of gp(33–41)-
specific memory CD8+ T cells in peripheral blood mononuclear cells (PBMC) in Tfap4–/– (n = 6), 
Tfap4F/F CD8-Cre+ (n = 7) or control C57BL/6 mice (n = 14) on day 60 after LCMV-Arm 
infection (c). (d) IFN-γ ELISPOT assay showing frequencies of OVA-specific memory CD8+ T 
cells in splenocytes of Tfap4–/– (n = 4) and control C57BL/6 mice (n = 4) on day 45 after LM-
OVA infection. All mice had less than 11 spots per million splenocytes when no antigen was 
included. NS: not significant by unpaired t-test.  
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Figure 2.9. AP4 is essential for the secondary population expansion of memory CD8+ T 
cells. (a,b) Flow cytometry analysis showing expression of CD8α, CD45.2, CD62L, KLRG1 and 
H-2Db–gp(33–41)-specific TCR in splenocytes of CD45.1 wild-type host mice on day 5 after 
LCMV-Arm infection. Before infection, the host mice received CD8+ T cells from Tfap4–/– or 
C57BL/6 mice, which were infected with LCMV-Arm 60 days before. (n = 8 in two independent 
experiments). Statistical analysis is shown in (f). (c) Flow cytometry analysis of PBMC of Tfap4–
/– (n = 15), Tfap4F/F CD8-Cre+ (n = 9), or control C57BL/6 mice (n = 14) 5 days after secondary 
challenge with LM-OVA. (d) Statistical analysis of numbers of total CD8+ T cell and OVA-
specific CD8+ T cells numbers in blood and spleen 5 days after secondary challenge with LM-
OVA is shown. Each symbol represents an individual mouse; small horizontal lines indicate the 
mean (± s.d.). * P < 0.01, ** P < 0.001, *** P < 0.0001, NS: not significant by unpaired t-test (b) 
or one-way ANOVA (d). Data are representative of three experiments. 
	  
	   	  
a
WT Tfap4–/–
CD45.2
C
D
8?
8.1 2.9 1.1 0.4
89 64
CD45.2
CD62L
K
LR
G
1
WT Tfap4–/–
0
0.5
1.0
1.5
2.0
2.5
C
D
45
.2
+   H
-­2
D
b –
gp
(3
3–
41
)+
K
LR
G
1+
  c
el
ls
  (p
er
  s
pl
ee
n  
x  
10
6 )
***
C
D
45
.2
+   H
-­2
D
b –
gp
(3
3–
41
)+
ce
lls
  (p
er
  s
pl
ee
n  
x  
10
6 )
0
0.5
1.0
1.5
2.0
2.5 **
b
H
-­2
D
b –
gp
(3
3-­
41
)
WT
Tfap4–/–
18 7.8
CD8?
C
D
4
WT Tfap4–/–
Tfap4F/F
CD8-­Cre+
2.5 0.5 1.1
CD8?
H
-­2
K
b –
O
va
c
11
0
50
100
150
**
*
C
D
8+
  T
  c
el
ls
  (p
er
  s
pl
ee
n  
x  
10
6 )
0
10
20
30
**
*
H
-­2
K
b –
O
va
+   C
D
8+
  T
  c
el
ls
(p
er
  s
pl
ee
n  
x  
10
6 )
d
0
5
10
15
***
**
H
-­2
K
b –
O
va
+   C
D
8+
  T
  c
el
ls
(p
er
  1
02
  P
B
M
C
)
0
10
20
30
40
***
***
  C
D
8+
  T
  c
el
ls
  (p
er
  1
02
  P
B
M
C
)
WT
Tfap4–/–
Tfap4F/F  CD8-­Cre+
	  
	  
65 
 
Figure 2.10. AP4 is required for the sustained clonal expansion of CD8+ T cells but not for 
their initial proliferation. (a) Expression of CD62L and CD44 (right) by Tfap4+/+ and Tfap4−/− 
P14 T cells (sorted by marker expression at left), assessed by flow cytometry 16 h after transfer 
together (at a ratio of 1:1) into congenic host mice. Numbers adjacent to outlined areas (left) 
indicate percent Thy-1.1+CD45.2+ (Tfap4+/+) P14 T cells (top) or Thy-1.1−CD45.2+ (Tfap4−/−) 
P14 T cells (bottom). (b) Frequency of CD8+ T cells in the spleen, mesenteric lymph nodes 
(MLN), lungs, liver and kidneys of Tfap4−/− mice and control wild-type C57BL/6 mice (WT) 
under steady-state conditions. Each symbol represents an individual mouse; small horizontal 
lines indicate the mean (± s.d.). (c) Flow cytometry of CFSE-labeled Tfap4+/+ and Tfap4−/− P14 
donor T cells before transfer (Pre-transfer) and after transfer into host mice, assessed 3 d after 
infection of the host with LCMV-Arm. (d) Flow cytometry of Tfap4+/+ and Tfap4−/− P14 donor 
cells transferred into host mice at a starting ratio of 1:1, assessed at various time points after 
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66 
infection of the host with LCMV-Arm (numbers in plots as in a). (e) Quantification of Tfap4+/+ 
and Tfap4−/− P14 donor cells in the spleen of host mice as in d (n = 9−13 (day 3), 8−18 (day 4), 
8−13 (day 5), 9−19 (day 6), 4−8 (day 7), 4−9 (day 8), 3 (day 10) or 5 (day 12)), normalized to 1 
× 104 transferred cells (left), and data for day 3 (outlined at left) on a log10 scale (right): each 
symbol represents an individual mouse; small horizontal lines indicate the mean (± s.d.). (f,g) 
Frequency of Tfap4+/+ and Tfap4−/− donor T cells in the mice in e, assessing chimerism (f), and 
frequency of BrdU+ cells following 2 h of pulse labeling in vivo in those mice (g). *P < 0.05, 
**P < 0.01 and ***P < 0.001 (unpaired t-test (b,e,g) or one-way analysis of variance (ANOVA) 
(j)). Data are representative of three (a,d) or two (c) experiments or are pooled from three (b,e–
g). 
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Figure 2.11. AP4-deficiency does not result in increased cell death or impaired CD8 T cell 
trafficking. (a) Statistical analysis of ratios between Tfap4–/– and Tfap4+/+ OT-I T cells. (n = 15 
for day 3, 18 for day 4, 6 for day 5, 8 for day 6, 8 for day 7). (b) Statistical analysis of 
percentages of BrdU+ OT-I T cells following 2 h pulse labeling. (n = 9 for day 3, 5 for day 4, 7 
for day 5, 6 for day 6, 8 for day 7). (c) Flow cytometry analysis of OT-I T cells showing levels of 
phosphorylated serine 235/236 of S6 ribosomal protein (p-S6) on day 4 after LM-OVA infection 
shown as histogram overlays. (n = 5). (d) Binding of annexin V (AnnV) in Tfap4+/+ and Tfap4−/− 
P14 donor cells and CD8+CD44+ effector host cells (Host) in the spleen 6 d after infection of the 
host with LCMV-Arm, assessed by flow cytometry. Numbers above bracketed lines indicate 
percent annexin V–positive cells. (e) Cumulative results from h (n = 5 host mice). (f) Ratio of 
Tfap4−/− P14 donor cells to Tfap4+/+ P14 donor cells (KO/WT) (transferred at a starting ratio of 
6:1) in various organs and blood of host mice 7 d after infection with LCMV-Arm. Each symbol 
represents an individual host mouse (n = 8); small horizontal lines indicate the mean (± s.d.). *P 
< 0.05, **P < 0.01 and ***P < 0.001 unpaired t-test. 
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Figure 2.12. AP4 is dispensable for early T cell activation in vitro. (a) Statistical analysis of 
ratios of Tfap4–/– and Tfap4+/+ OT-I T cells co-cultured with OVA peptide-pulsed irradiated 
splenocytes. Percentages of Tfap4–/– OT-I cells in total OT-I T cells are shown. (b) Flow 
cytometry analysis of Tfap4–/– and Tfap4+/+ OT-I T cells showing FSC after co-culture in the 
presence of irradiated splenocytes pulsed with 0.1 nM of OVA peptide. (n = 3). (c) Statistical 
analysis of percentages of IFN-γ-producing Tfap4–/– and Tfap4+/+ OT-I cells that had been 
initially activated by anti-CD3 and anti-CD28 and re-stimulated with OVA-peptide pulsed 
irradiated splenocytes. Values were normalized to the maximum percentage of cells producing 
IFN-γ. (n = 2). *** P < 0.001, NS: not significant by unpaired t-test. 
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Figure 2.13. AP4 is essential for host protection against infection with WNV, in a CD8+ T 
cell–intrinsic manner. (a) Survival of Tfap4F/FCre− control mice (Cre−; n = 16) and 
Tfap4F/FCD8-Cre+ mice (CD8-Cre+; n = 22) following infection with WNV. (b,c) Viral titers in 
the brain (b) and spleen (c) of Tfap4F/F Cre− and Tfap4F/F CD8-Cre+ mice on day 9 after infection 
with WNV. Each symbol represents an individual mouse (n = 18 (b) or 7 (c) per genotype); red 
horizontal lines (b) indicate the median; dashed horizontal lines indicate limit of detection. *P < 
0.05 and **P < 0.001 (log-rank test (a) or Mann-Whitney U-test (b,c)). Data are pooled from 
three (a), four (b) or two (c) independent experiments. 
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Figure 2.14. AP4 is required for the population expansion of antigen-specific CD8+ T cells 
after infection with WNV. Statistical analysis showing absolute numbers of total CD8+ T cells 
(a) H-2Db–NS4B-specific T cells as determined by H-2Db–NS4B tetramer binding (b) or 
intracellular staining for IFN-γ following NS4B peptide stimulation (c) in the spleen on day 7 
after WNV infection. Data is from one experiment using five Tfap4–/–, four Tfap4F/F CD8-Cre+, 
and four control age- and sex-matched C57BL/6 mice. * P < 0.05, NS: not significant by Mann 
Whitney U-test. Each symbol represents an individual mouse; small horizontal lines indicate 
median. 
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Figure 2.15. AP4 is dispensable for clearance of LM-OVA or LCMV Arm. (a) Quantitative 
RT-PCR analysis of the abundance of transcripts encoding LCMV-gp in the spleen, kidneys and 
liver of Tfap4F/FCD8-Cre+ and control Tfap4F/FCre− mice 6 d after infection with LCMV-Arm; 
results are presented relative to those of control transcripts encoding hypoxanthine guanine 
phosphoribosyl transferase (Hprt1). long dashed horizontal lines indicate the limit of detection. 
(b) Statistical analysis of LM-OVA bacterial titers in spleens and livers of Tfap4F/F CD8-Cre+ 
and Tfap4F/F Cre– mice on days 4 and 6 after infection. (n = 4 for Tfap4F/F Cre–, 6 for Tfap4F/F 
CD8-Cre+ in two experiments). Each symbol represents an individual mouse (n = 5 per 
genotype); small horizontal lines indicate the mean (± s.d.); NS, not significant by unpaired t-
test. 
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Figure 2.16. Myc induces AP4 after T cell activation. (a) Quantitative RT-PCR and 
immunoblot analysis showing c-Myc and AP4 expression at mRNA and protein levels in CD8+ T 
cells following stimulation with anti-CD3 and anti-CD28. (n = 2). (b) Flow cytometry of CD8+ T 
cells from OT-I c-Myc−GFP+ mice showing c-Myc−GFP expression after two-hour stimulation 
with anti-CD3 and anti-CD28 and quantitative RT-PCR analysis of transcripts encoding Myc or 
Tfap4 in purified GFPLo and GFPHi cells. (n = 2). (c,d) Immunoblot analysis of AP4 and c-Myc 
(c) and quantitative RT-PCR analysis of Myc and Tfap4 (d) in wild-type naive CD8+ T cells 
treated with 4-hydroxytamoxifen (N) and in MycF/+Cre− (Myc+/+), MycF/+ Rosa26-Cre-ERT2 
(Myc+/−) and MycF/F Rosa26-Cre-ERT2 (Myc−/−) CD8+ T cells treated with 4-hydroxytamoxifen 
and stimulated for 10 or 24 h in vitro with anti-CD3 and anti-CD28. (e) Quantitative PCR 
analysis of anti-c-Myc immunoprecipitated chromatin of activated CD8+ T cells showing 
enrichment of the Tfap4 intronic fragments containing c-Myc consensus binding sequences. PCR 
primers for Cd4 promoter (Cd4Pro), Hoxa13 promoter (Hoxa13) and Cd4 silencer (Cd4Sil) were 
used as negative control (n = 2). *P < 0.05, **P < 0.01 and ***P < 0.001 by unpaired t-test. 
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Figure 2.17. AP4 is dispensable for initial blasting and increase in glycolysis after T cell 
activation in vitro. (a) Flow cytometry of CD8+ T cells showing FSC in the naive state and 
following 24 h stimulation with anti-CD3 and anti-CD28 antibodies in vitro. (n = 3). (b) ECAR 
measurement showing glycolytic rates of Tfap4–/– and C57BL/6 CD8+ T cells after stimulation 
with anti-CD3 and anti-CD28 for 24 h. Data represent three independent experiments with three 
to four biological replicates in each experiment. (c) qRT-PCR analysis of RNA from CD8+ T 
cells showing 18S rRNA-normalized expression of Myc, Hif1a and genes encoding glycolytic 
enzymes at different time points following stimulation with anti-CD3 and anti-CD28 antibodies 
in vitro. (n = 3). NS: not significant by unpaired t-test. 
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Figure 2.18. AP4-deficient CD8 T cells fail to maintain cell growth. (a) Flow cytometry of 
Tfap4+/+ and Tfap4−/− OT-I donor T cells adoptively transferred into host mice, assessed before 
(Naive) or 3, 4 or 6 d after infection of the host with LM-OVA, assessing cell size as forward 
scatter (FSC). (b) Cumulative results for cells as in a: each symbol represents an individual host 
mouse (n = 8 (day 4) or 4 (day 6)); small horizontal lines indicate the mean (± s.d.). (c) Flow 
cytometry of co-transferred Tfap4–/– and Tfap4+/+ P14 T cells showing FSC after infection of 
recipient mice with LCMV-Arm. Representative histogram overlays at each time point are 
shown in the left panel. (n = 3). (d) Microarray gene expression analysis of C57BL/6 CD8+ T 
cells in the naive state, or after activation with anti-CD3 and anti-CD28 in vitro for 3 days (n = 
2), and OT-I T cells 2 days after LM-OVA infection in vivo (n = 3). Expression levels of the 479 
AP4/Myc co-regulated genes are shown by a heat map. Expression levels are normalized to those 
of naive CD8+ T cells. **P < 0.01 and ***P < 0.001 by unpaired t-test. 
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Figure 2.19. AP4 expression persists longer than MYC. (a) Size of Tfap4+/+ OT-I donor T 
cells (assessed as forward scatter; top) and expression of c-Myc−GFP (middle) and AP4 
(bottom) by Tfap4+/+ and Tfap4−/− OT-I T cells on days 0−5 after infection with LM-OVA, 
assessed by flow cytometry; c-Myc–GFP results obtained by subtraction of autofluorescence 
from the GFP fluorescence of OT-I T cells heterozygous for the knock-in allele encoding c-
Myc−GFP. Below, cumulative results obtained as above. (b) Immunoblot analysis of AP4 and c-
Myc in Tfap4+/+ OT-I donor T cells adoptively transferred into host mice, assessed in the naive 
state (0) or on days 3−5 after infection of the host with LM-OVA (left), and in Tfap4+/+ (WT) 
and Tfap4−/− (KO) OT-I donor T cells activated for 24 h in vitro with anti-CD3 and anti-CD28 
(In vitro) or adoptively transferred into host mice and activated in vivo by infection of the host 
for 4 or 5 d with LM-OVA (bottom), to demonstrate antibody specificity. 
	  
	   	  
a
FSC
c-­Myc–GFP
AP4
E
ve
nt
s  
(%
M
ax
) 100
80
60
40
20
0
E
ve
nt
s  
(%
M
ax
) 100
80
60
40
20
0
WT Tfap4–/–
c-­Myc-­GFP+ c-­Myc-­GFP–
Day  0 Day  1 Day  2 Day  3 Day  4 Day  5
E
ve
nt
s  
(%
M
ax
) 100
80
60
40
20
0
b
AP4
c-­Myc
3 4 50 WT KO
Time  (d) In  vitro
HDAC1
WT WTKO KO
Day  4 Day  5
LM-­Ova
AP4
c-­Myc
HDAC1
0 1 2 3 4 5
0
0.5
1.0
1.5
2.0
0 1 2 3 4 5
0
50
100
150
0 1 2 3 4 5
0
50
100
150
C
el
l  s
iz
e  
(F
S
C
  x
10
6 )
c-­
M
yc
–G
FP
  e
xp
re
ss
io
n  
(%
M
ax
)
Time  after  infection  (d)
A
P
4  
ex
pr
es
si
on
  (%
M
ax
)
Time  after  infection  (d) Time  after  infection  (d)
	  
	  
76 
 
Figure 2.20. AP4 sustains active transcription and glycolysis of CD8 T cells. (a) Total RNA 
in Tfap4+/+ and Tfap4−/− OT-I donor T cells adoptively transferred into host mice and assessed 4 
d after infection of the host with LM-OVA. Each symbol represents an individual host mouse (n 
= 5); small horizontal lines indicate the mean (± s.d.). (b) ECAR of Tfap4+/+ and Tfap4−/− OT-I 
CD8+ T cells left unstimulated (Naive), stimulated for 24 h in vitro with anti-CD3 and anti-CD28 
(middle) or adoptively transferred into host mice and analyzed on days 4 and 6 after infection of 
the host with LM-OVA, all assessed at baseline (without additional treatment (UT)) and after 
treatment with oligomycin (olig). (c) Quantitative RT-PCR analysis of genes encoding molecules 
involved in glycolysis in Tfap4+/+ and Tfap4−/− OT-I T cells adoptively transferred into host mice 
and assessed on day 4 or 6 after infection of the host with LM-OVA; results were normalized to 
those of 'spiked-in' control RNA ERCC-00108 and are presented relative to those of Tfap4+/+ 
OT-I T cells. *P < 0.05, **P < 0.01 and ***P < 0.001, NS: not significant by unpaired t-test. 
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Figure 2.21. AP4 is required for sustaining the expression of activation signature genes. (a) 
Normalized signal intensity (NSI) of endogenous transcripts in Tfap4+/+ and Tfap4−/− OT-I donor 
T cells adoptively transferred into host mice and assessed on day 4 after infection of the host 
with LM-OVA (top), and that of ERCC control RNA (bottom); numbers in plots indicate slope 
values obtained by linear regression (with 95% confidence interval in parentheses); slope of blue 
dashed lines, 1. WT1 and WT2, and KO1 and KO2, indicate two biological replicates of Tfap4+/+ 
OT-I samples and of Tfap4−/− OT-I samples, respectively (throughout). (b) Slopes of plots in a. 
(c) Heat maps of the expression of genes encoding molecules in pathways (top) identified by the 
bioinformatics database DAVID (version 6.7), assessed in cells as in (a) and presented relative to 
results for Tfap4+/+ OT-I T cells; red indicates genes bound by both c-Myc and AP4. *P < 0.05 
(unpaired t-test). 
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Figure 2.22. ChIP-sequencing analysis identifies AP4 and c-Myc target genes in CD8+ T 
cells. (a-d) Annotation and motif analysis of genomic sequences bound by AP4 (a,b) or c-Myc 
(c,d) in activated C57BL/6 CD8+ T cells. (e) Examples of AP4 and c-Myc binding to genes that 
are differently expressed between Tfap4–/– and Tfap4+/+ OT-I T cells in vivo. BedGraph 
histograms are shown with statistically significant peaks as red rectangles. P < 1 × 10-10 for anti-
AP4 ChIP, P < 5 × 10-9 for anti-c-Myc ChIP by Poisson distribution. ChIP-seq data for RNA 
polymerase II C-terminal domain (polII-CTD) serine phosphorylations (S2P and S5P) are shown 
as reference to transcribed regions. Data are from one experiment. 
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Figure 2.23. AP4 is essential for the sustained expression of genes that are targets of c-Myc. 
(a) Overlap of AP4-bound genes, c-Myc-bound genes and genes expressed differently in 
Tfap4−/− cells relative to their expression in Tfap4+/+ cells. (b) Kinetics of expression of the 479 
genes identified in d (middle) in Tfap4+/+ OT-I T cells adoptively transferred into host mice and 
assessed before (Naive) and on days 2, 4 and 6 after infection of the host with LM-OVA; results 
are presented relative to those of naive cells, set as 1. (c) Fluorescence of GFP in Tfap4+/+ P14 T 
cells (WT ctrl) and P14 T cells carrying a knock-in allele encoding c-Myc−GFP (c-Myc−GFP), 
adoptively transferred together into host mice and assessed by flow cytometry on days 3−5 after 
infection of the host with LCMV-Arm. (d) ChIP and quantitative PCR analysis of the binding of 
AP4 to genes targeted by both AP4 and c-Myc in Tfap4+/+ P14 T cells adoptively transferred into 
host mice and assessed on day 5 after infection with LCMV-Arm; results are presented as 
'enrichment' relative to the binding in their Tfap4−/− counterparts, set as 1 (dashed line). *P < 
0.05, **P < 0.01 and ***P < 0.001 (unpaired t-test). 
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Figure 2.24. Sustained c-Myc expression 'rescues' defects of Tfap4−/− CD8+ T cells. (a) Flow 
cytometry of Tfap4+/+ OT-I (control) T cells transduced with retrovirus containing an empty 
vector (WT + EV) cultured with Tfap4−/− OT-I T cells (KO + RV) transduced with that retrovirus 
or retrovirus containing a vector for the expression of AP4 or c-Myc(T58A) (left margin). 
Numbers along left margin indicate ratio of the forward scatter of Tfap4−/− OT-I T cells to that of 
Tfap4+/+ OT-I T cells. (b) Ratio of the forward scatter of Tfap4−/− OT-I T cells to that of Tfap4+/+ 
OT-I T cells (all transduced as in a). (c,d) ECAR (c) and incorporation of BrdU (d) of Tfap4+/+ 
and Tfap4−/− OT-I T cells transduced as in a. (e) Quantitative RT-PCR analysis of genes targeted 
by both AP4 and c-Myc (encoding molecules in various pathways (right margin)) in Tfap4+/+ and 
Tfap4−/− OT-I T cells transduced as in (a); results were normalized to those of 'spiked-in' RNA 
ERCC-108 and are presented relative to average results for the Tfap4+/+ OT-I T cells. (f) 
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and Tfap4−/− (Thy-1.1−) OT-I T cells transduced as in (a) and adoptively transferred into 
congenic wild-type host mice, assessed by on day 6 after infection of the host with LM-OVA. 
Numbers adjacent to outlined areas indicate percent cells in each. (g–j) Ratio of Tfap4−/− OT-I T 
cells to Tfap4+/+ OT-I T cells (KO/WT), all transduced as in (a) (g), and frequency of KLRG1+ 
cells (h), incorporation of BrdU (i) and FSC ratio (as in b) (j) among Tfap4+/+ and Tfap4−/− OT-I 
T cells transduced as in (a). Each symbol (b,g,h,j) represents an individual mouse; small 
horizontal lines indicate the mean (± s.d.). *P < 0.05, *P < 0.01 and ***P < 0.001 (one-way 
ANOVA). Data are representative of five (a), three (c) or two (d,f) experiments or are pooled 
from three (b) or two (e,g−j) experiments (error bars (c,d,i), s.d.). 
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Figure 2.25. AP4 and c-Myc have distinct biological functions. (a) An experimental scheme 
to retrovirally express AP4 in Myc-deficient CD8+ T cells. MycF/+Cre– (Myc+/+) or 
Myc+/+Rosa26-Cre-ERT2 and MycF/FRosa26-Cre-ERT2 (Myc–/– after 4OHT treatment) CD8+ T 
cells were transduced with empty-, FLAG-tagged AP4-, or Myc-expressing RV after activation 
with anti-CD3 and anti-CD28 for 24 h, and subsequently cultured in media containing IL-7 (10 
ng/ml) and 4-hydroxytamoxifen (4OHT, 500 nM) for 2 days. Transduced cells (GFP+) were 
sorted, labeled with the division-tracking dye CellTraceTM Violet (CTV), and restimulated with 
anti-CD3 and anti-CD28 for two days. (b) Immunoblot showing c-Myc and AP4 expression 48 h 
after re-stimulation under the same conditions. n = 2. (c) Quantitative RT-PCR analysis showing 
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the abundance of transcripts encoding Myc, Tfap4, or Il2ra after re-stimulation for 2 h. (n = 3). 
(d) Flow cytometry showing CTV fluorescence and FSC of RV-transduced Myc+/+, Myc+/+ Cre-
ERT2(+) and Myc–/– CD8 T cells shown as histogram overlays. (n = 3). (e) Microarray analysis 
of Myc+/+ and Myc–/– CD8+ T cells transduced with AP4- or c-Myc-expressing RV shown as a 
heat map. Genes that were differently expressed by >2-fold between EV-transduced Myc+/+ and 
Myc–/– cells are shown with the abundance normalized to Myc+/+ + EV samples. Datasets were 
analyzed by hierarchical clustering using Euclidean distance matrix with average linkage. (n = 
2). Error bars, s.d. * P < 0.0001, NS: not significant by one-way ANOVA. Data are 
representative of two experiments. 
	  
	  
84 
	  
	  
	  
	  
	  
	  
	  
	  
	  
CHAPTER 3: 
AP4 mediates resolution of chronic viral infection through amplification of germinal 
center B cell responses. 
 
 
 
The contents of this chapter have been previously published in Immunity.  
Chou C, Verbaro DJ, Tonc E, Holmgrem M, Cella M, Colonna M, Bhattacharya D, 
Egawa T. AP4 mediates resolution of chronic viral infection through amplification of 
germinal center B cell responses. Immunity. Manuscript accepted. 
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3.1 ABSTRACT 
B cells diversify and affinity-mature their antigen receptor repertoire in germinal centers 
(GC). GC B cells receive help signals during transient interaction with T cells, yet it 
remains unknown how these transient T-B interactions sustain the subsequent 
proliferative program of selected B cells that occurs in an anatomically distant area. Here 
we show that the transcription factor AP4 is required for sustained GC B cell 
proliferation and subsequent establishment of a diverse and protective antibody repertoire. 
AP4 is induced by c-MYC during the T-B interactions, maintained by T cell derived IL-
21 and promotes repeated rounds of divisions of selected GC B cells. B cell specific 
deletion of AP4 resulted in reduced GC sizes and somatic hypermutation and a failure to 
control chronic viral infection. These results indicate that AP4 integrates T cell mediated 
selection and sustained expansion of GC B cells for humoral immunity. 
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3.2 INTRODUCTION 
Upon infection or vaccination, antigen (Ag)-specific lymphocytes that are present 
at low frequencies under steady-state conditions undergo rapid clonal expansion to 
increase the magnitude of adaptive immune responses. While expansion of Ag-specific B 
cells ensures that sufficient quantities of antibodies are made, it also serves as a template 
for somatic hypermutation (SHM), affinity maturation, and the subsequent generation of 
protective humoral memory for long-term immunity 1, 2. These proliferating Ag-specific 
B cells form a specialized compartment in peripheral lymphoid organs, the germinal 
centers (GCs), in which B cells cyclically migrate between the light zone (LZ) and the 
dark zone (DZ) for selection and subsequent clonal expansion, respectively 1, 2, 3, 4, 5. In 
the LZ, signals from TFH cells facilitate the selection of clones that express B cell 
receptors (BCRs) with higher affinity for their cognate Ag relative to neighboring clones 
2, 3, 6, 7, 8. The important cues for clonal selection in the LZ include ligation of CD40 on B 
cells by CD40L on TFH cells, as well as cytokines, especially IL-21 1, 2, 9, 10, 11, 12, 13, 14. GC 
B cells that receive these signals migrate to the DZ, where they rapidly divide multiple 
times and accumulate somatic mutations in their immunoglobulin (Ig) genes 15. GC B 
cells can then re-enter the LZ for additional rounds of selection followed by clonal 
expansion for further affinity maturation 5. This process allows for the emergence of B 
cell clones expressing high affinity antibodies that carry multiple Ig mutations 16.  
The magnitude of expansion of selected B cell clones is programmed by T cell 
help that B cells receive during their transient interaction with TFH cells in the LZ. 
Increased amounts of the cognate peptide Ags presented by B cells to TFH cells in the 
context of MHC class II induce elevated production of cytokines, IL-4 and IL-21 by TFH 
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cells 17, and facilitate rapid expansion of selected B cells in the DZ and affinity 
maturation 15, 18. Thus, the transient T-B interaction in the LZ induces gene expression 
programs that allow selected B cells to sustain their proliferation in the DZ and establish 
a diverse BCR repertoire. The transcription factor c-MYC regulates proliferation of both 
pre-GC B cells and GC B cells, while mutations or translocations of the Myc gene are 
causally linked to GC-derived B cell lymphomas 1, 19, 20. Although T cell help controls 
cell cycle progression of selected B cells by inducing c-MYC, expression of this proto-
oncogene is detected only transiently in LZ B cells prior to their proliferation in the DZ 5, 
18, 19, 20. Thus, the identity of nuclear factors that are induced during the T-B interaction in 
the LZ and continue to be expressed in the DZ to potentiate proliferation of selected B 
cells remains unknown. 
In this study, we dissected the genetic program that is activated in selected B cells 
during their transient interaction with TFH cells in the LZ and supports sustained 
expansion of B cells in the DZ. Our data demonstrated that the transcription factor AP4 is 
essential for amplification of GC responses. AP4 is induced by c-MYC in B cells that 
receive T cell help through the CD40-CD40L interaction and maintained by IL-21 as they 
migrate toward the DZ. Although AP4 is dispensable for selection of B cells and their 
cell cycle progression in the LZ, it is essential for DZ B cells to re-enter additional 
division cycles after completing the one initiated in the LZ. This AP4-dependent 
proliferation of DZ B cells amplifies the magnitude of GC responses and suffices 
antibody diversification for protection against chronic viral infection. These results 
demonstrate that AP4 connects selection and enhanced expansion of Ag-specific B cells 
that occur in distinct locations in the GC.   
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3.3 RESULTS 
The c-MYC inducible factor AP4 is expressed in both LZ and DZ GC B cells. 
A number of transcription factors are upregulated in GC B cells during clonal 
selection. The expression of one such factor, AP4 (encoded by Tfap4), is significantly 
elevated in GC B cells expressing c-MYC compared to those lacking c-MYC based on 
previously reported gene expression data (Figure 1A) 20. Indeed, AP4 was induced in 
CD40-stimulated B cells in vitro, but this induction required c-MYC (Figures 1B and 
1C). c-MYC binds to an intronic region enriched for the H3K27ac enhancer mark in the 
Tfap4 locus, suggesting that c-MYC directly regulates Tfap4 expression (Figure 1D). 
Therefore, we hypothesized that AP4 lies downstream of c-MYC and controls GC B cell 
proliferation. AP4 protein was detected in splenic GCs, but not in follicular B cells, 
following immunization with sheep red blood cells (SRBCs) (Figure 2A, left), whereas 
this staining was absent following B cell-specific deletion of Tfap4 (Figure 2A, middle). 
The majority of AP4+ cells were also stained for AID (Figure 2A, right), which is 
expressed in both the LZ and DZ cells in mouse GCs 21. Within GC, the LZ is marked by 
the presence of CD23- and CD35-expressing follicular dendritic cells (FDCs) 19, 20, 22. As 
reported previously 5, 19, 20, c-MYC-expressing cells were detected exclusively in the LZ 
(Figure 2B, left). In contrast, AP4-expressing cells were distributed in both the LZ and 
DZ (Figure 2B, right). This result was further confirmed by immunoblotting showing 
AP4 expression in both CD86hiCXCR4lo LZ and CD86loCXCR4hi DZ GC B populations 
(Figure 2C). AP4 was also expressed in both LZ and DZ cells derived from human 
tonsillar GCs, while c-MYC expression was detected only in the LZ (Figure 2D). We 
next measured AP4 and c-MYC expression at the single cell level using mice harboring 
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c-MYC-GFP and AP4-mCherry fusion protein knock-in alleles (Figures 3A and 3B) 23. 
In the latter strain, mCherry was fused to the C-terminus of AP4, allowing for detection 
of AP4 by fluorescence with similar kinetics to endogenous protein (Figures 3C and 3D). 
In GC B cells, AP4 protein was specifically detected in mCherry+, but not in mCherry– 
cells (Figure 3E). AP4 was expressed in both LZ and DZ with ~50% of c-MYC+ LZ 
cells being AP4+ (Figures 3F, 4A and 4B). This was further confirmed by intracellular 
staining for AP4 in GC B cells (Figure 4C). These results suggest that c-MYC induces 
AP4 in the LZ, and that its expression persists as GC B cells migrate towards the DZ.  
 
AP4 is required for normal GC formation in a B cell-intrinsic manner. 
To test whether AP4 is required for GC responses, we immunized Tfap4–/– mice 
with the T-dependent Ag 4-Hydroxy-3-nitrophenylacetyl-chicken gamma globulin (NP-
CGG). Although AP4 is dispensable for normal B cell development in the bone marrow 
and spleen (Figure 5), the frequencies and numbers of B220+GL7+Fas+ GC B cells were 
reduced in Tfap4–/– mice following immunization (Figures 6A-6C). This defect was also 
observed in mixed bone marrow chimeras reconstituted with a mixture of WT and Tfap4–
/– bone marrow cells (Figures 6D and 6E), indicating that diminished GC response was a 
cell-intrinsic defect. Consistently, a comparable reduction of GC B cell numbers was seen 
in Tfap4F/F Mb1-iCre mice lacking AP4 specifically in B cells 24 (Figures 6A-6C). In the 
absence of AP4, individual splenic GC sizes were smaller (Figures 6F and 6G). GC B 
cell frequencies in Peyer’s patches were similarly reduced in the absence of AP4 
(Figures 6H and 6I). Following immunization with T-dependent Ag, c-MYC is 
expressed in activated B cells in a biphasic manner in pre-GC and GC B cells, and 
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essential for both initiation and maintenance of GCs 19, 20. AP4 was also expressed in pre-
GC B cells (Figure 7A), and B cell expansion was reduced at the pre-GC stage (Figures 
7B and 7C). However, numbers of total and Ag-binding GC B cells were significantly 
reduced when AP4 was deleted in ongoing GCs following immunization using Cγ1-Cre 
25 (Figures 8A and 8B), indicating that AP4 is cell-intrinsically required for the 
maintenance of GCs. This conclusion was further validated by a similar result observed 
when AP4 was deleted in GC B cells by Tamoxifen with the majority of TFH cells 
retaining intact AP4 (Figures 8C-8F). In contrast, AP4 was dispensable for a T-
independent response to NP-Ficoll (Figure 9), the formation of memory B cells (Figure 
10A) and bone marrow antibody secreting cells (Figure 10B). These results indicate that 
AP4 cell-autonomously regulates both GC initiation and maintenance.  
 
AP4 deficiency results in reduced proliferation of DZ B cells. 
GC B cells induce c-MYC upon selection in the LZ 19. The c-MYC induction was 
unimpaired in Tfap4–/– mice compared to control WT mice (Figure 11A), indicating that 
AP4 is dispensable for selection of LZ GC B cells. AP4 expression marked actively 
cycling cells both in the LZ and DZ B cell populations (Figure 11B). A considerable 
fraction of AP4+ LZ cells were in the S-phase with a reciprocal reduction of cells in the 
G1-phase, consistent with previous reports that c-MYC+ cells are actively cycling 19, 20. 
AP4+ DZ cells, which no longer expressed c-MYC, were also enriched for cells in S and 
G2/M phases of cell cycle, suggesting that continued expression of AP4 supports 
proliferation of selected GC B cells in the DZ. To assess whether AP4 is required for 
selected GC B cells to re-enter additional division cycles in the DZ after completing a 
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cycle initiated in the LZ, we examined sequential incorporation of EdU and BrdU 15 by 
Tfap4–/– and control Tfap4+/+ GC B cells in mixed bone marrow chimeras (Figure 11C). 
In the LZ, similar proportions of Tfap4–/– and Tfap4+/+ cells were distributed in distinct 
cell cycle phases. In contrast, frequencies of DZ cells in the early and mid/late S-phases 
were significantly reduced in the absence of AP4. These results indicate that AP4 is 
dispensable for cell cycle progression initiated in the LZ and an initial division in the DZ, 
but is necessary to promote subsequent divisions. As EdU and BrdU incorporation by 
CD45.1 WT GC B cells was comparable between Tfap4–/– and control mixed chimeras 
(Figure 11D), the requirement for AP4 in the cell cycle re-entry was cell-intrinsic. AP4 
thus amplifies proliferation of DZ B cells by promoting their re-entry to additional 
division cycles. Paradoxically, however, LZ to DZ cell number ratios were unaltered in 
the absence of AP4 (Figure 12) presumably because impaired expansion of DZ cells may 
reduce DZ to LZ trafficking of GC B cells, affecting cellularity in both zones.  
 
AP4 sustains GC B cell activation in the DZ. 
We next defined AP4-dependent gene regulatory programs for GC B cell 
expansion by profiling gene expression in c-MYC+AP4+ LZ cells and AP4+ DZ cells 
along with c-MYC–AP4– LZ cells (pre-selection LZ cells) and AP4– DZ cells (post-
mitotic DZ cells) (Figure 13A). Since AP4 was expressed in a small fraction of GC B 
cells, this method would better define AP4-dependent gene expression than directly 
comparing AP4-sufficient and -deficient GC B cells. A similar approach was used to 
determine c-MYC target genes 20. Consistent with their active cell cycle status (Figure 
11B), c-MYC+AP4+ LZ and AP4+ DZ cells were larger in size compared to total LZ and 
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DZ cells, respectively (Figures 13A and 13B). Gene expression profiling by RNAseq 
identified ~1,200 genes upregulated in c-MYC+AP4+ relative to c-MYC–AP4– LZ cells 
by more than 1.8-fold, which were clustered into three groups (Figure 13C). Among 
these genes, those in Cluster I were more highly expressed in AP4+ than AP4– DZ B cells 
and thus predicted to be relevant to AP4-dependent GC B cell expansion. Genes in 
Clusters II and III were expressed similarly in AP4+ and AP4– DZ B cells and included 
Myc and known c-MYC-target genes, such as Batf, Irf4, and Ccnd2 20. Genes in Cluster I 
were enriched for those in pathways related to protein translation and metabolism 
(Figure 13D). ChIPseq analysis for AP4 and c-MYC binding using purified GC B cells 
and activated B cells in vitro, respectively, revealed that ~75% and ~60% of genes in the 
ribosome and metabolic pathways were directly bound by c-MYC and AP4, respectively, 
with ~50% and ~20% of those being common direct targets of c-MYC and AP4 (Figures 
13E and 14). These data suggest that c-MYC and AP4 sequentially sustain transcription 
of genes in ribosome biogenesis and metabolic pathways in selected GC B cells. 
Interestingly, however, AP4 overexpression was insufficient to fully compensate for c-
MYC deficiency in B cells cultured in a condition mimicking GC differentiation 26 
(Figure 15). This result suggests that AP4-dependent proliferation program requires prior 
c-MYC expression.  
 
AP4 is required for accumulation of somatic mutations. 
Since expansion of GC B cells is essential for accumulation of somatic mutations 
and diversification of Ig repertoires, we next determined the frequencies of mutations in 
the JH4-adjacent intronic region of Igh 27. The overall frequencies of mutations and the 
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frequencies of clones carrying multiple mutations following NP-CGG immunization were 
substantially decreased in the absence of AP4 (Figures 16A and 16B). The mutation 
frequency in the VH186.2 BCR, which is over-represented in NP-reactive B cell clones 28, 
29, was also reduced (Figure 16C). However, Aicda mRNA expression was unaltered and 
frequencies of class switched IgG1+ GC B cells were increased in the absence of AP4 
(Figures 16D and 16E), suggesting that reduced somatic mutation unlikely resulted from 
impaired AID activity. The binding avidity of BCR to NP and the surrogate Ag 4-
hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) and the frequencies of NP- and NIP-
binding clones expressing an Igλ light chain 28, as well as NP-specific Igλ antibody titers 
in serum, were modestly reduced in the absence of AP4 (Figures 17A-17C and 18A-
18K). However, the frequencies of VH186 BCR clones carrying the affinity-enhancing 
W33L mutation and the ratio of titers between high-affinity anti-NP4 to low-affinity anti-
NP15 IgG1 were comparable between Tfap4–/– and control GC B cells (Figures 17D and 
18L). These results suggest that AP4 promotes expansion of selected GC B cells, thus 
diversifying BCR repertoires through somatic hypermutation, although it is dispensable 
for the selection of high-affinity clones and affinity maturation of anti-NP antibodies.  
 
AP4 is required for control of chronic viral infection. 
Our results demonstrate that AP4 contributes to diversification of BCR repertoire 
by promoting expansion of DZ GC B cells. Antibody diversification and accumulation of 
somatic mutations are critical for the generation of protective antibodies against chronic 
viral infections in mammals, as exemplified by broadly neutralizing antibodies (bnAbs) 
against HIV that harbor high frequencies of mutations 30, 31. These bnAbs against HIV 
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emerge years after the initial infection, raising the possibility that maximal diversification 
of the BCR repertoire by GCs as the virus mutates is essential for their emergence 32. In 
mice, the generation of high affinity antibodies during GC responses is required for 
control of chronic LCMV infection 33, 34. LCMV clone 13 (LCMV-c13) infection of 
Tfap4F/F Mb1-iCre mice induced GC formation; however, the numbers and frequencies of 
GC B cells were significantly reduced compared to control Tfap4F/F Cre(–) mice (Figures 
19A and 19B) despite normal numbers of CXCR5+PD-1+ TFH cells in the mutants 
(Figures 20). Consistent with previous studies 33, 35, the serum viral titers in control mice 
started to decline 30 days after infection, and viremia was mostly resolved by day 100 
(Figure 21A). In Tfap4F/F Mb1-iCre mice, despite comparable viremia 7 days post-
infection, viral loads remained high until day 100 (Figure 21A). Similarly defective 
control of viremia was seen in Tfap4F/– AID-Cre compared to Tfap4F/+ AID-Cre mice 
(Figure 21B). These results indicate that AP4 expression in B cells is essential for 
control of chronic LCMV infection. Consistent with the presence of GCs in Tfap4F/F 
Mb1-iCre mice, AP4 was dispensable for the production of class switched anti-LCMV 
antibodies (Figure 22). However, AP4-deficient GC B cells accumulated reduced 
numbers of mutations (Figure 23A). Consequently, heat-inactivated immune sera from 
Tfap4F/F Mb1-iCre mice were minimally able to neutralize LCMV in vitro, in sharp 
contrast to their WT counterparts (Figures 23B and 23C). These results demonstrate that 
induced and sustained AP4 expression in Ag-specific B cells is required for maximizing 
the magnitude of GC responses and for generating protective antibodies against viral 
infections.  
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AP4 is sustained by IL-21R signals following induction by c-MYC. 
The finding that AP4 is induced by c-MYC in selected GC B cells, but is 
maintained longer than c-MYC, suggests that help signals derived from TFH cells may 
sustain AP4 expression during migration of LZ B cells towards the DZ. To test this, we 
first induced c-MYC-dependent AP4 expression in B cells by co-culturing them on 
NIH3T3 feeders engineered to express CD40L at a level comparable to activated CD4+ T 
cells (Figure 24A). Under these conditions, both c-MYC and AP4 protein levels 
increased rapidly (Figure 24B). During GC reactions, selected B cells contact TFH cells 
and receive survival and proliferative signals through a CD40-CD40L ligation, and 
subsequently lose this contact as they migrate to the DZ 2, 5, 6, 11, 12, 13, 14, 36. Indeed, 
deprivation of CD40 stimulation reduced AP4 expression at both transcript and protein 
levels (Figures 24B and 24C). Importantly, subsequent stimulation of the CD40-primed 
cultured B cells with IL-21 sustained AP4 expression despite the absence of c-MYC 
protein, while TFH-derived cytokines, IL-4 and IFN-g, showed only a modest and no 
effect, respectively (Figure 24B). IL-21 increased the level of AP4 in a dose-dependent 
manner (Figures 24D and 24E). IL-21 was also sufficient to sustain AP4 expression in 
cultured GC B cells ex vivo following stimulation with CD40L (Figure 24F). However, 
IL-21 was insufficient to increase the AP4 level without priming of B cells with CD40L 
(Figure 25A). Furthermore, co-stimulation of B cells with IL-21 and CD40L reduced 
AP4 mRNA levels compared to CD40L stimulation alone, although its protein levels 
were not changed possibly due to compensation by IL-21-mediated elevation of protein 
translation (Figure 25B and 25C). Thus, IL-21 can maintain AP4 expression after c-
MYC expression is downregulated in B cells in vitro. In addition to upregulation of AP4 
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mRNA (Figure 24C), global protein translation as measured by a puromycin pulse 
labeling 37 was markedly elevated by IL-21 (Figure 24B). Interestingly, IL-21-mediated 
increase of protein translation was reduced in AP4-deficient B cells (Figure 26A). 
Therefore, prior expression of AP4 induced by CD40 signals and c-MYC amplifies the 
effect of IL-21 on protein translation, including accumulation of its own protein, which 
may be retained in a subset of DZ cells passively or post-transcriptionally. IL-21 is also 
necessary for upregulation of Bcl6 and Aicda transcripts 9, 38. However, expression of 
these genes were not affected in IL-21 stimulated Tfap4–/– B cells in vitro (Figures 26B 
and 26C), indicating that AP4 plays a targeted role in controlling the IL-21-dependent 
GC B cell program.  
To validate this finding in vivo, we generated bone marrow chimeras by 
reconstituting mice with a mixture of bone marrow cells from Igh–/– (75%) and Il21r–/– 
(25%) mice (Figure 27A). In the resulting chimeras, all B cells were exclusively derived 
from Il21r–/– bone marrow cells, while a large proportion of non-B cells, including TFH 
cells, were sufficient for Il21r (Figures 27B-27E). Consistent with previous reports 9, 10, 
GC responses were blunted in bone marrow chimeras with Il21r–/– B cells following NP-
CGG immunization, with a significant reduction in the levels of Bcl6 and Aicda 
transcripts compared to control chimera with Il21r+/+ B cells (Figure 28). In these 
chimeras, Il21r–/– LZ B cells expressed significantly reduced Tfap4, but not Myc 
transcripts compared to Il21r+/+ LZ B cells (Figure 29). Ccnd3, a direct AP4 target in GC 
B cells (Figures 13E and 14), was also downregulated in Il21r–/– GC B cells (Figure 
29A). While frequencies of c-MYC+ cells were similar between Il21r–/– and Il21r+/+ GCs, 
frequencies of AP4+ cells as well as AP4 protein levels were markedly diminished in both 
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LZ and DZ of Il21r–/– GCs (Figures 29B-29D). Furthermore, early and mid/late S-phase 
cells in the DZ, but not in the LZ, were reduced in the absence of IL-21R signals, which 
is similar to the phenotype observed in AP4-deficient GCs (Figures 30A and 30B). Thus, 
IL-21 amplifies GC response through sustaining AP4 expression.  
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3.4 DISCUSSION 
In the present work, we have defined a molecular mechanism by which T cell 
help signals received in the LZ programs repeated rounds of proliferation of selected GC 
B cells in the anatomically distant DZ. Studies using a DEC205-targeted Ag-delivery 
demonstrated that amounts of cognate Ag that GC B cells capture and present to TFH cells 
in the LZ regulate the magnitude of expansion of the selected B cells in the DZ through 
upregulation of c-MYC target genes 15, 18. However, expression of c-MYC is restricted to 
a small subset of LZ GC B cells, and it thus remains unknown how GC B cell 
proliferation initiated in the LZ is sustained in the DZ after they lose contact with TFH 
cells and expression of c-MYC. Our results indicate that AP4 connects the selection in 
the LZ to sustained proliferation in the DZ. AP4 is induced by CD40 signals in a c-MYC-
dependent manner and its expression is maintained after the c-MYC decay. AP4 is 
maintained by the cytokine IL-21, which is upregulated in TFH cells during their transient 
interaction with Ag-presenting GC B cells 17. IL-21 may continue to provide T cell help 
to selected B cells during the T-B interaction and during their migration towards the DZ 
to express important genes for GC reactions, including AP4. This effect is mediated at the 
transcriptional level, and also at the translational level in part in an AP4-dependent 
manner. Thus, IL-21 may specifically act on selected B cells that have upregulated AP4. 
However, it may not reach the DZ B cells since IL-21R-dependent upregulation of AP4 
at the transcript level was observed only in the LZ B cells.  
GCs are essential for the generation of protective antibodies that accumulate 
multiple somatic mutations in their Ig genes. Recent studies identified bnAbs against HIV 
that are characterized by substantially high quantities of somatic hypermutations 32, 
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suggesting that enhanced BCR diversification by sustained GC responses is critical for 
the generation of these antibodies. Strains of LCMV have been used to study both 
humoral and cellular immune responses against chronic viral infection in mice. GC 
responses and expression of AID are essential for the control of chronic LCMV infection 
33, 34. Our data indicate that AP4-mediated durable GC response is required for the control 
of chronic LCMV infection in a B cell-intrinsic manner. This was evidenced by reduced 
accumulation of somatic mutations and the impaired development of antibodies with 
neutralizing activities in the absence of AP4. Although these results indicate that AP4 is 
required for diversification of antibody repertoire and subsequent affinity maturation, 
AP4 deficiency had no substantial impact on antibody affinity maturation to NP. This can 
be explained by recent reports that anti-hapten antibody affinity is robustly increased by a 
few dominant mutations, whereas affinity maturation against complex protein Ag 
requires sequential accumulation of many mutations during GC reaction 39, 40.  
We previously demonstrated that AP4 maximizes acute CD8+ T cell responses by 
sustaining c-MYC-initiated gene expression program 41. Together with our current study, 
both T and B cells seem to be dependent on restricted c-MYC expression and 
subsequently utilize its downstream factor AP4 to achieve the maximal magnitude of 
adaptive immune response. After induction by c-MYC, expression of AP4 is sustained in 
an IL-2 or IL-21-dependent manner in CD8+ T or GC B cells, respectively, and 
compensates for the early termination of c-MYC expression 41. It is unclear why activated 
lymphocytes utilize c-MYC only for a brief window and terminate its expression 
prematurely before the completion of their clonal expansion. Although c-MYC is critical 
for the establishment of highly proliferative states of lymphocytes upon Ag receptor 
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stimulation, prolonged expression of c-MYC may make the cells prone to apoptosis 42 or 
increase the risk of transformation in the presence of genotoxic stress during GC 
responses. Aberrant expression of c-MYC has been causally linked to increased incidence 
of pre-B cell leukemia and B cell lymphoma 43. The Myc locus is also efficiently targeted 
by AID 44. Therefore, restriction of c-MYC at both protein and transcript levels may be 
necessary to prevent transformation during GC responses, although extensive lymphocyte 
proliferation is critical for protection against virulent pathogens.  
Collectively, our results demonstrate that direct T cell help during the T-B 
interaction and potential remote help mediated by IL-21 sequentially induce transient 
expression of c-MYC and sustained expression of AP4 to drive sufficient expansion of 
GC B cells following clonal selection by TFH cells. Such sustained GC responses are 
necessary for the generation of mutated antibodies with protective activity against 
chronic viral infection in the mouse model and may also be important for the generation 
of the anti-HIV bnAbs in humans. In conjunction with our previous study, the current 
data suggest that activated B and T cells both utilize a transcription factor cascade in 
which c-MYC hands off its role to AP4, a relay that is required to maximize clonal 
expansion to drive effective antiviral immunity.  
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3.5 MATERIALS AND METHODS 
Mice 
C57BL/6N and B6-CD45.1 mice were purchased from Charles River Laboratory. 
Rosa26-CreERT2 mice 45, Cγ1-Cre mice 25, AID-Cre mice 46, Igh–/– (µMT) mice 47, and 
Il21r–/– mice 48 were purchased from the Jackson Laboratory. Tfap4F 41, Tfap4− 49, MycF 50, 
Mb1-iCre 24 and MycGFP 23 alleles have been described. A Tfap4mCherry allele was 
generated by inserting a sequence encoding the mCherry fluorescence protein to the 
carboxyl terminus of AP4. A targeting vector was constructed with 5-kb 5’ homologous 
and 5-kb 3’ homologous arms cloned into a targeting cassette containing HSVtk and 
loxP-flanked Pgk Neor selection cassettes. NotI linearized targeting vector DNA was 
electroporated into JM8.N4 ES cells (KOMP Repository), and G418/Gancyclovir double-
resistant clones were screened for homologous recombination by Southern blotting. 
Targeted ES cells were injected into B6(Cg)-Tyrc-2J blastocysts, and chimeric males were 
crossed to EIIa-cre females 51 (Jackson Laboratory) to obtain germ-line transmission and 
to delete the selection cassette. For the experiments with bone marrow chimeras, B6-
CD45.1 mice were lethally irradiated (10.5 Gy) and reconstituted with donor bone 
marrow cells for at least 8 weeks before experiments. All mice were maintained in the 
C57BL/6 (B6) background, were housed in a specific pathogen-free facility at 
Washington University in St. Louis, and were analyzed at 6–14 weeks of age unless stated 
otherwise. Both sexes were included without randomization or blinding. All experiments 
were performed according to a protocol approved by Washington University's Animal 
Studies Committee.  
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Human tissue samples 
Tonsils were obtained from routine tonsillectomies performed at the Barnes-Jewish 
Hospital according to a protocol approved by an Internal Review Committee at 
Washington University School of Medicine. 
 
LCMV Infection 
Mice were infected with 2 x 106 plaque-forming units (PFU) of LCMV-c13 by 
intravenous injection. For the quantification of serum viral load, RNA was extracted from 
10 µl of serum from LCMV-infected mice using Trizol. 1 µl of ERCC RNA Spike-In 
Control Mixes, at a concentration of 1:10,000, was added to the lysate before RNA 
extraction and reverse transcription. The level of the LCMV NP transcript relative to that 
of ‘spiked-in’ RNA was determined by real-time quantitative RT-PCR using the primers 
previously described 41, 52. In vitro neutralization assay was performed according to a 
previously described protocol with some modifications 53. Vero cells were plated at 5 x 
104 cells per well in a flaT-Bottom 96-well plate one day before infection. Heat-
inactivated (one hour at 55 °C) sera from LCMV-infected and control mice were serially 
diluted with media and incubated with an equal volume of viral supernatant containing 
300 PFU of LCMV clone 13 at 37 °C for 90 min. Infectivity of the mixtures was 
determined by intracellular staining for LCMV NP of Vero cells that were incubated with 
the mixture for 48 hours 54. For each dilution of serum samples, the percentage of LCMV 
NP+ Vero cells treated with LCMV-immune serum was normalized to that treated with 
control serum. A neutralization curve and an EC50 value for each sample were obtained 
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using the non-linear fit equation "log (inhibitor) vs. normalized response -- variable 
slope" in Prism 6 software (Graphpad).  
 
Immunization protocols and treatments 
Mice were immunized with either ~8-10 x 108 SRBC (Lampire), 100 µg of NP-
conjugated chicken gamma globulin (NP-CGG, Biosearch) precipitated in alum, or 100 
µg of NP-Ficoll (Biosearch) in PBS by intraperitoneal injection. NP- and NIP-APC were 
prepared by conjugating allophycocyanin (Sigma-Aldrich) with NP or NIP ester 
(Biosearch) as previously described 55. 
 
In vitro B cell culture 
CD40L-expressing feeders were generated by infecting NIH-3T3 cells with a retrovirus 
expressing CD40L and sort-purified based on surface CD40L expression. The feeders 
were seeded in RPMI-1640 supplemented with 10% FBS (Gibco) at a density of 4 x 106 
cells per 6-, or 12- well plate, or 100mm dish one day before adding splenic B cells 
purified from B6 mice using anti-CD19-microbeads (Miltenyi). B cells were removed 
from feeders by gentle shaking and pipetting. For liquid culture of B cells, CD40L-
activated B cells were incubated in medium containing IL-4 (eBioscience), IL-21 
(Peprotech), or IFN-γ (Peprotech) for additional 16-18 hours. To measure protein 
translation, B cells were treated with 10 µg/ml of puromycin (Sigma) for 10 min at 37°C 
before lysis. CD40L- and murine BAFF-expressing feeders 26 were used for culturing of 
GC B cells ex vivo. 
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Real-time quantitative RT-PCR 
RNA was extracted with Trizol (Life Technologies) and was reverse-transcribed with 
qScript Supermix (Quanta Bio). DyNAmo ColorFlash SYBR green qPCR mix 
(Thermofisher) and a LightCycler 480 (Roche) were used for real-time quantitative RT-
PCR. Quantities of transcripts were normalized to that of 18S ribosomal RNA unless 
specified otherwise. For quantification of gene expression normalized to that of 'spiked-
in' RNA, 1 µl of ERCC (External RNA Controls Consortium) RNA Spike-In Control 
Mixes (Ambion) was added at a dilution of 1:10,000 to lysates from 1 × 106 cells prior to 
RNA extraction. Primers for 18S-rRNA, ERCC-00108, LCMV-NP, Tfap4, Myc and Bcl6 
were described previously (Chou et al., 2014). The following primers were used:  
Aicda, CGTGGTGAAGAGGAGAGATAGTG and 
CAGTCTGAGATGTAGCGTAGGAA;  
Atic, CGTCTCTTGGTTTGAGTCTGGT and GGAACCCTGTTAGCTCAGACAC;  
Cad, GTACGAAGATTGGGAGTTGCAT and CTACGCAGTTCTCATCGACCAT;  
Ccnd2, CAGACCTTCATCGCTCTGTG and CGTGAGTGTGTTCACTTCATCA;  
Ccnd3, GAAGATGCTGGCATACTGGAT and CCAGGTAGTTCATAGCCAGAGG;  
Eif3b, AGGATTTCGTAGACGACGTGAG and CCGATCTTTGAGTACATCACCA;  
Eif4g1, CCTACCGAGTTTGGGACCTAT and ACTAGCAGGAAACTGCTGCAC;  
Gar1, TGTCAGAAAACATGAAGGCATC and GCAGCAGCTTGTATGGGTCTAT;  
Gart, AGTCTCCTCAGGTCAAGCAAGT and GCACTGTGATCATTGACAGAGAC;  
Il21r, TCTGAGAAAGACCCTGAAGGAG and CATGGAGAATCAGCAGGAGTAA 
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Lap3, AGTGAGAGGTCTCTGGGATCG and TTGTAAATTGTGGCAGGTCATC;  
Lsm2, GGAACTCAAGAATGACCTGAGC and TGAGGGTATTTCTCAGGGTCTG;  
Nme1, CGGTAAAGCCTTGTCATCTGAA and CTCGAACCGCTTGATGATCT;  
Ran, CAGCACAGTACGAGCATGATTT and CCAGCTTCACTTTCTCACAGGT;  
Rpl23, CCACAGTTAAGAAAGGCAAACC and CTATGACCCCTGCGTTATCTTC;  
Rpl27, TCCAAGATCAAGTCCTTTGTGA and AACAGTCTTGTCCAAGGGGATA;  
Rpl35a, AAAGGCCATTGGACACAGAAT and TAGTTTAAATCCGGGATGGGTA;  
Rplp0, TGGAAGTCCAACTACTTCCTCAA and GTTGTCTGCTCCCACAATGAAG;  
Rplp2, AATACTAGACAGCGTGGGCATC and TTTCCATTCAGCTCACTGATGA;  
Rps10, GGAGGCTGACAGAGACACCTAC and CCTCTAAACTGGAACTCAGTGG;  
Rps16, GTCCCCTGGAGATGATCGAG and AGAAGCAAAACAGGCTCCAGTA;  
Rps29, ACAGAAATGGCATCAAGAAACC and ATTGTTGGCCTGCATCTTCTT;  
Snrpd1, GTGGATGTTGAACCTAAGGTGA and ACCACGTCCTCTTCCTCTACC;  
Snrpe, CAAAAGGTGCAGAAGGTGATG and TTCACTTGTTCATACAGCCACA;  
Xpot, GCGAGGAAGAGATATTGGAGTG and ATCACAACAGACGTGGCTTCTA.  
 
Flow cytometry 
Single-cell suspensions were prepared as described 41. The following monoclonal 
antibodies were used in this study: For sorting of GC B cells, splenocytes were stained 
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with monoclonal antibodies (identified above) before being sorted as B220+IgD–
GL7+Fas+ cells or B220+IgD–CD38–GL7+ on a FACSAria II (BD). For analysis, cells 
were stained with monoclonal antibodies and were analyzed with an LSRII (BD) or LSR 
Fortessa (BD), with staining with DAPI (4, 6-diamidino-2-phenylindole; Sigma) or Aqua 
Live/Dead (L34957, Life Technologies) for the exclusion of dead cells. Intracellular 
staining of AP4 was performed as previously described 41. For cell cycle analysis, mice 
were injected intravenously 1 mg EdU (Sigma-Aldrich), followed by 2 mg BrdU (Sigma-
Aldrich) in PBS one hour later as described 15. Cells were harvested 30 minutes after 
BrdU injection and processed using an APC BrdU Flow Kit (BD Pharmingen) and a 
Click-iT Plus EdU Pacific Blue Flow Cytometry Kit (Invitrogen). BrdU was detected 
using an AF647-conjugated anti-BrdU antibody (MoBU-1, Invitrogen). Data were 
analyzed with FlowJo software (TreeStar). 
 
Immunofluorescence microscopy 
For the detection of AP4 and c-MYC, tissues were fixed in 4% paraformaldehyde at 4 °C 
over night before embedding in OCT compound (Sakura Finetek). 8 µm sections were 
cut on a cryostat (Microm HM 550), fixed in ice-cold acetone, and stained. Sections were 
mounted with ProLong Gold Antifade Mountant with DAPI (P36935, Life 
Technologies). For the detection of AID, a Tyramide Signal Amplification System 
(T30955, Life Technologies) was used. Images were acquired with Zeiss AxioCam MRn 
microscope equipped with an AX10 camera. Subsequent color balancing, overlaying, and 
area measurements were performed in an ImageJ software (NIH) and Photoshop (Adobe). 
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Antibodies 
The following antibodies were used in Immunofluorescence microscopy: Alexa Fluor 
(AF) 488-conjugated anti-IgD (11-26c.2a, Biolegend), AF647-conjugated anti-GL7 (GL-
7, Biolegend), anti-Rabbit IgG (4414S, Cell Signaling), biotinylated anti-TCRb (H57-
597, Biolegend), anti-CD35 (8C12, BD), unconjugated anti-AID (MAID-2, eBioscience), 
anti-human CD23 (NCL-L-CD23-1B12, Leica), anti-Myc (ab32072, Abcam), anti-AP4 
49. Secondary reagents: Streptavidin-conjugated AF555 (S32355, Life Technologies), 
biotinylated anti-Rat IgG (6430-08, Southern Biotech), anti-Mouse IgG1 (A85-1, BD). 
The following antibodies were used in Flow cytometry: AF488-conjugated anti-CD86 
(GL-1, Biolegend), anti-IgD (11-26c.2a, Biolegend), anti-CD45.1 (A20, Biolegend), anti-
CD23 (B3B4, Biolegend); FITC-conjugated anti-GL7 (GL-7, Biolegend); PE-conjugated 
anti-GL7 (GL-7, BD), anti-CD40L (MR1, Biolegend), anti-Igl (RML-42, Biolegend), 
anti-CD43 (S7, Biolegend), anti-CD5 (53-7.3, BD), anti-CD93 (AA4.1, Biolegend); 
PerCP-Cy5.5-conjugated anti-CXCR4 (L276F12, Biolegend), anti-IgG1 (RMG1-1, 
Biolegend), anti-IgD (11-26c.2a, Biolegend), anti-B220 (RA3-6B2, Biolegend); PE-Cy7-
conjugated anti-Fas (Jo2, BD), anti-B220 (RA3-6B2, Biolegend), anti-CD24 (M1/69, 
Biolegend); APC-conjugated anti-CD19 (6D5, Biolegend), anti-PD1 (29F.1A12, 
Biolegend); AF647-conjugated anti-CD45.2 (104, Biolegend), anti-GL7 (GL-7, 
Biolegend), anti-CD86 (GL-1, Biolegend), anti-IgM (RMM1, Biolegend), anti-CD38 (90, 
Biolegend); AF700-conjugated anti-CD19 (6D5, Biolegend); APC-Cy7-conjugated anti-
CD45.2 (104, Biolegend), anti-B220 (RA3-6B2, Biolegend); Pacific Blue-conjugated 
anti-IgD (11-26c.2a, Biolegend), anti-B220 (RA3-6B2, Biolegend), anti-CD21/35 (7E9, 
Biolegend), anti-CD19 (6D5, in house); Brilliant Violet (BV) 510-conjugated anti-B220 
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(RA3-6B2, Biolegend); BV605-conjguated anti-CD45.1 (A20, Biolegend); and 
biotinylated anti-CXCR5 (2G8, BD), anti-BP-1 (6C3, Biolegend). 
 
Enzyme-linked immunosorbent assay (ELISA) 
Anti-NP antibody titers were assessed using NP4-BSA (Biosearch), NP15-BSA 
(Biosearch), biotinylated anti-mouse IgG1 (A85-1, BD), anti-mouse Igl (1175-08, 
Southern Biotech), and horseradish peroxidase-conjugated Streptavidin (554066, BD), 
which was developed with TMB substrate (S1599, Dako). Anti-LCMV antibody titers 
were measured as previously described using LCMV virion purified on a 20% sucrose 
cushion, biotinylated anti-mouse IgG1 antibody and anti-mouse IgG2c antibody (1077-08, 
SouthernBiotech) 56, 57. Endpoint titers were calculated by a one-phase exponential decay 
curve using a Prism 6 software (Graphpad) 58. 
 
Immunoglobulin sequence analysis 
An intronic sequence 3’ to the JH4 exon of Igh and the VH186.2 sequences were PCR 
amplified from genomic DNA extracted from 3,000-5,000 GC B cells using Phusion HF 
(Thermo) and oligonucleotide primes described previously 15. PCR products were gel 
extracted, cloned into a pCR2.1-TOPO vector (Life Technologies), and sequenced. 
Obtained JH4 intronic sequences were aligned to the mm9 assembly of the mouse 
genomic sequence. VH186.2 sequences were analyzed with ImMunoGeneTics (IMGT) V-
QUEST (http://www.imgt.org/) 59, 60. Mutation frequencies in the JH4 intronic region 
were calculated by dividing the total number of mutations from all clones with the total 
number of base pairs analyzed for each group. For mutation analysis of the 
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immunoglobulin heavy chain gene, 5,000-20,000 GC B cells were purified from spleens 
30 days after LCMV clone 13-infection. Total RNA was extracted using TRIzol and 
cDNA was synthesized using the SuperScript III first-strand synthesis system 
(Invitrogen) with a Cγ2c (Outer) primer 61, followed by a semi-nested PCR using Phusion 
HF. An adaptor-tagged promiscuous VH (MsVHE) primer (5’-
TCTTTCCCTACACGACGCTCTTCCGATCTGGGAATTC 
GAGGTGCAGCTGCAGGAGTCTGG-3’) and an adaptor-tagged Cγ2c primer (5’-
GTGACTGGAGTTCAGACGTGTGCTCTTCCGAGCTCAGG 
GAAATAACCCTTGAC-3’) were used for the first round PCR 61. The following primers 
were used for the second round PCR: 5’-AATGATACGGCGACCACCGA 
GATCTACACTCTTTCCCTACACGAC-3’ and 5’-CAAGCAGAAGACGGCATACG 
AGATNNNNNNNGTGACTGGAGTTCA GACG-3’ (NNNNNNN: sample-specific bar 
codes). The PCR products were quantitated using Qubit (Invitrogen) and pooled in 
equimolar ratios for paired-end 2x250 bp sequencing on an Illumina MiSeq DNA 
sequencer. To determine the mutation frequency in the VDJ coding regions, only reads 
longer than 400 bp and with an average qscore > 30 were analyzed with IMGT HighV-
QUEST 59, 60. All sequences with >90% identity to the reference sequences from the 
IMGT database were used for mutation analysis. Only mutations with a qscore > 22 were 
counted. 
 
Chromatin Immunoprecipitation Assay 
For anti-c-MYC ChIP, splenic naive B cells, purified with anti-CD19 microbeads 
(Miltenyi), were activated with 10 µg/ml of anti-IgM (115-005-020, Jackson 
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ImmunoResearch) for two days, and further cultured on CD40L-expressing NIH 3T3 
feeder cells for 24 hours. For anti-AP4 ChIP, splenic LZ and DZ GC B cells eight days 
after immunization with SRBCs were purified by sorting on a FACS AriaII. Anti-c-
MYC, anti-AP4 and anti-H3K27ac (ab4729, Abcam) ChIPs were performed as 
previously described 41. Sequence tags were mapped onto the NCBI37 mm9 with 
Bowtie2 62. The Homer software package 63 was used for peak calling with a Poisson P-
value cutoff of 1 × 10−40 for AP4 and 1 × 10−6 for c-MYC for extraction of the 4758 and 
4046 peaks with the highest statistical significance, respectively. 
 
RNAseq Analysis 
Total RNA was purified from 3,000 – 10,000 sorted MYC–AP4– LZ, MYC+AP4+ LZ, 
AP4+ DZ, and AP4– DZ GC cells from AP4-mCherry/c-MYC-GFP reporter mice eight 
days after immunization with SRBCs (Figure 4A) using a Nucleospin RNA XS extraction 
kit (Macherey-Nagel) according to the manufacturer’s instructions. The purified RNA 
was reverse-transcribed and amplified using a SMART-Seq v4 Ultra Low Input RNA Kit 
(Clonetech), followed by library construction using a Nextera DNA Library Prep Kit 
(Illumina). High throughput sequencing was performed using a HiSeq 2500 sequencer 
(Illumina) with a 50 bp single read option. Sequence tags were mapped onto the NCBI37 
mm9 with TopHat 64, followed by transcript assembly and RPKM estimation using 
Cufflinks 65, 66, 67, 68 on the Galaxy platform (https://usegalaxy.org/). Analysis was done 
with three biological replicates and genes upregulated in MYC+AP4+ relative to MYC–
AP4– LZ cells by more than 1.8-fold with a Student’s t-test P-value less than 0.1 were 
analyzed by hierarchical clustering using Euclidean distance matrix with centroid 
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linkage. Pathway analysis was performed using a web-based gene set analysis toolkit 
(http://bioinfo.vanderbilt.edu/webgestalt/).  
 
Immunoblot analysis 
Whole cell extracts were prepared by lysis of cells in Laemmli buffer containing 1% SDS 
and 2% 2-mercaptoethanol. Lysates from equal numbers of cells were separated by 8% or 
10% SDS PAGE and transferred to PVDF membranes (Roche). Membranes were 
incubated with primary antibodies (identified below), followed by detection with 
horseradish peroxidase–conjugated species-specific antibody to immunoglobulin light 
chain (115-035-174, 211-032-171; Jackson ImmunoResearch) and a Luminata HRP 
substrate (Millipore). Anti-AP4 was described 41. The following antibodies were 
purchased: anti-Puromycin (MABE343; Millipore), anti-c-MYC (9402S; Cell Signaling), 
anti-phospho-STAT3 (Tyr705) (9145; Cell Signaling) and anti-BCL6 (4242S, Cell 
Signaling). Anti-HDAC1 (ab7028; Abcam) was used as loading controls. 
 
Statistical analysis 
P values were calculated with an unpaired two-tailed Student's t-test for two-group 
comparisons and by one-way ANOVA for multiple-group comparisons with the Tukey 
post-hoc test using Prism 6 software (Graphpad) unless specified otherwise. For the 
comparison of cumulative frequencies between two datasets and the frequency of W33L+ 
clones between two groups, the Kolmogorov-Smirnov test and χ2 test with Yates 
correction were used, respectively. P values of <0.05 were considered significant. N.S., 
not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
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Figure 3.1. MYC is required for AP4 induction after B cell activation. (A) Expression 
levels of transcription factors upregulated in MYC+ relative to MYC– GC B cells 12 days 
after immunization with SRBC shown as a heat map. (B and C) AP4 protein expression 
and Tfap4 mRNA levels (2 hours) in B cells that were harvested from Tamoxifen-treated 
MycF/F Rosa26-CreERT2 or Rosa26-CreERT2 mice and co-cultured with CD40L-
expressing feeders. Data are representative of three experiments. (D) Binding of c-MYC 
to the Tfap4 locus in CD40L-activated B cells. Histograms of sequence tags pulled down 
with anti-c-MYC or anti-H3K27ac antibody are shown. Data are shown by means ± SD. 
Unpaired Student’s t test. n = 3 per group (B and C).  
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Figure 3.2. AP4 is expressed in both LZ and DZ GC B cells. (A) Staining for AP4, 
AID and IgD of spleen sections eight days after SRBC immunization. B cell follicles (Fo) 
and GCs are marked by white and yellow dashed lines, respectively. Data are 
representative of two experiments. (B) Staining for AP4 and c-MYC of spleen sections 
eight days after SRBC immunization. LZ and DZ of GCs defined by the presence of 
CD35+ FDCs are shown with white and yellow dashed lines, respectively. Data are 
representative of two experiments. (C) AP4, c-MYC, and BCL6 protein levels in naive 
(N), total B220+GL7+Fas+ GC, CD86hiCXCR4lo LZ and CD86loCXCR4hi DZ B cells 
eight days after SRBC immunization. (D) Immunofluorescence microscopy showing 
expression of AP4, c-MYC, AID, and CD23 in human tonsils. LZ and DZ are surrounded 
by white and yellow dashed lines, respectively. Data are representative of three 
independent experiments. Data are representative of three experiments. *: non-specific 
band. Scale bar, 100 µm. n = 4 (A and B); n = 3 (C); n = 2 (D) 
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Figure 3.3. Generation of Tfap4mCherry protein reporter allele. (A) A targeting strategy 
to generate the AP4-mCherry fusion protein reporter allele. (B) Southern blot analysis of 
targeted ES clones. Genomic DNA from WT and one representative targeted ES clone 
was digested with EcoRI and probed with the 5’ probe (left panel) and 3’ probe (right 
panel). (C and D) Immunoblot analysis showing AP4 and AP4-mCherry expression in 
GC B cells from Tfap4mCherry/+ mice eight days after immunization with SRBCs (C), or 
splenic B cells from the same strain activated with CD40L followed by treatment with 
cycloheximide (D). Data are representative of two independent experiments.  (E) AP4 
and AP4-mCherry protein expression in total, AP4-mCherry+, and AP4-mCherry– GC B 
cells in (C). Data are representative of three independent experiments. (F) Flow 
cytometric analysis showing mCherry and GFP expression in GC B cells from the 
indicated mice eight days after immunization with SRBCs. Data are representative of two 
independent experiments. 
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Figure 3.4. MYC+ GC B cells co-express AP4. (A and B) Expression of GFP and 
mCherry in GC B cells of MycGFP/+ Tfap4mCherry/+ mice eight days after SRBC 
immunization (A). Distribution of AP4-mCherry+ or c-MYC-GFP+ cells in the LZ and 
DZ defined by CD86 and CXCR4 expression is shown in the right panels (A). 
Frequencies of AP4- or c-MYC-expressing cells in total GC, LZ and DZ GC B cells from 
two independent experiments are shown in (B). (C) Intracellular staining for AP4 in c-
MYC-GFP+ LZ GC B cells eight days after SRBC immunization. Staining for AP4 in 
Tfap4–/– LZ cells is shown as control. Data are pooled from two experiments. Data are 
shown by means ± SD. n = 6 for (A and B); n = 4 for MycGFPTfap4+/+ and n = 2 for 
Tfap4–/– mice (C) 
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Figure 3.5. AP4 is dispensable for B cell development and homeostasis. (A) Flow 
cytometric analysis showing expression of CD11b, B220, CD43, BP-1, CD24, IgM and 
IgD in bone marrow cells from Tfap4F/– Mb1-iCre (N=4) and control Tfap4F/+ Mb1-iCre 
mice (N=3). (B) Absolute numbers of B220+CD43+ and B220+CD43– bone marrow cells 
per femur in each developmental stage as color-coded in (A). (C) Expression of B220, 
IgD, IgM, AA4.1, CD23, and CD21 in splenocytes from Tfap4F/– Mb1-iCre and control 
Tfap4F/+ Mb1-iCre mice. (D) Absolute number of B220+ splenocytes in each 
developmental stage as color-coded in (C). (E) Expression of IgD, IgM, CD5 and CD19 
in cells in peritoneal cavity lavage from Tfap4F/– Mb1-iCre and control Tfap4F/+ Mb1-
iCre mice. (F) Frequencies of B1a and B1b cells in (E). Data are pooled from two 
independent experiments, and shown by means ± SD in (B, D and F). Unpaired Student’s 
t test. 
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Figure 3.6. AP4 is required for normal GC formation in a B cell-intrinsic manner 
(A-C) Expression of GL7 and Fas in B220+ splenocytes ten days after NP-CGG 
immunization (A). Statistical analysis of frequencies (B) and absolute numbers (C) of 
GL7+Fas+ cells in B220+ splenocytes from four independent experiments is shown. (D 
and E) Flow cytometric analysis of CD45.2 donor cell contribution to the follicular 
(IgD+CD19+) and GC (IgD–CD19+GL7+Fas+) B cell compartments in mixed bone 
marrow chimeras 12 days after NP-CGG immunization (D). Statistical analysis of 
CD45.2 donor cell contribution to GC normalized to that of follicular B cells from five 
independent experiments is shown in (E). (F) Staining for GL7, IgD and TCRβ of spleen 
sections from mice with indicated genotypes ten days after NP-CGG immunization. 
Representative data from four independent experiments are shown. Scale bar: 100 µm. 
(G) Statistical analysis of the size of each GC in (F). Data are pooled from four 
independent experiments. (H and I) Flow cytometric analysis showing expression of 
GL7 and Fas on B220+-gated cells in Peyer’s patches from Tfap4–/– (N=6), Tfap4F/F Mb1-
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iCre (N=7) and control Tfap4F/F Cre(–) (N=7) mice (H). Statistical analysis of data from 
two independent experiments is shown in (I). Data in (B, C, E, G and I) are shown by 
means ± SD. One-way ANOVA for (B, C and G). Unpaired Student’s t test for (E and I). 
n = 10 for Tfap4–/– and Tfap4F/F Mb1-iCre, and n = 28 for Tfap4F/F Cre(–) (A-C, F and G); 
n = 12 for Tfap4F/F Cre(–) and n = 16 for Tfap4–/– (D and E). 
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Figure 3.7. AP4 is essential for expansion of pre-GC B cells.  (A) Intracellular staining 
for AP4 in c-MYC-GFP+ pre-GC B cells four days after immunization with SRBCs 
(N=5). AP4 staining in Tfap4–/– cells is shown as negative control. Data are pooled from 
two experiments. (B and C) Flow cytometric and statistical analysis showing the 
contribution of CD45.2 donor cells to the follicular (IgD+CD19+) and pre-GC (IgD–
CD19+GL7+Fas+) B cell compartments in mixed bone marrow chimeras (N=5 per group) 
five days after NP-CGG immunization. Donor cell contribution to the pre-GC 
compartment was normalized to that of follicular B cells. Data are pooled from three 
independent experiments. Data are shown by means ± SD. Unpaired Student’s t test. 
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Figure 3.8. AP4 is necessary for GC maintenance. (A and B) Expression of GL7 and 
Fas in B220+ splenocytes and NIP-allophycocyanin (APC)- binding by B220+GL7+Fas+ 
cells from Tfap4F/F Cγ1-Cre and control Tfap4+/+ Cγ1-Cre mice ten days after NP-CGG 
immunization. Statistical analysis from two independent experiments is shown in (F). (C) 
Experimental scheme for the generation of mixed bone marrow chimeras used in (B-D). 
A three to one mixture of bone marrow cells from Igh–/– mice and Tfap4+/+ Rosa26-
CreERT2, Tfap4F/F Rosa26-CreERT2, or MycF/F Rosa26-CreERT2 mice were transplanted 
into lethally irradiated B6-CD45.1 hosts. Tamoxifen was administered on days eight, 
nine, and ten after immunization with NP-CGG, followed by analysis of GC responses on 
day 12. (D) Expression of GL7 and Fas on donor-derived B220+ splenocytes from the 
indicated mixed bone marrow chimeras (N=4-11). Data are representative of four 
independent experiments. (E) Frequencies of GL7+Fas+ in B220+ cells (left panel) and 
absolute numbers of B220+GL7+Fas+ cells in the spleens (right panel) from indicated 
mixed bone marrow chimeras. Data are pooled from four independent experiments. (F) 
Tfap4 mRNA levels in B220+GL7+Fas+ splenocytes from the bone marrow chimeras. 
Data are pooled from two independent experiments. Data are shown by means ± SD. 
Unpaired Student’s t test for (B and F). One-way ANOVA for (E). 
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Figure 3.9. AP4 is dispensable for responses to T-independent antigen. (A) 
Expression of B220, CD138, and IgD in splenocytes and intracellular NP-binding in 
CD138+B220– splenocytes from Tfap4F/– Mb1-iCre (N=4) and control Tfap4F/+ Mb1-iCre 
(N=4) mice seven days after immunization with NP-Ficoll. Data are representative of two 
independent experiments. (B) Frequencies and absolute numbers of CD138+B220– cells 
per spleen and the frequency of NP-binding cells in CD138+B220– splenocytes in (A). 
Data are pooled from two independent experiments. (C) Serum NP-specific IgM titers 
seven days after NP-Ficoll immunization in (A). Data are shown by means ± SD. 
Unpaired Student’s t test. 
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Figure 3.10. AP4 is dispensable for the formation of memory B cells and bone 
marrow antibody secreting cells (ASCs). (A) Binding to APC-NP and expression of 
IgG1 in B220+CD38+IgM–IgD– splenocytes from Tfap4F/– AID-Cre (N=6) and Tfap4F/+ 
AID-Cre (N=4) mice eight weeks after immunization. (B) Statistical analysis of the 
number of NP-specific bone marrow ASCs in (A). Data are pooled from two experiments 
and shown by means ± SD. Unpaired Student’s t test. 
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Figure 3.11. AP4 enhances GC B cell proliferation through the regulation of cell 
cycle re-entry in the DZ. (A) Flow cytometric analysis showing c-MYC-GFP expression 
in Tfap4–/– and control Tfap4F/F Cre(–) LZ GC B cells eight days after NP-CGG 
immunization (N=7-8 per group). Data are pooled from three independent experiments. 
(B) Cell cycle analysis by DNA content measurement of AP4-mCherry+ LZ and DZ cells 
compared to total LZ and DZ cells from Tfap4mCherry reporter mice eight days after SRBC 
immunization. Data are pooled from two independent experiments. (C) Cell cycle 
analysis by sequential EdU and BrdU labeling of CD45.2 Tfap4–/– and control Tfap4F/F 
Cre(–) donor LZ and DZ GC B cells in mixed bone marrow chimeras eight days after 
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NP-CGG immunization. Early-, mid/late-, and post-S phases of the cell cycle were 
defined as previously described. Representative plots and statistical analysis from two 
independent experiments are shown. (D) EdU and BrdU incorporation by LZ and DZ GC 
B cells derived from WT CD45.1 donor cells in mixed bone marrow chimeras following 
sequential pulse labeling with EdU and BrdU as described in (C). Data are pooled from 
two independent experiments. Unpaired Student’s t test. 
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Figure 3.12. AP4-defieincy does not alter LZ-DZ segregation. (A-C) Expression of 
CD86 and CXCR4 in B220+GL7+Fas+ GC B cells from mice with indicated genotypes 
ten days after NP-CGG immunization. Representative plots (A) and statistical analysis of 
frequencies of LZ (CD86hiCXCR4lo) and DZ (CD86loCXCR4hi) cells in the GC B cell 
compartment (B) and DZ to LZ ratios (C) from four independent experiments are shown. 
One-way ANOVA. 
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Figure 3.13. AP4-expressing DZ cells maintain activation signatures following c-
MYC downregulation. (A and B) Relative cell sizes (forward scatter) of MYC+AP4+ 
LZ and DZ B cells from AP4-mCherry/c-MYC-GFP knock-in mice eight days after 
SRBC immunization (A). Statistical analysis from three independent experiments is 
shown in (B). (C) RNAseq analysis of MYC–AP4– LZ, MYC+AP4+ LZ, AP4+ DZ and 
AP4– DZ cells. Expression of genes which were expressed higher by >1.8-fold in 
MYC+AP4+ LZ cells than MYC–AP4– LZ cells is shown as a heat map following 
unsupervised clustering analysis that yielded three major clusters. (D) Pathway analysis 
of Cluster I genes in (C) combined with ChIPseq analysis showing the frequencies of 
genes directly bound by AP4, c-MYC, or both in each pathway. The number of genes in 
each pathway is shown to the right of the bar with P-values for enrichment. (E) Spike-in 
qPCR validation of representative AP4-MYC-cobound genes in (D). Expression levels in 
four independent samples from two experiments are shown as a heatmap. Data are shown 
by mean ± SD. Unpaired Student’s t test. 
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Figure 3.14. Identification of AP4 and c-MYC co-target genes. Examples of c-MYC 
and AP4 binding to genes shown in Figure 14E determined by ChIPseq using sorted LZ 
or DZ GC B cells or in vitro activated B cells. 
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Figure 3.15. Overexpression of AP4 does not rescue defects of Myc–/– B cells.  Flow 
cytometric analysis showing CellTrace Violet dilution of Myc-deficient B cells infected 
with a control retrovirus (RV) or one expressing AP4 or MYCT58A. CD40L-primed 
MycF/F Rosa26-CreERT2 or Myc+/+ Rosa26-CreERT2 splenic B cells were infected with 
indicated RV, followed by treatment with 4-hydroxytamoxifen (4-OHT), and 
proliferation was analyzed. Data are representative of two independent experiments. One-
way ANOVA. 
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Figure 3.16. AP4 is necessary for the accumulation of somatic mutations.  (A) 
Frequencies of mutations in an JH4 adjacent intronic region in Tfap4–/– and control 
Tfap4F/F Cre(–) donor GC B cells from mixed bone marrow chimeras 12 days after NP-
CGG immunization. Data are pooled from three independent experiments. (B) 
Frequencies of clones carrying multiple mutations in (A). (C) Cumulative frequency 
distribution of VH186.2 somatic mutations in CD45.2 donor GC B cells in (A). Data are 
pooled from three independent experiments. (D and E) Expression of Aicda mRNA and 
frequencies of CD45.2 donor-derived IgG1+ GC B cells in (A). Data are pooled from 
three independent experiments. Data in (A, D, E) are shown by means ± SD, with 
unpaired Student’s t test. Kolmogorov-Smirnov test for (C). n = 6 for each group (A-C); 
n = 17 for Tfap4F/F Cre(–) and n = 14 for Tfap4–/– (D). 
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Figure 3.17. AP4 is dispensable for accumulation of W33L mutations. (A) 
Frequencies of Igλ+ cells in NIP-APC-binding GC B cells from Tfap4F/F Cγ1-Cre and 
control Tfap4+/+ Cγ1-Cre mice ten days after NP-CGG immunization. Data are pooled 
from two independent experiments. (B) NIP-APC-binding by GC B cells in (F). Data are 
pooled from two independent experiments. (C) NP4-specific serum Igλ titers in Tfap4F/F 
Mb1-iCre and control Tfap4F/F Cre(–) mice 56 days after NP-CGG immunization. Data 
are pooled from two independent experiments. (D) Frequencies of the W33L mutation in 
VH186.2 BCR+ clones in CD45.2 GC B cells. Numbers of W33L bearing clones and total 
number of clones sequenced are shown. Data are pooled from four independent 
experiments. Data in (A-D) are shown by means ± SD, with unpaired Student’s t test. χ2 
test with Yates correction for (D). n = 6 for each group. 
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Figure 3.18. Antibody responses in GC B cell- and activated B cell-specific AP4 
conditional knockout mice following immunization with NP-CGG in Alum. (A) Flow 
cytometric analysis showing Igλ expression in NIP-Allophycocyanin (APC) binding 
GL7+Fas+B220+ splenocytes from Tfap4F/F Cγ1-Cre (N=5) and control Tfap4+/+ Cγ1-Cre 
(N=6) mice ten days after NP-CGG immunization. (B) Expression of GL7 and Fas in 
B220+ splenocytes from Tfap4F/– AID-Cre (N=5) and control Tfap4F/+ AID-Cre (N=4) 
mice ten days after NP-CGG immunization. (C) Statistical analysis of frequencies of 
GL7+Fas+ cells in B220+ splenocytes in (B). (D and E) NP- and NIP-conjugate APC 
binding by B220+GL7+Fas+ splenocytes and Igλ expression in NP-APC- or NIP-APC-
binding GC B cells in (B). (F-K) Absolute numbers of and Igλ expression in NP-APC- (F 
and H) and NIP-APC-binding B220+GL7+Fas+ splenocytes (G and I), as well as NP-
APC- (J) and NIP-APC-binding (K) by B220+GL7+Fas+ splenocytes in (B). (L) Ratio of 
NP4- to NP15-specific serum IgG1 titers from Tfap4F/F Mb1-iCre (N=6) and control 
Tfap4F/F Cre(–) (N=6) mice 56 days after NP-CGG immunization. Data are representative 
of (A, B, D and E) or pooled from (C and F-L) two independent experiments. Data are 
shown by means ± SD.  Unpaired Student’s t test. 
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Figure 3.19. AP4 maximizes GC expansion against LCMV clone 13 infection. (A and 
B) Frequencies and absolute numbers of B220+GL7+Fas+ cells in the spleens of Tfap4F/F 
Mb1-iCre and control Tfap4F/F Cre(–) mice 30 days after infection with LCMV-c13. Data 
are pooled from two independent experiments. Unpaired Student’s t test. n = 7 for 
Tfap4F/F Cre(–) and n = 11 for Tfap4F/F Mb1-iCre. 
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Figure 3.20. AP4 is dispensable for the expansion of TFH cells.  (A-C) Flow cytometric 
analysis showing CXCR5 and PD1 expression in CD4+ splenocytes from Tfap4F/F Mb1-
iCre (N=11) and control Tfap4F/F Cre(–) (N=7) mice 30 days after infection with LCMV-
c13. Statistical analysis from two independent experiments is shown by means ± SD in 
(B and C). Unpaired Student’s t test. 
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Figure 3.21. AP4 is required for B cell-dependent clearance of LCMV clone 13. (A 
and B) Analysis of plasma LCMV loads in Tfap4F/F Mb1-iCre and control Tfap4F/F Cre(–
) mice (A) and Tfap4F/– AID-Cre and control Tfap4F/+ AID-Cre mice (B) after infection. 
Data are pooled from six (A) and three (B) independent experiments. Lines in represent 
medians. Mann-Whitney’s ranked test. For each time point n = 10–19 for Tfap4F/F Cre(–) 
and n = 16–25 for Tfap4F/F Mb1-iCre (A); for each time point n = 9–11 per group (B) 
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Figure 3.22. AP4 is dispensable for the development of LCMV-specific isotype 
switched antibodies. (A) Titers of LCMV-binding serum IgG in Tfap4F/F Mb1-iCre and 
control Tfap4F/F Cre(–) mice 80 days after infection. Data are pooled from six 
independent experiments. Data in are show by means ± SD. (B and C) Binding curves 
showing the reactivity of serum IgG1 and IgG2c from mice infected with LCMV-c13 to 
LCMV virion, as determined by ELISA. The thick curves in each group represent the 
average reactivity to LCMV virion. Green curves, showing reactivity of West Nile Virus 
vaccine-induced serum IgG to LCMV virion, serve as background controls. Each 
character symbol represents an individual mouse. Data are pooled from six independent 
experiments. n = 12 for Tfap4F/F Cre(–) and n = 14 for Tfap4F/F Mb1-iCre  
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Figure 3.23. AP4 is necessary for the development of LCMV-neutralizing 
antibodies. (A) Cumulative frequency distribution of somatic mutations of the Igh 
variable regions in GC B cells 30 days after infection. Data are pooled from two 
independent experiments.  (B) Neutralizing serum antibody titers from Tfap4F/F Mb1-iCre 
and control Tfap4F/F Cre(–) mice 80 days after LCMV infection. Neutralizing titers were 
shown as 1/EC50. Data are pooled from six independent experiments. Lines in (B) 
represent medians. (C) Inhibition of LCMV infection of Vero cells by heat-inactivated 
sera collected from Tfap4F/F Mb1-iCre (N=25) and control Tfap4F/F Cre(–) (N=14) mice 
80 days after infection. Data are pooled from six independent experiments. Kolmogorov-
Smirnov test for (A). Mann-Whitney’s ranked test for (B). n = 6 per group (A); n = 14 for 
Tfap4F/F Cre(–) and n = 25 for Tfap4F/F Mb1-iCre (B). 
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Figure 3.24. IL-21 sustains AP4 expression after CD40 stimulation is withdrawn. (A) 
Flow cytometric analysis showing expression of CD40L on NIH-3T3 cells infected with 
a CD40L-expressing retrovirus compared to that in CD4+ T cells polarized in vitro for 2 
days. (B) AP4 and c-MYC protein levels and puromycin (Puro) incorporation in naive 
(N), stimulated B cells with CD40L, and those subsequently stimulated with cytokines 
without CD40L (off CD40L). (–) denotes no cytokines added. Data are representative of 
three independent experiments. (C) Cell-number normalized Tfap4 mRNA levels in 
activated B cells from (B). Data are pooled from two independent experiments. (D and 
E) Cell-number normalized Tfap4 mRNA and protein levels in B cells stimulated with 
CD40L and those subsequently stimulated with IL-21. Data are pooled from three 
independent experiments. (F) AP4 and c-MYC protein levels in GC B cells ex vivo that 
were untreated, CD40L-stimulated, and those subsequently stimulated with cytokines 
without CD40L signals (off CD40L). (–) denotes no cytokine added. GC B cells were 
purified eight days after SRBC immunization. Data are representative of two independent 
experiments. Data in are shown by means ± SD. One-way ANOVA. n = 4–6 (B-E); n = 2 
(F). 
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Figure 3.25. IL-21 does not increase AP4 expression when CD40L is engaged.  (A) 
Immunoblot analysis showing AP4 and phosphorylated STAT3 protein levels in naive B 
cells (N), naive B cells cultured in the presence of IL-21 (IL-21 alone) for 24 hours, and 
CD40-primed B cells subsequently cultured in the presence of IL-21 (CD40L -> IL-21). 
(B and C) Tfap4 mRNA levels (B) and AP4 protein levels (C) in B cells co-stimulated 
with CD40L and each cytokine (0, 10, 30, 100 ng/ml). Cell number normalized transcript 
levels are shown. Data are representative (A and C) of or pooled (B) from two 
independent. 
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Figure 3.26. AP4 is specifically required for increased protein translation by IL-21 
signal. (A) Puromycin incorporation by Tfap4F/– Mb1-iCre and control Tfap4F/+ Mb1-
iCre naive B cells (N), CD40L-stimulated B cells, and those subsequently stimulated with 
different concentrations of IL-21 without CD40L. Data are representative of two 
independent experiments. (B and C) Bcl6 and Aicda mRNA levels in Tfap4–/– (N=5) and 
control Tfap4+/+ (N=4) B cells that were sequentially stimulated by CD40 ligation and IL-
21. Cell number normalized transcript levels are shown. Data representative (A) or 
pooled (B and C) from two independent experiments are shown by means ± SD. 
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Figure 3.27. Il21r is dispensable for expansion of TFH cells. (A) A schematic showing 
the generation of mixed bone marrow chimeras, in which Il21r is deficient in all B cells. 
A three to one mixture of bone marrow cells from Igh–/– mice and Il21r–/– or Il21r+/+ mice 
were transplanted into lethally irradiated B6-CD45.1 hosts, followed by NP-CGG 
immunization and analysis of GC responses on day ten. (B) Flow cytometric analysis 
showing CXCR5 and PD1 expression in CD4+ splenocytes from mixed bone marrow 
chimeras (N=4-6 per group) in (A). (C and D) Frequencies (C) and absolute numbers (D) 
of CXCR5+PD1+ cells in CD4+ cells in (B). (E) Il21r mRNA levels in 
CXCR5+PD1+CD4+ splenocytes in (B). Data representative (B) or pooled (C-E) from two 
independent experiments are shown by means ± SD. Unpaired Student’s t test. 
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Figure 3.28. Il21r is required for GC response. (A) GL7 and Fas expression in donor-
derived B220+ splenocytes (N=6-9 per group) in Figure 27. (B and C) Frequencies of 
GL7+Fas+ cells in donor-derived B220+ splenocytes (B) and absolute numbers of 
B220+GL7+Fas+ cells per spleen (C) in (A). (D) Bcl6 and Aicda mRNA levels in total 
GC, LZ, and DZ cells in (A). Data representative (A) or pooled (B-D) from two 
independent experiments are shown by means ± SD. Unpaired Student’s t test. 
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Figure 3.29. Il21r is required for maximal AP4 expression in GC B cells. (A) Tfap4, 
Myc, Ccnd3 mRNA levels in Il21r+/+ and Il21r–/– CD86hiCXCR4lo LZ and 
CD86loCXCR4hi DZ GC B cells from mixed bone marrow chimeras (Figure 27) ten days 
after NP-CGG immunization. Data are pooled from three independent experiments. (B 
and C) Staining for c-MYC and AP4 expression of spleen sections from mice in (A). LZ 
and DZ defined as in Figure 2. Data are representative of three independent experiments. 
Scale bar, 100 µm. Statistical analysis of c-MYC- and AP4-expressing cell frequencies 
per 1,000 µm2 of LZ or DZ is shown in (C). Data are pooled from three independent 
experiments. (D) AP4 protein levels in LZ and DZ GC B cells in (A). Data are 
representative of three independent experiments. Data in are shown by means ± SD. 
unpaired Student’s t test. n = 6 for Il21r+/+ and n = 8 for Il21r–/– (A); n = 4 for Il21r+/+ and 
n = 6 for Il21r–/– (B-D). 
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Figure 3.30. Il21r promotes cell-cycle re-entry of DZ GC B cells.  (A and B) Cell 
cycle analysis by sequential EdU and BrdU labeling of CD45.2 Il21r–/– and control 
Il21r+/+ donor LZ and DZ GC B cells from mixed bone marrow chimeras in Figure 27. 
Data are pooled from two independent experiments and shown by means ± SD. unpaired 
Student’s t test.  n = 4 for Il21r+/+ and n = 6 for Il21r–/– 
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CHAPTER 4: 
Discussion 
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 In the study, we have demonstrated that for both CD8 T cells and GC B cells, c-
MYC initiates the activation and proliferation program that are later on maintained by 
AP4 (Figure 1). Sustained AP4 expression after c-MYC downregulation is necessary for 
the continued proliferation of lymphocytes. In CD8 T cell responses, full-blown clonal 
expansion provides sufficient tissue infiltration and subsequent protection of host from 
certain neurotropic viruses.  For GC B cells response, sustained proliferation in the DZ 
after selection by TFH is required for diversification of BCR repertoire to increase the 
probability of generating rare affinity enhancing mutations critical for the protective 
activities of antibodies. Thus, both CD8 T cells and GC B cells utilize the c-MYC-AP4 
hand-off mechanism to maximize their responses. 
Our conclusion that AP4 sustains c-MYC’s function after c-MYC is 
downregulated is primarily based on the observation that the appearance of defective cell 
growth, metabolism and proliferation in Tfap4–/– CD8 T cells coincided with the 
downregulation of c-MYC after the priming phase. Although gene expression and ChIP-
seq analyses, as well as rescue experiments support this conclusion, we did not 
completely rule out the possibility that AP4 is required during CD8 T cell priming to 
program a durable response later in the infection. This can be tested by reconstituting 
AP4 protein in Tfap4–/– CD8 T cell only after c-MYC is downregulated, using the 
Rosa26-sAP4 mice generated in our lab (see Appendix). Likewise, we also did not rule 
out the possibility that residual c-MYC expression, which falls below detection limit, 
contributes to driving continued expansion of CD8 T cells. This can be tested by 
genetically ablating Myc at various time points after infection. These experiments will be 
difficult to conduct in the context of GC reaction, however, due to the cyclic nature of the 
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response and asynchrony of selection events. But nevertheless, our data indicate that c-
MYC and AP4 regulate overlapping target genes that are involved in lymphocyte 
activation. 
How does AP4 maintain transcription of thousands of target genes? Recent 
studies on the mechanisms by which c-MYC amplifies the transcription of activated 
genes in lymphocytes may provide some insights1. Binding of c-MYC to genomic loci 
can be sequence specific and promiscuous, depending on the level of its expression 2. c-
MYC activates the gene transcription by regulating the ‘pause-release’ of RNA 
polymerase II. Several studies demonstrated that RNA polymerase II “pauses” at a short 
distance downstream of transcriptional start sites (TSS) across the metazoan genome, 
yielding abortive transcripts of 20 – 65 nucleotides in length 3, 4, 5, 6. The establishment of 
pausing generates accessible chromatin configuration, likely through the recruitment of 
DNA-binding transcription factors 7. RNA polymerase II then initiates RNA synthesis but 
is stalled by two pause-inducing factors: negative elongation factor complex (NELF) and 
DRB sensitivity-inducing factor (DSIF) 8. The “release” from elongation inhibition 
requires phosphorylation of NELF by the kinase positive elongation factor b (pTEF-b) 9, 
which is recruited by a distinct class of transcription factors, exemplified by c-MYC and 
NFκB 6, 10, 11. Thus, the ability to interact with pTEF-b allows c-MYC to “amplify” 
transcription. However, to activate transcription of a large number of genes, c-MYC must 
also exhibit promiscuity in DNA binding. In a recent study using human cancer cell lines, 
c-MYC was reported to interact with sequences containing E-box motifs other than the 
consensus “CACGTG” 12. In support of this, our ChIP-seq analysis also shows that only 
30% of the c-MYC-bound genes contain the consensus c-MYC-binding motif (Chapter 
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2). Our evidence that AP4 binds to and regulates over 50% of c-MYC targets leads us to 
hypothesize that AP4 is also able to stimulate transcription through triggering the release 
of RNA polymerase II. Whether AP4 also interacts with the two components of pTEF-b: 
Cdk9 and cyclin T1 in activated primary CD8 T and B cells remains to be tested. 
 Why did two distinct transcription factors evolve to have significantly 
overlapping functions? Why is it necessary for c-MYC expression to be rapidly 
terminated? The evolutionary pressure that drove the development of this “hand-off” 
mechanism remains an outstanding question. Chromosomal translocation involving the 
immunoglobulin loci and Myc is causally linked to GC-derived lymphomas13, 14, 15, likely 
a result of AID activity on actively transcribed Myc locus16. In addition, enforced Myc 
expression is sufficient to drive GC lymphomagenesis in the presence of constitutive 
PI3K signaling12. Thus, it is possible that Myc is transcriptionally silenced in the DZ 
where AID-mediated SHM takes place, to minimize deleterious chromosomal 
translocation, and post-transcriptionally restricted to suppress malignant transformation 
in the presence of other oncogenic mutations. The maintenance of cellular activation and 
rapid proliferation in the absence of Myc requires a second factor, AP4. Long-term 
studies that define functional differences between c-MYC and AP4 in cancer models will 
further clarify the biological role of the MYC-AP4 hand off in sustaining lymphocyte 
proliferation, while staving off their transformation. 
 It is hardly convincing that the sole function of AP4 is to sustain gene expression 
programs initiated by c-MYC. While the majority of AP4-bound genes are indeed bound 
by c-MYC, a significant number of genes are bound only by AP4. One of these genes, 
Il2ra (which encodes the high affinity IL-2 receptor alpha subunit, also known as CD25) 
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was in fact downregulated in the absence of AP4 in the later, but not early, phase of the 
acute infection (Figure 2a). Consistent with the lack of c-MYC binding in the locus, 
ectopic c-MYC expression failed to rescue Il2ra levels in Tfap4–/– CD8 T cells (Figure 
2b,c). Signaling through CD25 is required for granzyme B expression and differentiation 
into KLRG1+ effector cells17, 18, 19, 20, 21. Consistent with premature downregulation of 
CD25, Tfap4–/– CD8 T cells expressed reduced amount of Granzyme B on day 4 after 
infection (data not shown) and failed to express the KLRG1 marker at the peak of 
response (Chapter 2). So far, our preliminary data suggest that prolonged CD25 
expression failed to rescue the blasting defect of Tfap4–/– CD8 T cells in vitro (data not 
shown). Given the mild defect in proliferation seen in Il2ra–/– CD8 T cells during acute 
infection, we found it unlikely that the severely impaired clonal expansion of Tfap4–/– 
CD8 T cells was caused by their failure to sustain CD25 expression. Further experiments 
need to be done to distinguish between CD25- and AP4-dependent programs in 
controlling CD8 T cell expansion and effector differentiation. Rescue experiments by 
CD25 overexpression in Tfap4–/– CD8 T cells or vice versa will address these issues. 
 Signaling through the IL-2R is required for sustained expression of both c-MYC 
22, 23 and AP4 24. However, AP4, but not c-MYC, promotes the expression of CD25 (data 
now shown). These data suggest a feed-forward loop in which IL-2 signals promote the 
accumulation of AP4, which in turn sustains CD25 expression, thus increasing sensitivity 
to decreasing amount of IL-2 present in the later phase of immune response. Such a 
mechanism may ensure acquisition of effector functions, including Gzmb expression, 
especially in non-lymphoid tissues where IL-2 is limiting. As an anti-tumor therapy, 
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ectopic expression of AP4 may allow autologous T cells to efficiently compete against 
Treg for IL-2, thereby enhancing the efficacy of IL-2-based therapies.  
   Are there other transcription factors that relay the effects of AP4 after AP4 is 
downregulated? Our data on expansion kinetics and BrdU incorporation indicate that 
both CD8 T cells and GC B cells continue to proliferate, albeit at a significantly slower 
rate than earlier time points, after AP4 is downregulated. It is possible that AP4 is the 
terminal factor in the cascade and allows the cells to build up enough energy and building 
blocks for the last couple rounds of cell divisions. Alternatively, other transcription 
factors, induced by AP4, promote CD8 T cell proliferation late in the infection. Further 
analyses on AP4 target genes in both CD8 T cells and GC B cells are instrumental to 
addressing this question. 
 CD8 T cell response is regulated by the sequential activation of regulatory 
modules 25. The mechanism by which each module is temporally induced still remains 
unknown. Our study uncovers a transcription factor cascade between c-MYC and AP4 
utilized by lymphocytes to maximize their responses. Along the same line, Kaech and 
colleagues recently identified a cascade between Tbet (encoded by Tbx21) and Zeb2 that 
promotes effector differentiation of CD8 T cells 26. Not unlike CD8 T cell response, GC 
response is likely regulated in a modular fashion as well. However, the cyclic nature and 
asynchronous selection events make it difficult to define each module. Studies that 
dissect the underlying regulatory networks connecting individual module to allow for 
their sequential activation will provide significant insights into how adaptive immune 
response is regulated and create opportunities to manipulate the response for therapeutic 
purposes.    
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Figure 4.1. Lymphocytes utilize the c-MYC-AP4 hand-off to maximize adaptive 
immune responses. c-MYC induces AP4 during lymphocyte activation. While c-MYC is 
transient, AP4 sustains longer than c-MYC. Sustained AP4 expression promotes 
continued proliferation of activated lymphocytes. This conserved mechanism is required 
in CD8 T cells for maximal clonal expansion, and in GC B cells, to maximally diversify 
BCR repertoire.  
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Figure 4.2. AP4 is required for sustained CD25 expression. a, Flow cytometric 
analysis showing CD25 expression of WT and Tfap4–/– OT-I cells at various time points 
after infection with LM-OVA. b, AP4 and c-MYC binding to the Il2ra locus determined 
by ChIP-seq analysis. c, Expression of CD25 on WT and Tfap4–/– CD8 T cells infected 
with an empty retrovirus, or retroviruses expressing AP4 or c-MYC.  
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Appendix: 
Identification and use of a stabilized form of AP4 to enhance CD8 T cell activities.  
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A.1 BACKGROUND 
The concept of “exhaustion” was first used to describe the observation that during 
chronic LCMV infection, antigen-specific, tetramer-binding CD8 T do not produce 
cytokines 1. During “exhaustion”, effector functions of CD8 T cells are gradually lost in a 
defined hierarchical order 2, 3. Cytotoxic activity, high proliferative capacity, and IL-2 
production are typically lost first, followed by the ability to produce tumor necrosis factor 
α (TNFα). Severe “exhaustion” leads to complete abolishment of IFNγ expression. The 
ultimate outcome of “exhaustion” is the physical deletion of antigen-specific CD8 T cells 
3, 4. The loss of effector function is partly a result of high level of inhibitory receptor 
expression, such as PD-1, Lag-3, 4-1BB, and CLTA4. PD-1 ligation is known to inhibit 
membrane-proximal T cell receptor signaling 5. Consistently, Lag-3 has been shown to 
negatively affect cell cycle progression 6. Over the past few years, several studies have 
reported complete or partial reversal of CD8 T cell “exhaustion” by blocking PD-1, Lag-
3, CTLA-4, or combinations of the three 7, 8, 9. 
Many attempts have been made to reverse CD8 T cell “exhaustion” induced by 
viral persistence 7, 10, 11, with most focusing on targeting the inhibitor receptor PD-1. 
Recently, whole genome microarray analysis on exhausted CD8 T cells revealed that 
several pathways involved in glucose metabolism and ribosome biogenesis were down-
regulated compared to effector T cells 12, 13, a signature partly reminiscent of Tfap4–/– T 
cells during acute infection. These studies, together with the finding that AP4 protein was 
hardly detectable in exhausted P14 cells (data not shown), led us to hypothesize that 
forced expression of AP4 in antigen-specific CD8 T cells may restore expansion capacity 
and effector function lost during exhaustion. 
	  
	  
166 
The role of CD4 help to CD8 T cells during acute infection has been elegantly 
shown by Bevan’s group 14. CD4 T cells also play a vital role in controlling chronic 
infections. Using LCMV clone 13 infection model, several groups demonstrated 
exacerbation of chronic infection in the absence of CD4 T cells 3, 15. In mice deficient for 
or depleted of CD4 T cells, antigen-specific CD8 T cells lost their effector functions and 
some were even deleted from the effector pool 1, 16. However, it is unclear from these 
studies whether CD4 T cells contribute directly to control viral infection or indirectly 
through supporting B and CD8 T cells 17. The most convincing data came from three 
back-to-back publications establishing IL-21 as a key factor produced by CD4 T cells to 
re-invigorate CD8 T cells 18, 19, 20. These results were later on extended to HIV infection 
showing that the presence of IL-21-producing CD4 T cells was associated with improved 
control of infection and function of CD8 T cells in humans 21, 22. In addition to functional 
CD8 T cell responses, antibody production by B cells were also required to control 
chronic LCMV infection 23. Robust antibody response is intimately associated with T 
follicular helper (TFH) differentiation. Prolonged viral persistence seemed to 
preferentially generate TFH cells 24. Consistent with this, signal through IL-6R on CD4 T 
cells was required to sustain TFH response in a Bcl-6-dependent manner during the later 
phase of chronic infection 25. Thus, CD4 T cells are likely to have an indirect role in 
controlling chronic infection. Despite phenotypic characterization of CD4 T cell response, 
the knowledge on the transcriptional control of high-quality CD4 help is still lacking.                 
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A.2 RESULTS 
AP4-deficient mice show significantly delayed viral clearance during chronic 
infection 
Given that AP4 regulates the magnitude and duration of CD8 T cell expansion 
during acute infection, and that functional CD8 T cell response is also required for the 
timely resolution of chronic LCMV infection 26, we hypothesized that kinetics of viral 
clearance would be significantly delayed in mice lacking AP4 in CD8 T cells. To address 
this, we infected Tfap4F/F;Cd8-Cre and WT mice with LCMV clone 13 and monitored 
serum viral titer over 60 days. We also included Tfap4–/– and Tfap4F/F;Cd4-Cre mice in 
our pilot experiments to determine whether successful response to LCMV clone 13 
requires the presence of AP4 in non-CD8 T cells, in particular, CD4 T cells. On day 7 
post infection, all groups developed similarly severe viremia (Figure 1). By day 30 post 
infection, while WT mice began to control viral replication 24, all three groups of AP4-
deficient mice retained significantly higher serum viral titer (2 to 3 logs compared to WT) 
(Figure 1). Delayed viral clearance in AP4-deficient animals was also apparent on day 45 
post infection, although by day 60, viral transcripts in the blood fell below detection limit 
for all groups of mice (data not shown). Interestingly, both Tfap4–/– and Tfap4F/F;Cd4-Cre 
mice retained substantially higher viral load than Tfap4F/F;Cd8-Cre animals, suggesting 
immune response against chronic viral infection may require AP4 in CD4 T cells and/or 
other cell types.  
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Antigen specific CD8 T cells exhibit profound “exhaustion” phenotype in the 
absence of AP4 
Because viral titer was significantly higher in AP4-deficient mice compared to 
WT controls regardless of where AP4 is deleted, we expected a more profound 
“exhaustion” phenotype exhibited by CD8 T cells from Tfap4–/–, Tfap4F/F;Cd4-Cre, and 
Tfap4F/F;Cd8-Cre mice. Indeed, LCMV GP33-41-specific splenic CD8 T cells from AP4-
deficient mice expressed 10- to 20-fold higher level of surface PD-1 compared to WT 
controls at day 60 post LCMV clone 13 infection (Figure 2a and b). Next, we assessed 
production of effector cytokines, IFNγ and TNFα, by splenic CD8 T cells when re-
stimulated with cognate LCMV antigens. Whereas the frequency of GP33-tetramer 
positive splenic CD8 T cells was only slightly reduced in AP4-deficient mice compared 
to WT controls at this point, IFNγ and TNFα production was severely compromised 
(Figure 2c). Based on these data, we concluded that CD8 T cells from AP4-deficient 
mice were more “exhausted” than WT controls. While we considered this defect 
secondary to prolonged viral persistence in the absence of AP4, we have not ruled out the 
possibility that AP4-deficient CD8 T cells are intrinsically prone to “exhaustion” and 
therefore fail to eliminate pathogens efficiently in the first place. 
 
The requirement for AP4 during robust CD4 T cell responses is CD4 T cell-intrinsic. 
To determine whether AP4 is required for robust CD4 T cell responses during 
chronic infection, we infected WT, Tfap4–/–, Tfap4F/F;Cd4-Cre and Tfap4F/F;Cd8-Cre 
mice with LCMV clone 13 and analyzed immune responses on day 7 post infection. We 
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included Tfap4F/F;Cd8-Cre mice as control because Cd4-Cre is active at the DP stage in 
thymic development, resulting in the deletion of AP4 in both CD4 and CD8 lineages. The 
choice of an early time point for analysis was made based on the finding that on day 7, 
viral titer was not different between WT and AP4-deficient mice. Consistent with our 
data from experiments using LCMV-Arm, in the absence of AP4, antigen-specific CD8 T 
cells showed highly impaired clonal expansion 7 days after infection with LCMV clone 
13 (Figure 3a and c). Interestingly, the number of effector CD4 T cells was also 
moderately reduced specifically in Tfap4–/– and Tfap4F/F;Cd4-Cre mice, but not in 
Tfap4F/F;Cd8-Cre animals, compared to WT controls (Figure 3b and d), suggesting that 
AP4 is required for the expansion of CD4 T cells in a cell-intrinsic manner. We have not 
yet tested whether the functions of CD4 T cell were also affected in the absence of AP4.   
 
N-terminal Flag-tag and S139A mutation enhance the stability of AP4 protein 
Many attempts have been made to reverse CD8 T cell “exhaustion” induced by 
viral persistence 7, 10, 11, with most focusing on targeting the inhibitor receptor PD-1. 
Recently, whole genome microarray analysis on exhausted CD8 T cells revealed that 
several pathways involved in glucose metabolism and ribosome biogenesis were down-
regulated compared to effector T cells 12, 13, a signature partly reminiscent of Tfap4–/– T 
cells during acute infection. These studies, together with the finding that AP4 protein was 
hardly detectable in exhausted P14 cells (data not shown), led us to hypothesize that 
forced expression of AP4 in antigen-specific CD8 T cells may restore expansion capacity 
and effector function lost during exhaustion. A major obstacle that hindered us from 
carrying out the experiment was the instability AP4 protein, with an estimated half-life of 
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2 hours in in vitro activated CD8 T cells and readily subject to proteosomal degradation 
(Chapter 2 Figure 1e and f). Compounding this was the observation that overexpression 
of AP4 resulted in proteolytic cleavage of the full-length form into a 5-kDa shorter 
product. This cleavage product, existing at approximately 3:1 ratio with the full-length 
AP4, lost the nuclear localization sequence and was constantly found in the cytoplasm 
(Figure 4). Thus, its intrinsic nature of instability and unexpected cleavage event 
prevented us from overexpressing AP4 at the maximal level. To overcome this problem, 
we sought to construct an AP4 mutant with prolonged half-life and reduced proteolytic 
cleavage when overexpressed. 
Since serine/threonine phosphorylation commonly signals for proteasome-
dependent degradation 27, we hypothesized that AP4 protein may undergo certain post-
translational modifications that impact its stability. To test this, we utilized a publicly 
available proteomics software (PhosphoSitePlus) to search for phosphorylation sites in 
AP4. PhosphoSitePlus is not a prediction program. Rather, it sieves published phospho-
mass spectrometry data into a list of peptides with confirmed phosphorylated residues. 
We found three highest hits in AP4 protein: T37, S124, and S139 (Table 1). 
We mutated each of the three phosphorylated residues to alanine: T37A, S124A, 
and S139A, and tested the stability of each construct in primary CD8 T cells. Remarkably, 
S139A, but not T37A or S124A, significantly prolonged the half-life of AP4 (Figure 5a 
and b). Despite its enhanced stability, AP4-S139A still underwent proteolytic cleavage 
(Figure 5a and b). To determine at which termini the cleavage occurred, we Flag-tagged 
AP4 at either the N- or C-terminus, and analyzed the cleavage pattern by Western blot. 
Both the full-length and 5-kDa shorter products of C-terminal flag-tagged AP4 could be 
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detected with an anti-Flag antibody, suggesting that the cleavage occurs at the N-
terminus (Figure 5c). Consistently, the very same antibody did not detect any cleavage 
product of N-terminal Flag-tagged AP4 (Figure 5c). Strikingly, anti-AP4 antibody also 
failed to detect the cleaved form, suggesting that N-terminal Flag-tag significantly 
reduced proteolytic cleavage (Figure 5c). From these structural studies, we concluded 
that N-terminal Flag-tag and S139A mutation enhance the stability of AP4 protein.  
We also confirmed that the addition of Flag tag and point mutation did not impair 
the transcriptional activity of AP4, as both mutants were able to restore CD25 expression 
when overexpressed in Tfap4–/– CD8 T cells, compared to a mutant lacking the DNA 
binding domain (Figure 6). 
 
Stabilized AP4 sustains CD8 T cell activation after IL-2 withdrawal 
We found that S139A on AP4 is critically important for its stability. Another 
group has also confirmed this finding28. We next generated a mouse where an inducible 
enhanced AP4 is knocked into the Rosa26 locus (Figure 7). mCherry expression allows 
tracking of CD8 T cells that have undergone Cre-mediated deletion of the STOP cassette 
following in vitro activation and transduction of a Cre-expressing retrovirus (Figure 8a). 
Consistent with their significantly elevated AP4 expression levels, mCherry+ CD8 T cells 
sustain high levels of CD25 and a blasting phenotype compared to control cells after IL-2 
withdrawal (Figure 8b, c).  
Interestingly, both the frequency and number of TCRβ+ cells in the spleen were 
reduced in Rosa26sAP4/+ Cd4-Cre mice compared to controls at the steady-state (Figure 
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9a-c). Thymocyte development was normal, however (data not shown), suggesting that 
overexpression of AP4 has negative effects on peripheral T cell homeostasis. An 
increased proportion of both CD4+ and CD8+ T cells displayed an activated phenotype in 
Rosa26sAP4/+ Cd4-Cre spleens compare to WT controls (Figure 9d), a phenomenon also 
seen in mice with constitutive PI3K activity (unpublished observation).   
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A.3 CONCLUSIONS AND FUTURE DIRECTIONS 
 In this preliminary study, we identified key phosphorylated residues on AP4 that 
are required for proteasome-mediated degradation of the protein. In addition, we also 
uncovered the proteolytic cleavage of AP4 when the protein is expressed at 
supraphysiological levels. The truncated form of AP4 is excluded from the nucleus, 
suggesting another layer of regulation of AP4 activity in addition to its short half-life and 
low transcript levels. This cleavage event was prevented by tagging the N-terminus of 
AP4. Thus, by mutating S139 to alanine and adding a N-terminal Flag-tag, we 
significantly enhanced the stability and function of AP4 in CD8 T cells in vitro. Whether 
this mutant form of AP4 is able to prevent CD8 T cell exhaustion during LCMV clone 13 
infection remains to be tested. Expression of a constitutive form of PI3K and genetic 
deletion of Vhl in T cells enhanced effector functions, but also resulted in lethal 
immunopathology during LCMV clone 13 infection 29. It will be interesting to test 
whether mutant AP4 is sufficient to promote T cell effector functions without inducing 
immunopathology.  
 Rejection of antigenic tumors requires T cell responses 30. However, tumors 
establish an immunosuppressive environment that induces dysfunction or 
hyporesponsiveness of infiltrating T cells, thereby evading T cell-mediated destruction 31, 
32. Chronic TCR stimulation, lack of co-stimulation signals, suppression by other cells, 
and deprivation of mitogenic cytokines all contribute to T cell dysfunction 33. Indeed, 
depleting regulatory T cells and blocking the PD-1 inhibitory receptor with checkpoint 
blockade therapies sufficiently reinvigorate T cell functions to mediate tumor rejection 34, 
35. Despite the efficacy seen in a wide variety of cancer patients, many tumors show little 
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susceptibility to checkpoint blockade therapies 36, suggesting that other inhibitory 
pathways are engaged in T cells. Defining, characterizing, and targeting these cell 
extrinsic pathways may prove fruitful, but is time-consuming and costly. 
 The use of autologous tumor-specific T cells as anti-cancer therapy provides an 
opportunity to engineer cell-intrinsic pathways for sustained effector functions, thus 
circumventing the need to target multiple surface receptors. By targeting common 
signaling pathways dampened by inhibitory receptor engagement, engineered T cells may 
be resistant to signals through multiple inhibitory receptors. This strategy is best 
exemplified by the successful use of CD137 and intracellular domain of CD28 to 
improve CAR T cell functions 37. Because these signaling pathway ultimately activate 
transcription factors that promote the expression of genes related to survival, proliferation 
and cytokine production, directly targeting key transcription factors, either by modulating 
their transcriptional activities using small molecules or overexpression/silencing with a 
retrovirus/lentivirus may prove to be a successful ambition.       
 For this reason, enhanced AP4 mutant offers therapeutic potential. By 
overexpressing mutant AP4 in autologous or CAR T cells, one may prolong the effector 
functions of the transferred cells. Although such a strategy, like many others involving 
the use of a retrovirus, raises the critical concern of whether AP4 has oncogenic potential 
and whether transferred T cells can cause immunopathology, the risk can be significantly 
minimized by inserting a suicide cassette into the retroviral construct 38, 39, 40.  
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Figure A.1. AP4-deficient mice exhibit delayed kinetics of viral clearance. (a,b) 
Analysis of plasma LCMV loads in Tfap4–/–, Tfap4F/F Cd4-Cre, Tfap4F/F Cd8-Cre  and 
control Tfap4F/F Cre(–) mice at various time points after infection with LCMV clone 13. 
Data are shown by means ± SD. 
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Figure A.2. CD8 T cells from AP4-deficient mice appear more “exhausted” than 
WT controls. (a) Expression of CD4, CD8α, CD44, PD-1, and CD62L on splenocytes as 
well as H-2Db-GP(33-41) binding by CD8α+ cells 30 days after infection with LCMV 
clone 13. (b) Statistical analysis showing the frequency and absolute number of H-2Db-
GP(33-41)-specific CD8α+ cells per spleen in (a). (c) Frequency of IFNγ+ CD8α+ 
splenocytes in (a) after re-stimulation with indicated peptides, as determined by 
intracellular flow cytometry. Data are shown by means ± SD.  
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Figure A.3. AP4 is required for optimal expansion of both CD4 and CD8 T cells 
during chronic infection. (a) Frequency of CD8α+ H-2Db-GP(33-41)-binding cells in 
PBMC 30 days after infection with LCMV clone 13. (b) Expression of CD62L and CD44 
in CD4+ PBMC in (a). (c) Statistical analysis showing the frequency of H-2Db-GP(33-
41)-specific CD8α+ cells in PBMC in (a). (d) Statistical analysis showing the frequency 
of CD44+CD62L–CD4+ cells in PBMC in (a).  Data are shown by means ± SD. 
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Figure A.4. AP4 protein is unstable and subject to rapid proteosomal degradation. 
Western blot analysis showing expression of AP4 and phospho-STAT5 in the cytoplasm 
or nucleus of Tfap4–/– CD8+ T cells transduced with a control retrovirus or one expressing 
AP4, and subsequently cultured in the presence of absence of IL-2. Note the difference in 
size between cytoplasmic and nuclear AP4 protein. 
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Figure A.5. Point mutation at S139 and N-terminal Flag tag confer AP4 with 
enhanced stability. (a,b) Western blot analysis showing expression of AP4 in CD8T 
cells transduced with retrovirus expressing WT AP4 or AP4 with point mutations, and 
subsequently cultured in the presence or absence of IL-2 (a) or CHX (b). (c) Expression 
of Flag-tagged AP4.   
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Figure A.6. S139A and N-terminal Flag-tagged AP4 still retain their transcriptional 
activity. Flow cytometric analysis showing expression of CD25 on Tfap4–/– CD8+ T cells 
transduced with WT or mutant forms of AP4. 
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Figure A.7. Generation of the inducible super-AP4 knock-in allele. (a) A targeting 
strategy to knock-in an inducible stabilized mutant AP4 (sAP4) into the Rosa26 locus. (b) 
PCR analysis of targeted ES clones. The expected band size for corrected targeted ES cell 
clones is indicated with a red arrow. Clones 5 and 24 were used for microinjection.  
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Figure A.8. Stabilized AP4 sustains CD25 expression and cell size after IL-2 
withdrawal. (a) Expression of GFP and mCherry in Rosa26WT or Rosa26sAP4/+ CD8 T 
cells transduced with a retrovirus expressing the Cre-recombinase. (b) Expression of 
CD25 and forward scatter of CD8 T cells in a. (c) Western blot analysis showing AP4 
protein expression in CD8 T cells in a. 
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Figure A.9. CD4 and CD8 T cells expressing ectopic sAP4 display effector 
phenotypes under the steady state. (a,b) Flow cytometric analysis showing the 
expression of mCherry, TCRβ, CD4 and CD8α in MHCII–B220– splenocytes from 
Rosa26WT CD4-Cre and Rosa26sAP4/+ CD4-Cre mice. (c) Frequencies of TCRβ+, CD4+ 
and CD8+ cells per spleen. (d,e) Expression of CD62L and CD44 on CD4+ (d) and 
CD8α+ (e) splenocytes.  
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MS  MOUSE  HUMAN 
1 Y3 _____MEYFMVPTQK Y3-p _____MEyFMVPTQK 
1 S13 VPTQKVPSLQHFRKT S13-p VPTQKVPsLQHFRKT 
18 T37 SLANIPLTPETQRDQ T37-p SLANIPLtPETQRDQ 
2 K114 LQQNTQLKRFIQELs K114-u LQQNTQLkRFIQELs 
2 S121-p KRFIQELsGSsPKRR S121-p kRFIQELsGssPKRR 
3 S123 FIQELsGSsPKRRRA S123-p FIQELsGssPKRRRA 
24 S124-p IQELsGSsPKRRRAE S124-p IQELsGssPKRRRAE 
7 S139-p DKDEGIGsPDIWEDE S139-p DKDEGIGsPDIWEDE 
1 K189 HMYPEKLKVIAQQVQ K189-u HMYPEKLkVIAQQVQ 
2 T282 AIQHIEGTQDKQELE T282-p AIQHIEGtQEKQELE 
Table A.1. A list of phosphorylated peptides from AP4 protein. Data generated by 
PhosphoSitePlus (http://www.phosphosite.org/homeAction.action) 
 
